Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
  • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
  • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
  • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
  • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
  • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
  • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
  • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
  • C07K2317/565—Complementarity determining region [CDR]
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
  • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
  • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
  • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
  • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
  • C07K2317/734—Complement-dependent cytotoxicity [CDC]
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
  • C07K2317/74—Inducing cell proliferation
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
  • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
  • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
  • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
  • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

• the present invention relates to multispecific antibodies and fragments and variants thereof that specifically bind the T cell receptor of gamma delta T cells, and specifically bind to EGFR.
• T cell immunotherapy for cancer has focused on the evident capacity of subsets of CD8+ and CD4+ alpha beta (ab) T cells to recognize cancer cells and to mediate host-protective functional potentials, particularly when de-repressed by clinically mediated antagonism of inhibitory pathways exerted by PD-1 , CTLA-4, and other receptors.
• ab T cells are MHC-restricted which can lead to graft versus host disease.
• Gamma delta T cells represent a subset of T cells that express on their surface a distinct, defining gd T-cell receptor (TCR).
• This TCR is made up of one gamma (g) and one delta (d) chain, each of which undergoes chain rearrangement but have a limited number of V genes as compared to ab T cells.
• the main TRGV gene segments encoding ⁇ /g are TRGV2, TRGV3, TRGV4, TRGV5, TRGV8, TRGV9 and TRGV11 and non-functional genes TRGV10, TRGV11 , TRGVA and TRGVB.
• TRDV gene segments encode V61 , V62, and V63, plus several V segments that have both V6 and Va designation (Adams etal., 296:30-40 (2015) Cell Immunol.).
• Human gd T cells can be broadly classified based on their TCR chains, as certain g and d types are found on cells more prevalently, though not exclusively, in one or more tissue types. For example, most blood-resident gd T cells express a V62 TCR, commonly ng9 ⁇ /d2, whereas this is less common among tissue-resident gd T cells such as those in the skin, which more frequently use the V61 TCR paired with gamma chains, for example often paired with ng4 in the gut.
• gd T cells play a critical role in immune surveillance, recognising malignant or transformed cells (such as cancer cells) through a pattern of stress markers and then exerting potent and selective cytotoxicity gd T cells can therefore act as orchestrators of an immune response. Modulation of these cells in situ provides the potential to increase immunogenicity even in tumours with low mutational load which have proven challenging with other immunotherapies. Recognition of tumours by gd T cells is not dependent on any single tumour antigen and modulators of gd T cells therefore have potential in a range of disease indications, including both haematological and solid malignancies. The recognition mechanism o ⁇ gd T cells is not MHC restricted.
• gd T cells have pro-tumour activity or inhibit the anticancer immune response mediated by crt3 ⁇ 4 T cells.
• anti-gd antibodies will negatively modulate gd cell function by blocking or killing such cells, it has been found that a positive correlation between gd T cell infiltration and prognosis and/or survival in patients exists.
• nd1 TCR receptor/ligand interactions are limited.
• antibodies which recognize nd1 TCRs to date are mainly exploratory tools to probe this interaction.
• Such tools are typically crude, blocking antibodies which suggest TCR receptor/ligand interactions results in blocking, suppression or ablation of nd1+ cells.
• tool antibodies TS8.2 and TS-1 are employed as anti-gd blocking antibodies in studies which suggest said antibodies reduce the cytotoxicity of nd1 cells.
• gd T cells To exploit gd T cells for immunotherapy requires either a means to expand the cells in situ or to harvest them and expand them ex vivo priorto re-infusion. The latter approach has previously been described using the addition of exogenous cytokines, for example see WO2017/072367 and WO2018/212808. Methods for expanding a patients’ own gd T cells has been described using pharmacologically modified forms of hydroxy-methyl but-2-enyl pyrophosphate (HMBPP) or clinically-approved aminobisphosphonates. By these approaches, over 250 cancer patients have been treated, seemingly safely, but with only rare incidences of complete remission. However, there is still a need for activating agents that have the proven capacity to expand large numbers of gd T cells.
• HMBPP hydroxy-methyl but-2-enyl pyrophosphate
• a binding or activating agent capable of preferentially targeting or binding or recognizing or specifically modulating or increasing the numbers of V61 + cells in-situ may be highly desirable as a medicament.
• an ideal medicament capable of modulating V61 + would also exhibit fewer ‘off-target’ undesirable effects and rapid renal clearance.
• said undesirable effects can manifest when employing small-molecule chemicals.
• the aforementioned aminobisphosphonates shown capable of modulating the separate class of V62+ cells are associated with renal toxicity which manifests as deterioration of renal function and potential renal failure (e.g. Markowitz et al. (2003) Kidney Int. 64(1):281-289).
• nd1 + cells Additional undesirable effects as listed by the European Medicine Agency for Zometa include anemia, hypersensitivity reactions, hypertension, arterial fibrillation, myalgia, general pain, malaise, blood urea increase, vomiting, joint swelling, chest pain, etc. Further consideration must also be given to the in situ milieu in which nd1 + cells find themselves. For example, it has previously been shown that non-haematopoietic, tissue-resident gd T cells showed a strong proliferative response when first separated from tissue but only if they were not in direct cellular contact with autologous fibroblasts. It is found that the non-haematopoietic tissue-resident T cells (gd T cells) must be separated from the non-haematopoietic cells, (e.g.
• stromal cells particularly fibroblasts
• stromal cells in order to function. This is because direct contact of the lymphocytes with stromal or epithelial cells appears to inhibit expansion of tissue-resident gd T cells.
• nd1 cells have not been considered a promising therapeutic target to date, Indeed, until the discoveries described herein it has not been conceived how one could favourably and selectively modulate these cells in situ, where blood and tissue nd1 + cells are typically considered ‘resting’, ‘pre-activated’ or ‘non-activated’.
• medicaments specifically designed to target V61+ cells and for the treatment of infections, autoimmune conditions, and cancer.
• medicaments that can be administered to ameliorate signs and symptoms of disease by specifically binding V61+ cells, targeting V61+ cells, specifically activating V61+ cells, specifically enhancing proliferation and/or cytotoxicity activity V61+ cells, or specifically blocking activation of ⁇ /d1+ cells.
• bispecific and multispecific antibodies can be divided into separate, although overlapping, classes based on the types of biological targets and modes of action.
• multispecific antibodies can be divided into classes such as cytotoxic effector cell redirectors (also known as bispecific, T-cell-recruiting antibodies, bispecific T-cell engagers, TCEs, or BiTEs) and dual immunomodulators (Dls).
• cytotoxic effector cell redirectors also known as bispecific, T-cell-recruiting antibodies, bispecific T-cell engagers, TCEs, or BiTEs
• Dls dual immunomodulators
• TCEs T-cell engagers
• TCEs are intended to enhance the patient’s immune response to tumours by targeting T cells to tumour cells or vice versa, and work by targeting a first epitope of a T-cell receptor complex of a T- cell (usually CD3) and a second epitope, which is a cancer antigen or a cancer-associated antigen, such as a tumour associated antigen (TAA).
• TAA tumour associated antigen
• Such antibodies colocalize tumour cells and T-cells to promote tumour cell killing.
• Examples of BiTEs include the CD3 x CD19 bispecific antibody blinatumomab, the CD3 x EpCAM bispecific antibody catumaxomab, and the CD3 x HER2 bispecific antibody ertumaxomab.
• TCEs such as BiTEs are generally provided in an scFv format, although other formats have been provided.
• BiKEs are similar to BiTEs, but they target CD16 on NK cells, rather than CD3.
• the T-cell receptor has been described as the most intricate receptor structure of the mammalian immune system. It comprises a transmembrane multi-protein receptor complex comprises a T-cell receptor in close proximity to a number of CD3 chains.
• a typical such complex comprises a T-cell receptor, a CD3Y chain, a, CD36 chain, and two CD3s chains. These chains associate with the T-cell receptor (TCR) alongside a z-chain (zeta-chain) which combined then generate typical activation signals in T lymphocytes.
• TCR T-cell receptor
• zeta-chain z-chain
• T-cell receptor complexes comprising a T-cell receptor and a zeta chain homodimer have been described.
• CD4 and CD8 can also aid TCR function. Regardless of receptor complex composition, it is well established that said complexes translate cell surface binding events to intracellular phosphorylation signaling cascade. These phosphorylation events culminate in the activation of transcription factors such as NFAT and NFkB that lead to increased expression of cytokines and effector proteins such as granzymes and perforin.
• TCEs to treat cancer
• many of such bispecific antibodies have exhibited lackluster safety, efficacy and manufacturability profiles. Indeed, as of January 2020, blinatumomab remains the only approved TCE not then withdrawn.
• This TCE multispecific antibody fragment binds the T-cell receptor complex on a first binding arm and a CD19 target on a second binding arm.
• bispecific, T-cell-recruiting antibodies are discussed in Lejeune et al., 2020, Front Immunol., 11 :762.
• the existing bispecific antibodies in this category in particular those that recruit T-cells via CD3 binding, have significant off-target effects that result in severe adverse effects, given the potency of the CD3 antigen as signal transducer and its ubiquity in a patient’s T-cell population.
• systemic delivery e.g. intravenous
• more contained delivery such as intra-operative, intra- peritonea I, intraabdominal etc. is more often contemplated.
• bispecifics as medicaments.
• effector-attenuated anti-CD3 antibodies i.e. a CD3 targeting T-cell complex engager but not a bispecific
• the associated toxicity makes I.V. delivery challenging.
• the anti-CD3 antibody Foralumab is now most often being contemplated for oral delivery (e.g. in treatment of gut disease).
• TCEs require the complete suppression of the Fc-mediated effector functions in order to maximize therapeutic efficacy and to minimize off-target toxicity because binding of Fc to Fc gamma receptor (FcyR) leads to activation of immune effector cells.
• FcyR Fc gamma receptor
• the majority of the CD3-targeting bispecific antibodies currently in clinical practice have Fc domains with reduced binding activity to FcyR or are bispecific fragments intentionally without the Fc region. It would generally be expected that a TCE with unattenuated Fc function would induce an antibody-dependent cell-mediated cytotoxicity (ADCC) effect and thereby deplete the population of gd T-cells recognized by the antibody.
• ADCC antibody-dependent cell-mediated cytotoxicity
• TCE therapeutic windows have been termed prohibitively narrow’.
• TAAs solid tumor TAAs are often also expressed on tissues of healthy organs, which can in turn lead to immune pathology and organ failure with potential fatality, as shown in a preclinical mouse study using a CD3-bispecific.
• TAE tumor microenvironment
• conventional CD3+ ‘naive’ T-cells exist primarily in the blood and lymph system without any additional dendritic cell mediated activation.
• TILs tumour infiltrating lymphocytes
• CD3-targetting bispecifics may induce TIL apoptosis via activation-induced cell death, which hampers a strong anti-tumor response.
• multispecific immunomodulatory medicaments wherein at least one binding domain binds a T-cell and at least one second binding domain targets a TAA.
• the present invention relates to high-affinity antibodies that comprise multiple antigen-binding sites (“multispecific antibodies”), including an antigen-binding site for TCR delta variable 1 (V61) and an antigenbinding site for EGFR. More specifically, the present invention relates to multispecific antibodies comprising a Fab region and an Fc region, wherein the Fab region comprises a binding site specific for an epitope of the variable delta 1 (V61) chain of a gd T cell receptor (TCR); and the Fc region comprises an binding site specific for EGFR.
• multispecific antibodies comprising a Fab region and an Fc region, wherein the Fab region comprises a binding site specific for an epitope of the variable delta 1 (V61) chain of a gd T cell receptor (TCR); and the Fc region comprises an binding site specific for EGFR.
• the multispecific antibodies of the present invention are in the format known as "mAb 2 antibodies or "mAb squared antibodies", which are antibodies comprising an Fc region that has been engineered to contain antigen-binding loops in its CH3 domain - this modified Fc region is termed an "Fcab” (Fc with antigen binding).
• the resulting Fcabs can be rapidly inserted into a natural IgG antibody format to create tetravalent mAb 2 bispecific antibodies that bind to two different antigens.
• the mAb 2 antibody therefore further comprises a Fab region, comprising a VH-VL domain pair providing an antigen-binding site.
• mAb 2 molecules of the present invention comprise a EGFR binding Fcab and an nd1- binding Fab.
• the antibodies of the present invention have an advantageous functional profile.
• the antibodies of the present invention are useful for the activation of V61 T-cells. Although they may cause downregulation of the TCRs on T-cells to which they bind, they do not cause V61 T-cell depletion, but rather they stimulate the T-cells and hence may be useful in therapeutic settings that would benefit from the activation of this compartment of T-cells. Activation of V61 T-cells is evident through TCR downregulation, changes in activation markers such as CD25, Ki67, degranulation marker CD107a, NCRs (natural cytotoxicity receptors) and/or 4-1 BB.
• Activation ofVbl T-cell in turn triggers release of inflammatory cytokines such as INFy and TNFato promote immune licencing.
• cytokines such as INFy and TNFato promote immune licencing.
• antibodies having suitably high affinity for TRDV1 elicit increased V61 T- cell killing and, unlike (for example) antibodies that target CD3, the provision of high affinity antibodies is possible without adverse effects associated with large-scale activation via CD3.
• the high affinity antibodies are able to induce strong immunostimulatory effects via tumour-infiltrating lymphocytes (TILs). This can be achieved with minimal exhaustion or killing of the V61 cells. Therefore, the multispecific antibodies of the invention may be considered agonistic antibodies.
• the Fcab regions comprised within the multispecific antibodies of the present invention have a smaller binding interface than typical monoclonal antibody binding sites.
• the binding sites of Fcabs form a compact antibody fragment with two binding sites situated close together.
• the two antigen binding sites of an Fcab are also spatially close to each other, as compared with those of a typical mAb. Based on this smaller binding interface and reduced flexibility of the two binding sites it is surprising that the multispecific antibodies of the invention (comprising Fcab regions) are able to bind to and inhibit EGFR with similar affinity and potency as a monoclonal antibody benchmark.
• a multispecific antibody comprising a Fab region and an Fc region, wherein the Fab region comprises a binding site specific for an epitope of the variable delta 1 (V61) chain of a gd T cell receptor (TCR); and the Fc region comprises an EGFR binding site.
• a polynucleotide sequence encoding a multispecific antibody of the invention For example, there is provided a polynucleotide sequence encoding the anti-V61 first binding domain comprising a sequence having at least 70% sequence identity with SEQ ID NO: 199 to 222, 224 to 247, 249 to 259 or 261 to 271.
• an expression vector comprising the polynucleotide sequence of the invention.
• a host cell comprising a polynucleotide sequence of the invention or an expression vector of the invention.
• a method for producing any multispecific antibody or antigen-binding fragment thereof of the invention comprising culturing a host cell of the invention in a cell culture medium.
• compositions comprising a multispecific antibody of the invention.
• pharmaceutical composition comprising a multispecific antibody of the invention and a pharmaceutically acceptable diluent or carrier.
• Compositions and pharmaceutical compositions may optionally further comprise one or more additional therapeutically active agents.
• kits comprising a multispecific antibody of the invention or a pharmaceutical composition of the invention, optionally comprising instructions for use and/or an additional therapeutically active agent.
• a method of treating a disease or disorder in a subject comprising administering to the subject a multispecific antibody of the invention, or a pharmaceutical composition of the invention.
• a method of modulating an immune response in a subject comprising administering to the subject a multispecific antibody of the invention, or a pharmaceutical composition of the invention.
• Administration of antibodies to a subject may be administration in a therapeutically effective amount.
• a multispecific antibody of the invention, or a pharmaceutical composition of the invention, or a kit of the invention for use in medicine.
• the use of an a multispecific antibody of the invention in the manufacture of a medicament.
• FIG. 1 Phage selection rounds.
• A Phage selections round 1 to 3 for the ADT1-7 library.
• B Phage selections round 1 to 3 for the ADT1-7 library.
• Phage selections Round 1 to 3 for the ADT1-4 library (C) Phage selections Round 1 to 3 for the ADT1-4 library with a selection strategy for isolating cyno cross-reactive binders.
• FIG. 1 A schematic overview of selection of matured antibodies by mammalian display.
• C ADT1-4 Lineage Mammalian Display Outputs: Correlation between Human Antigen Dissociation Off-Rate (SPR) improvements vs Cyno Antigen Dissociation Off-Rates (SPR) plus LC 74S (open circle) or 74L (filled circle) usage indicated.
• SPR Human Antigen Dissociation Off-Rate
• SPR Cyno Antigen Dissociation Off-Rates
• LC 74S open circle
• 74L filled circle
• FIG. 4 CDR3 usage and cross-sharing.
• A Example heavy chain and light chain cross-sharing between affinity matured antibodies in ADT1-4 (G04) lineage (0.4nM Human TRDV1 ELISA results heat- map graded).
• This “heat map” demonstrates the cross-sharing of CDR3 sequences between different affinity matured antibodies in the ADT1-4 lineage, showing the affinity maturation process provided antibody sequences that do not have to be provided as specific heavy and light chain pairs.
• the results highlight the affinity matured antibodies can cross-share light chains and heavy chains and that differing LC/HC combinations generate equivalent or improved outcomes in a high-stringency antigen binding study.
• ADT1-4 (G04) parent clone (bottom left).
• Figure 5 Fold enhancement in binding and for ADT1-4 linage compared to ADT1-4 parental
• B Fold improvement in binding to cyno antigen (DV1/GV77 containing Cyno SEQ ID NO: 308 (mature, minus leader)).
• C Fold improvement in binding to human antigen.
• Figure 9 Binding affinity analysis (KD by SPR) to human V51 antigen.
• A Surface plasmon resonance for ADT1-4 lineage.
• B Surface plasmon resonance for ADT1-7 lineage.
• C KD values and fold change against parental clone for ADT1-4 lineage.
• D KD values and fold change against parental clone for ADT1-7 lineage.
• E Fold change of KD against parental clone for ADT1-4 lineage.
• F Fold change of KD against parental clone for ADT1-7 lineage.
• FIG. 10 Binding affinity analysis (KD by SPR) to cyno antigen.
• A Surface plasmon resonance for ADT1-4 lineage for cyno antigen.
• B KD values for ADT1-4 lineage for cyno antigen.
• Vd1 mAbs The level of binding by the Vd1 mAbs to two gd T cell donors, ATS006 (A) and TS164 (B).
• C Bar chart representing the average 50% binding values from the ADT1-4 and ADT1-7 clones binding to V61-positive gd T cell, represented as the mean two donors, with these values provided in tables with % improvement.
• D Table summarizing the IC50s plotted in (A) & (B), and V61 -negative cell types including HEK293A, Raji cells and various leukocyte subsets with primary blood mononuclear cells. For nd1 -positive gd T cell, data is represented as the mean two donors.
• FIG. 12 TCR downregulation.
• A,B ADT1-4 lineage (A) and ADT1-7 lineage (B).
• C Average TCR downregulation - IC50 results from two GD cell donors.
• D,E Fold TCR downregulation improved from the parental ADT1-4 clone (D) and the ADT1-7 clone (E).
• F 50% effect values from (C), with the percentage improvement calculated from the respective parents of ADT1-4 (upper) and ADT1-7 (lower).
• G 50% effect values from (C) with the fold improvement calculated from the respective parents of ADT1- 4 (upper) and ADT1-7 (lower).
• C,D ADT1-7-3 clone in cells GD cells alone (C) or with THP-1 cells (D).
• E Table representing the percentage increase in gd CD107a expression from cocultured cells treated with the highest concentration of V61 mAb compared to untreated non- cocultured gd cells.
• F Table representing the percentage increase in gd CD107a expression from cocultured cells treated with the highest concentration of nd1 mAb compared to untreated, co- and non- cocultured gd cells.
• C,D ADT1-7-3 clone in cells GD cells alone (C) or with THP-1 cells (D).
• E Table representing the percentage increase in gd CD25 expression from cocultured cells treated with the highest concentration of V61 mAb compared to untreated non- cocultured gd cells.
• F Table representing the percentage increase in gd CD25 expression from cocultured cells treated with the highest concentration of V61 mAb compared to untreated, co- and non-cocultured gd cells.
• FIG. 15 Cyno TCR Downregulation.
• A Comparison of ADT1-4-2 and ADT1-4 capability to engage and reduce the expression of VD1 on cynomolgus gd-T cells.
• B Percentage of cell surface expression of VD1 upon treatment with ADT1-4-2.
• C individual EC50 value for the different donors combined with the mean and standard deviation.
• FIG. 16 Quantification of live THP-1 cell numbers after 24 hours co-culture with gd T-cells in the presence of V61 mAbs or controls.
• A THP-1 cell killing assay for ADT1-4 clones.
• B THP-1 cell killing assay for ADT1-7 clones.
• C Mean EC50s in THP-1 killing assay for ADT1-4 and ADT1-7 clones.
• D Table summarizing the EC50s plotted in (C).
• FIG. 20 Effect of anti-V61 antibodies on TIL populations from primary tumour biopsies.
• A,B Shows % decrease in V61 TCR expression on total tumour infiltrating-gd T cells following 48 (A) or 72 (B) hours mAb stimulation in two separate donors, confirming target engagement in each case.
• C Shows enhanced expression of both CD25 and Ki67 on V61+ T cells following 48 hour stimulation with ADT1-4-2 compared with stimulation with lgG1 isotype control or ADT1-4.
• D Shows substantial fold increases in IFN-g production by TILs stimulated with ADT1-4-2 or ADT1-7-3 for 72 hours in the presence of 50 ng/ml IL-15.
• (E) Shows that stimulation of TILs with ADT-1-4-2 or ADT1-7-3 did not enhance secretion of type 17-associated cytokines IL-6 or IL-17 at this timepoint.
• (F,G) Shows the % decrease in V61 TCR expression on total tumour infiltrating-gd T cells following mAb stimulation at 24 (F) or 72 (G) hours in two individual donors, confirming target engagement in TILs isolated by enzymatic digestion.
• (H) Shows dose- dependent enhanced expression of Ki67 on gd T cells following 72 hours stimulation with ADT1-4-2.
• (I,J) Shows the fold increase in IFN-g produced by TILs isolated from two individual donors by enzymatic digestion and stimulated with ADT1-4-2 at a concentration of 6.66 nM in the presence of 2 ng/ml IL-15 at 24 (I) or 72 (J) hours.
• concentration of the control anti-RSV and parent ADT1 -4 are matched to highest concentration used in study (i.e. a cone of 6.66n for A, C, F, G, H, I, J and a concentration of 66.6nM for B and E).
• FIG. 21 Effect of anti-V51 antibodies on TIL populations from primary tumour biopsies.
• Figure 23 Sequences of ADT1-4 linage clones (heavy chains).
• Figure 24 Sequences of ADT1-7 lineage clones (light chains).
• V51/EGFR bispecific antibodies exhibit high affinity binding to human EGFR and a human V61 -binding affinity comparable to their parental mAbs.
• A, B Surface Plasmon Resonance (SPR) analysis was performed with V61/EGFR bispecific variants to assess binding to human V61 (A) and human EGFR antigen (B).
• the parental mAbs, cetuximab and negative control mAbs were included for comparison purposes.
• FIG. 27 V51/EGFR bispecific antibody binds to EGFR* A431 target cells and V51 gd T-cells (A)
• FIG. 28 V51/EGFR bispecific antibodies induces EGFR-specific T cell activation and degranulation leading to increased gd T cell-mediated cytotoxicity of A431 target cells.
• A Cell surface expression of Y6TCR on primary V61 gd T-cells following culture with bispecific antibodies for 24 hours in the presence or absence of A431 cells.
• B, C The number of viable A431 cells (B) and activation status of primary V61 gd T-cells following co-culturing at 1 :1 ratio alongside varying concentrations of antibody for 24 hours. Viability was measured by viability dye and activation status using a CD25 antibody.
• Figure 29 Further evidence of non-depletion and CD3 downregulation in both blood-derived and tumour -associated V61 T cells.
• A shows the nd1 TCR MFI upon antibody stimulation as an indication of mAb target engagement on blood derived V61 T cells.
• B shows the MFI of CD3 expression on positively gated blood derived nd1 cells. Stimulation with the nd1 antibody engaged nd1 cells and resulted in down-regulation of both nd1 and CD3 on nd1 cells.
• FIG. 30 ADCC reporter bioassay shows no ADCC as a result of the anti-nd ⁇ antibodies.
• Target cells ie. gd cells
• ADCC bioassay effector cells in presence of anti-nd ⁇ antibodies, anti-nd ⁇ LAGA antibodies (Fc disabled), and RSV Isotype control.
• Luminescence signal was recorded as relative light units (RLU) and fold induction was calculated as described in the methods.
• N 2 gd donors (performed in technical duplicates) for “anti-nd ⁇ antibody”, “anti-nd ⁇ LAGA antibody”, “RSV”, ⁇ KT3”.
• FIG 31 Multispecific antibody conferred enhancement of V51+ effector cell mediated cytotoxicity.
• the targeting of a tissue-centric disease associated antigen A-D
• EGFR anti-V61 x anti-TAA
• E-H Example coculture of V61 + effector cells with A-431 cancer cells +/- multispecific antibodies comprising anti-V61 x anti- TAA (EGFR) bispecific binding moieties wherein the anti-V61 binding domain (to the first target) comprises a full-length antibody (VH-CH1-CH2-CH3/VL-CL) then combined with an anti-EGFR cetuximab-derived scFv binding moiety (to the second target).
• EGFR anti-V61 x anti- TAA
• Figure 32 Sequences of EGFR binding domains (lgG1 CH1-CH2-CH3) showing the sequence alignments and changes to lgG1 CH3 (EU numbering).
• Figure 33 A table showing cross referenced CH3 residue numbering.
• the table is adapted from IMGT.org.
• the positions of the modified amino acids as per IMGT (standard), IMGT (exon), EU, and Kabat numbering referred to elsewhere herein are highlighted by shading.
• IMGT exon column 361.1
• EU column EU
• Kabat numbering Kabat numbering
• Figure 34 Manufacturability/Stability Assessment of V51xEGFR multispecific antibodies: Expression and Analytical Studies on six molecules.
• A Yields in CHO.
• B Stability under accelerated storage conditions.
• C Aggregation Propensity.
• D Decay profile under accelerated conditions (non-reduced analysis).
• E Decay Profile under accelerated conditions (reduced analysis).
• F Overall Summary / Conclusion
• Figure 35 An extended study on VDIxEGFR multispecific antibodies and the differing effects conferred by dialing up/down affinity on the VD1 binding arm.
• A Affinity Summary.
• D (E) Impact on V61 TCR internalization of tissue- resident V61+ cells.
• F (G) Impact on degranulation of tissue-resident V51+ cells.
• H (l) Impact on multispecific cytolytic function towards EGFR+ cancer cells.
• J (K) Impact on proliferation of tissue-resident V 1+ cells.
• M Impact of TAA copy number.
• Figure 36 An extended study on VDIxEGFR multispecific antibodies and the differing effects conferred by dialing up/down affinity on the EGFR binding arm.
• A Affinity Summary.
• B (C) Impact on multispecific binding to EGFR+ colon cancer cell line HT-29.
• D (E) Impact on V61 TCR downregulation of tissue-resident V61 + cells.
• F (G) Impact on degranulation of tissue-resident V61 + cells.
• H (1) Impact on 41 BB activation status of tissue-resident V61+ cells.
• J (K) Impact on multispecific cytolytic function towards EGFR+ cancer cells.
• L (M) Impact on proliferation of tissue-resident V61+ cells.
• N Affinity to EGFR and impact of cancer cell TAA copy number.
• Figure 37 Impact of affinity on preferential binding to V61 versus EGFR cells. Impact of affinity on preferential binding to V61 versus EGFR cells as a bar chart (A), table (B) and ratio (C).
• Figure 38 Impact of affinity to EGFR on multispecific antibody internalization by A431 tumour cells.
• A (B) Affinity to EGFR; impact on multispecific antibody internalization by A431 tumour cells.
• Figure 39 Impact of affinity to EGFR on multispecific antibody inhibition of EGF ligand binding and tumour cell proliferation.
• A Impact of affinity to EGFR on multispecific antibody inhibition of EGF ligand binding and tumour cell proliferation.
• C Impact of affinity to EGFR on multispecific inhibition of EGFR+ tumour cell proliferation.
• FIG 40 VDIxEGFR multispecific antibodies: Sparing of healthy EGFR+ cells.
• A (C) Dose titration effects presented.
• B Representative microscopy images from the experiment described in (A).
• Figure 41 VDIxEGFR multispecific antibodies: ADT1-4-2xFS1-67 comparison to lower affinity ‘parent’ ADT1-4xFS1-67 (alias G04 FS1-67).
• A TCR downregulation - Dose response comparison of ADT1-4-2xFS1-67 with ADT1-4xFS1-67.
• B TCR downregulation Comparison - Result Summary.
• FIG. 42 VDIxEGFR multispecific antibodies: Comparison to a CD3xEGFR multispecific antibody.
• A (B)(C) Impact of T cell target receptor on V61 TCR and CD3s downregulation.
• D (E) Impact on multispecific cytolytic function towards EGFR+ cancer cells.
• F (G) Impact on induced cytokine secretion by activated T cells.
• H (l) Impact on proliferation of tissue-resident V61 + cells.
• the present invention provides multispecific antibodies and fragments and variants thereof that specifically bind the T cell receptor of gamma delta T cells, and specifically bind to EGFR.
• the present invention relates to high-affinity antibodies that comprise multiple antigenbinding sites, including an antigen-binding site for TCR delta variable 1 (V51) and an antigen-binding site for EGFR (“multispecific antibodies”).
• the multispecific antibodies of the present invention are in mAb 2 format and comprise a Fc region that has been engineered to contain antigen-binding loops in its CH3 domain - this modified Fc region is termed an "Fcab".
• the mAb 2 antibody further comprises a Fab region, comprising a VH-VL domain pair providing an antigen-binding site.
• mAb 2 molecules of the present invention comprise a EGFR binding Fcab and an nd1- binding Fab.
• the present invention relates to the provision and characterisation of optimised multispecific antibodies, for example antibodies prepared according to an optimised selection procedure beginning from parental anti-V61 antibodies, such as the parental antibodies referred to herein as G04, E07, C08, B07, C05, E04, F07, G06, G09, B09, G10 and E01.
• the present invention relates in particular to optimised multispecific antibodies derived from G04 and E07.
• Gamma delta (gd) T cells represent a small subset of T cells that express on their surface a distinct, defining T Cell Receptor (TCR).
• TCR T Cell Receptor
• This TCR is made up of one gamma (y) and one delta (d) chain.
• Each chain contains a variable (V) region, a constant (C) region, a transmembrane region and a cytoplasmic tail.
• the V region contains an antigen-binding site.
• V62 delta variable 2 chain
• V61 T cells or “V61 + T cells” referto gd T cells with a V61 chain, i.e. V61 + cells.
• references to ‘‘delta variable 1” may also referred to as V61 or Vd1 , while a nucleotide encoding a TCR chain containing this region or the TCR protein complex comprising this region may be referred to as “TRDV1”.
• Antibodies or antigen-binding fragments thereof which interact with the V61 chain of a gd TCR, and also interact with EGFR are all effectively antibodies or antigen-binding fragments thereof which bind to V61 and may referred to as “anti-TCR delta variable 1 antibodies or antigen-binding fragments thereof or “anti-V61 antibodies or antigen-binding fragments thereof or ‘‘anti-TRDV1 antibodies or antigen-binding fragments thereof or “anti-V61xEGFR antibodies or antigen-binding fragments thereof”.
• delta variable 2 chains can be referred to as V62, while a nucleotide encoding a TCR chain containing this region orthe TCR protein complex comprising this region may be referred to as “TRDV2”.
• multispecific antibodies or antigen-binding fragments thereof which interact with the V61 chain of a gd TCR do not interact with other delta chains such as V62.
• the antibodies are specific to TRDV1 and do not bind to TRDV2 (SEQ ID NO: 310) or other antigens present on a gamma delta T-cell receptor, such as TRDV3 (SEQ ID NO: 311).
• TRGV4 refers to ng4 chain.
• multispecific antibodies orantigen-binding fragments thereof which interact with the V61 chain of a gd TCR do not interact with gamma chains such as ng4 (e.g. SEQ ID NO: 309).
• the antibodies also do not bind or interact with other domains found within a gd TCR, such as TRDJ, TRDC, TRGJ or TRGC
• T-cell receptor complex is the complex of proteins comprising the “T-cell receptor” (or “TCR”) found on the surface of T-cells responsible for recognising a variety of antigens.
• the T-cell receptor complex comprises either the alpha and beta chains of the T-cell receptor, or in the case of gamma delta T cells, the gamma and delta chains of the T-cell receptor, and up to 6 additional chains or more, such as CD36, CD3Y, CD3e and O ⁇ 3z, although the precise makeup of T-cell receptor complexes can vary.
• the T-cell receptor complex mediates intracellular signalling in the T-cell, which may lead to T-cell activation.
• antibody includes any antibody protein construct comprising at least one antibody variable domain comprising at least one antigen-binding site (ABS).
• Antibodies include, but are not limited to, immunoglobulins of types IgA, IgG, IgE, IgD, IgM (as well as subtypes thereof).
• the overall structure of Immunoglobulin G (IgG) antibodies assembled from two identical heavy (H)-chain and two identical light (L)-chain polypeptides is well established and highly conserved in mammals (Padlan (1994) Mol. Immunol. 31:169-217).
• a conventional antibody or immunoglobulin (Ig) is a protein comprising four polypeptide chains: two heavy (H) chains and two light (L) chains.
• VH heavy chain variable domains
• VL light chain variable domains
• CDRs complementarity determining regions
• FRs framework regions
• each VH and VL is composed of three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1 , CDR1 , FR2, CDR2, FR3, CDR3, FR4.
• the conventional antibody tetramer of two heavy immunoglobulin chains and two light immunoglobulin chains is formed with the heavy and the light immunoglobulin chains inter-connected by e.g. disulphide bonds, and the heavy chains similarly connected.
• the whole antibody thus comprises two Fabs, each Fab comprising a VH-VL domain pair.
• the heavy chain constant region includes three domains, CH1 , CH2 and CH3.
• the light chain constant region is comprised of one domain, CL.
• the variable domain of the heavy chains and the variable domain of the light chains are binding domains that interact with an antigen.
• the constant regions of the antibodies typically mediate the binding of the antibody to host tissues or factors, including various cells of the immune system (e.g. effector cells) and the first component (C1q) of the classical complement system.
• EU numbering refers to a numbering convention used for the numbering of amino acid residues in antibodies. Each residue of the antibody is assigned a number to allow comparison of antibodies. Where a variant antibody contains a residue that was not present in the wildtype antibody (e.g. an insertion mutation) decimals are used to indicate the insertion. For example, if a residue was inserted between the residues designated numbers 361 and 362, the new residue would be given the EU number 361.1. EU numbering is an alternative numbering scheme to others such as Kabat, (Kabat etal. Sequences of Proteins of Immunological Interest, Fifth Edition U.S. Department of Health and Human Services, (1991) NIH Publication Number 91-3242). Chothia (Chothia et al.
• Figure 33 shows the correspondence between EU numbering, IMGT numbering and Kabat numbering for the CH3 domain residues.
• Figure 32 shows how the residues of the multispecific antibodies of the invention are numbered according to the EU numbering scheme.
• a “Fab region” as used herein refers to a portion of an antibody (or constructs that contain said portion) comprising a VH-VL domain pair providing an antigen-binding site (also known as a CDR based antigen binding site).
• the Fab region may further comprise the CL and CH1 domains.
• a conventional antibody with two heavy and two light chains thus comprises two Fabs, each Fab comprising a VH-VL domain pair.
• a “Fc region” (fragment crystallizable region), as used herein refers to a portion of an antibody (or constructs that contain said portion) comprising the CH2 and CH3 domains.
• the Fc region is the C-terminal region of an immunoglobulin heavy chain, including wild-type-sequence Fc regions and modifed Fc regions.
• An Fc region is dimeric and thus comprises paired heavy chain constant regions each comprising a CH2 and CH3 domain.
• a “fragment” of the antibody refers to a portion of an antibody (or constructs that contain said portion) that specifically binds to the first target, the delta variable 1 (V61) chain of a gd T cell receptor or the second target, EGFR (e.g. a molecule in which one or more immunoglobulin chains is not full length, but which specifically binds to the target).
• antibody fragment e.g. a molecule in which one or more immunoglobulin chains is not full length, but which specifically binds to the target.
• Fab fragment (a monovalent fragment consisting of the VL, VH, CL and CH1 domains);
• a F(ab')2 fragment (a bivalent fragment consisting of two Fab fragments linked by a disulphide bridge at the hinge region);
• scFv a single chain variable fragment, scFv (consisting of VL and VH domains joined, using recombinant methods, by a synthetic linker that enables them to be made as a single protein chain in which the VL and VH regions pair to form monovalent molecules);
• VH an immunoglobulin chain variable domain consisting of a VH domain
• VL an immunoglobulin chain variable domain consisting of a VL domain
• a domain antibody (dAb, consisting of either the VH or VL domain);
• a diabody consisting of a noncovalent dimer of scFv fragments that consist of a VH domain from one antibody connected by a small peptide linker a VL domain from another antibody
• Human antibody refers to antibodies having variable and constant regions derived from human germline immunoglobulin sequences. Human subjects administered with said human antibodies do not generate cross-species antibody responses (for example termed HAMA responses - human-anti-mouse antibody) to the primary amino acids contained within said antibodies. Said human antibodies may include amino acid residues not encoded by human germline immunoglobulin sequences (e.g. mutations introduced by random or site-specific mutagenesis or by somatic mutation), for example in the CDRs and in particular CDR3. However, the term is not intended to include antibodies in which CDR sequences derived from the germline of another mammalian species, such as a mouse, have been grafted onto human framework sequences.
• Human antibodies that are prepared, expressed, created or isolated by recombinant means such as antibodies expressed using a recombinant expression vector transfected into a host cell, antibodies isolated from a recombinant, combinatorial human antibody library, antibodies isolated from an animal (e.g. a mouse) that is transgenic for human immunoglobulin genes or antibodies prepared, expressed, created or isolated by any other means that involves splicing of human immunoglobulin gene sequences to other DNA sequences, may also be referred to as “recombinant human antibodies”.
• Humanisation Substituting at least one amino acid residue in the framework region of a non-human immunoglobulin variable domain with the corresponding residue from a human variable domain is referred to as “humanisation”. Humanisation of a variable domain may reduce immunogenicity in humans.
• Specificity refers to the number of different types of antigens or antigenic determinants to which a particular antibody or antigen-binding fragment thereof can bind.
• the specificity of an antibody is the ability of the antibody to recognise a particular antigen as a unique molecular entity and distinguish it from another.
• An antibody that “specifically binds” to an antigen or an epitope (or is “specific” for an antigen or epitope) is a term well understood in the art.
• a molecule is said to exhibit “specific binding” if it reacts more frequently, more rapidly, with greater duration and/or with greater affinity with a particular target antigen or epitope, than it does with alternative targets.
• An antibody “specifically binds” to a target antigen or epitope if it binds with greater affinity, avidity, more readily, and/or with greater duration than it binds to other substances.
• the antibodies of the present invention are multispecific antibodies.
• a “multispecific antibody” is an antibody that is capable of binding a plurality of different epitopes simultaneously or sequentially. Generally, the epitopes will not be on the same antigen. Hence a multispecific antibody has the capability to selectively bind to epitopes present on different antigens via a plurality of different binding domains. This contrasts with conventional mono-specific antibodies which do not have this capability. Rather, a “monospecific antibody” only has binding specificity for one antigen, although they may have multiple binding sites for that one antigen (e.g.
• the valency of a full human IgG antibody is 2, and the valency of other antibodies may be higher, but if the antibody only recognises one antigen, it is still classed as a monospecific antibody).
• the multispecific antibodies of the invention bind multiple different antigens simultaneously and/or sequentially.
• the antibodies are bispecific antibodies.
• a “bispecific antibody” is an antibody that is capable of binding two different epitopes simultaneously and/or sequentially. Generally, the epitopes will not be on the same antigen. Hence bispecific antibodies have the capability to selectively bind to two different epitopes present on two different antigens via two different binding domains. This contrasts with conventional monospecific antibodies which do not have this capability. Hence, the bispecific antibodies of the invention bind two different antigens simultaneously and/or sequentially.
• mAb 2 antibody or “mAb squared antibody” refers to a bispecific antibody format according to which the bispecific antibodies comprise an Fc region that has been engineered to contain antigen-binding loops in its CH3 domain. This modified Fc region is termed an "Fcab”.
• the mAb 2 antibody further comprises a Fab region, comprising a VH-VL domain pair providing an antigen-binding site.
• the CH3 domain of human lgG1 starts at residue number 341 and ends at residue number 447 (EU numbering). Residue number 447 (EU numbering) is sometimes cleaved during manufacture so it does not always appear in the final molecule.
• the CH3 domain of human lgG1 (SEQ ID NO:563) is comprised of two b-sheets formed by three and four b strands, respectively. Three structural loops connect these b- strands at the C-terminus of the CH3 domain. In antibodies of this invention, these loops have been modified to form the EGFR binding site.
• Residues 355 to 362 were defined as the loop connecting strands A and B of the CH3 domain “AB loop”, residues 383 to 391 as the loop connecting strands C and D of the CH3 domain “CD loop” and residues 413 to 422 as the loop connecting strands E and F of the CH3 domain “EF loop”. EU numbering is used (see Figure 32).
• affinity represented by the equilibrium constant for the dissociation of an antigen with an antigen-binding polypeptide (KD), is a measure of the binding strength between an antigenic determinant and an antigenbinding site on the antibody (or antigen-binding fragment thereof): the lesser the value of the KD, the stronger the binding strength between an antigenic determinant and the antigen-binding polypeptide.
• the affinity can also be expressed as the affinity constant (KA), which is 1/KD. Affinity can be determined by known methods, depending on the specific antigen of interest. For example. KD may be determined by surface plasmon resonance.
• any KD value less than 10 6 is considered to indicate binding.
• Specific binding of an antibody, or antigenbinding fragment thereof, to an antigen or antigenic determinant can be determined in any suitable known manner, including, for example, Scatchard analysis and/or competitive binding assays, such as radioimmunoassays (RIA), enzyme immunoassays (EIA) and sandwich competition assays, equilibrium dialysis, equilibrium binding, gel filtration, ELISA, surface plasmon resonance, or spectroscopy (e.g . using a fluorescence assay) and the different variants thereof known in the art.
• RIA radioimmunoassays
• EIA enzyme immunoassays
• sandwich competition assays such as enzyme immunoassays (EIA) and sandwich competition assays, equilibrium dialysis, equilibrium binding, gel filtration, ELISA, surface plasmon resonance, or spectroscopy (e.g . using a fluorescence assay) and the different variants thereof known in the
• “Avidity” is the measure of the strength of binding between an antibody, or antigen-binding fragment thereof, and the pertinent antigen. Avidity is related to both the affinity between an antigenic determinant and its antigen-binding site on the antibody and the number of pertinent binding sites present on the antibody.
• in situ means in the natural or original place, instead of being moved to another place.
• an in situ V61 + cell in a patient refers to a nd1 cell in vivo, as opposed to an in vitro or ex vivo cell.
• Human tissue V51+ cells and “haemopoietic and blood V51+ cells” and “tumour infiltrating lymphocyte (TIL) V61+ cells,” are defined as V61+ cells contained in or derived from either human tissue or the haemopoietic blood system or human tumours respectively. All said cell types can be identified by their (i) location or from where they are derived and (ii) their expression of the V61 + TCR.
• Modulating antibodies are antibodies that confer a measurable change including, but not limited to, a measurable change in cell cycle, and/or in cell number, and/or cell viability, and/or in one or more cell surface markers, and/or in the secretion of one or more secretory molecules (e.g., cytokines, chemokines, leukotrienes, etc.), and/or a function (such as cytotoxicity towards a target cell or diseased cell), upon contacting or binding to a cell expressing the target to which the antibody binds.
• a method of “modulating” a cell, or population thereof refers to a method wherein in at least one measurable change in said cell or cells, or secretion therefrom, is triggered to generate one or more “modulated cells”.
• an “immune response” is a measurable change in at least one cell, or one cell-type, or one endocrine pathway, or one exocrine pathway, of the immune system (including but not limited to a cell-mediated response, a humoral response, a cytokine response, a chemokine response) upon addition of a modulating antibody.
• an “immune cell” is defined as a cell of the immune system including, but not limited to, CD34+ cells, B- Cells, CD45+ (lymphocyte common antigen) cells, Alpha-Beta T-cells, Cytotoxic T-cells, Helper T-cells, Plasma Cells, Neutrophils, Monocytes, Macrophages, Red Blood Cells, Platelets, Dendritic Cells, Phagocytes, Granulocytes, Innate lymphoid cells, Natural Killer (NK) cells and Gamma Delta T-cells.
• immune cells are classified with the aid of combinatorial cell surface molecule analysis (e.g., via flow cytometry) to identify or group or cluster to differentiate immune cells into sub-populations. These can be then still further sub-divided with additional analysis. For example, CD45+ lymphocytes can further subdivided into nd positive populations and nd negative populations.
• Model systems are biological models or biological representations designed to aid in the understanding of how a medicine such as an antibody or antigen-binding fragment thereof may function as a medicament in the amelioration of a sign or symptom of disease.
• Such models typically include the use of in vitro, ex vivo , and in vivo diseased cells, non-diseased cells, healthy cells, effector cells, and tissues etc., and in which the performance of said medicaments are studied and compared.
• Diseased cells exhibit a phenotype associated with the progression of a disease such as a cancer, an infection such as a viral infection, or an inflammatory condition or inflammatory disease.
• a diseased cell may be a tumour cell, an autoimmune tissue cell or a virally infected cell. Accordingly said diseased cells may be defined as tumorous, or virally infected, or inflammatory.
• Healthy cells refers to normal cells that are not diseased. They may also be referred to as “normal” or “non-diseased” cells. Non-diseased cells include non-cancerous, or non-infected, or non-inflammatory cells. Said cells are often employed alongside relevant diseased cells to determine the diseased cell specificity conferred by a medicament and/or better understand the therapeutic index of a medicament.
• Diseased-cell-specificity is a measure of how effective an effector cell or population thereof, (such as, for example, a population of V61+ cells) is at distinguishing and killing diseased cells, such as cancer cells, whilst sparing non-diseased or healthy cells.
• This potential can be measured in model systems and may involve comparing the propensity of an effector cell, or a population of effector cells, to selectively kill or lyse diseased cells versus the potential of said effector cell/s to kill or lyse non-diseased or healthy cells. Said diseased-cell-specificity can inform the potential therapeutic index of a medicament.
• “Enhanced diseased-cell specificity” describes a phenotype of an effector cell such as, for example, a V61+ cell, or population thereof, which has been modulated to further increase its capacity to specifically kill diseased cells. This enhancement can be measured in a variety of ways inclusive of fold-change, or percentage increase, in diseased-cell killing specificity or selectivity.
• ADCC antibody-dependent cell-mediated cytotoxicity
• an immune effector cell such as a NK cell, for example
• recognise cell bound antibodies triggering degranulation and lysis of the target cell.
• this is mediated via Fc-Fcy interactions.
• the Fc region of the cell-bound antibody recruits effector cells expressing Fey receptors (eg. NK cells), leading to effector cell degranulation and death of the target cell.
• Fc enabled refers to an antibody that comprises a functional Fc region (fragment crystallizable region), i.e. a Fc region that has not been disabled by mutation or otherwise. Fc enabled antibodies demonstrate unattenuated Fc function.
• the Fc enabled antibody may comprise human IGHC heavy chain sequence as listed by IMGT that has not been modified or engineered or constructed to reduce binding to one or more Fc gamma receptors. For example, via IGFIC hinge mutation or by construction of an antibody comprising heavy chain constant domains which are chimeric or hybrid for lgG1/lgG2A or lgG1/lgG4 IGFIC sequences.
• the antibody or antigen-binding fragment thereof (i.e. polypeptide) of the invention is isolated.
• An “isolated” polypeptide is one that is removed from its original environment.
• isolated may be used to refer to an antibody that is substantially free of other antibodies having different antigenic specificities (e.g. an isolated antibody that specifically binds V61 , or a fragment thereof, is substantially free of antibodies that specifically bind antigens other than V61).
• isolated may also be used to refer to preparations where the isolated antibody is sufficiently pure to be administered therapeutically when formulated as an active ingredient of a pharmaceutical composition, or at least 70-80% (w/w) pure, more preferably, at least 80-90% (w/w) pure, even more preferably, 90-95% pure; and, most preferably, at least 95%, 96%, 97%, 98%, 99%, or 100% (w/w) pure.
• the polynucleotides used in the present invention are isolated.
• An “isolated” polynucleotide is one that is removed from its original environment.
• a naturally-occurring polynucleotide is isolated if it is separated from some or all of the coexisting materials in the natural system.
• a polynucleotide is considered to be isolated if, for example, it is cloned into a vector that is not a part of its natural environment or if it is comprised within cDNA.
• the antibody or antigen-binding fragment thereof may be a "functionally active variant" which also includes naturally occurring allelic variants, as well as mutants or any other non-naturally occurring variants.
• an allelic variant is an alternate form of a (poly)peptide that is characterized as having a substitution, deletion, or addition of one or more amino acids that does essentially not alter the biological function of the polypeptide.
• said functionally active variants may still function when the frameworks containing the CDRs are modified, when the CDRs themselves are modified, when said CDRs are grafted to alternate frameworks, orwhen N- orC-terminal extensions are incorporated.
• binding domains may be paired with differing partner chains such as those shared with another antibody. Upon sharing with so called ‘common’ light or ‘common’ heavy chains, said binding domains may still function. Further, said binding domains may function when multimerized. Further, ‘antibodies or antigen-binding fragments thereof may also comprise functional variants wherein the VH or VL or constant domains have been modified away or towards a different canonical sequence (for example as listed at IMGT.org) and which still function.
• the “% sequence identity” between a first polypeptide sequence and a second polypeptide sequence may be calculated using NCBI BLAST v2.0, using standard settings for polypeptide sequences (BLASTP).
• the “% sequence identity” between a first nucleotide sequence and a second nucleotide sequence may be calculated using NCBI BLAST v2.0, using standard settings for nucleotide sequences (BLASTN).
• Polypeptide or polynucleotide sequences are said to be the same as or “identical” to other polypeptide or polynucleotide sequences, if they share 100% sequence identity over their entire length. Residues in sequences are numbered from left to right, i.e. from N- to C- terminus for polypeptides; from 5’ to 3’ terminus for polynucleotides.
• any specified % sequence identity of a sequence is calculated without the sequences of all 6 CDRs of the antibody.
• the anti-V61 antibody or antigen-binding fragment thereof may comprise a variable heavy chain region sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% to a specified variable heavy chain region sequence and/or a variable light chain region sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to a specified variable light chain region sequence, wherein any amino acid variations occur only in the framework regions of the variable heavy and light chain region sequences.
• the anti-V 1 antibody or antigen-binding fragment thereof having certain sequence identities retain the complete heavy and light chain CDR1 , CDR2 and CDR3 sequences of the corresponding anti-V61 antibody or antigen-binding fragment thereof.
• an anti-V61 antibody or antigen-binding fragment thereof comprising a VH comprising or consisting of an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 15 and a VL comprising or consisting of an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 40, wherein any amino acid variations occur only in the framework regions of the variable heavy and light chain region sequences.
• the antibody of this specific example therefore further comprises a VHCDR1 comprising the amino acid sequence of SEQ ID NO: 51 , a VHCDR2 comprising the amino acid sequence of SEQ ID NO: 53, a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 68, a VLCDR1 comprising the amino acid sequence of SEQ ID NO: 79, a VLCDR2 comprising the amino acid sequence of SEQ ID NO: 80 and a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 95.
• multispecific antibodies provided herein may comprise a kappa light chain variable sequence and retain an amino acid residue at position 74 according to the IMGT numbering system that is not serine, for example a non-polar and/or non-human-germline residue, for example they may comprise a leucine residue at this position.
• an anti-V61 antibody or antigen-binding fragment thereof comprising a VH comprising or consisting of an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 15 and a VL comprising or consisting of an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 40, wherein any amino acid variations occur only in the framework regions of the variable heavy and light chain region sequences, and wherein the antibody comprises a kappa light chain variable sequence comprising an amino acid residue at position 74 according to the IMGT numbering system that is non-human-germline and/or non-polar (for example a leucine residue at this position).
• the antibody of this specific example further comprises a VHCDR1 comprising the amino acid sequence of SEQ ID NO: 51 , a VHCDR2 comprising the amino acid sequence of SEQ ID NO: 53, a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 68, a VLCDR1 comprising the amino acid sequence of SEQ ID NO: 79, a VLCDR2 comprising the amino acid sequence of SEQ ID NO: 80 and a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 95.
• a “difference” between sequences refers to an insertion, deletion or substitution of a single amino acid residue in a position of the second sequence, compared to the first sequence.
• Two polypeptide sequences can contain one, two or more such amino acid differences. Insertions, deletions or substitutions in a second sequence which is otherwise identical (100% sequence identity) to a first sequence result in reduced % sequence identity. For example, if the identical sequences are 9 amino acid residues long, one substitution in the second sequence results in a sequence identity of 88.9%. If first and second polypeptide sequences are 9 amino acid residues long and share 6 identical residues, the first and second polypeptide sequences share greater than 66% identity (the first and second polypeptide sequences share 66.7% identity).
• the number of additions, substitutions and/or deletions made to the first sequence to produce the second sequence may be ascertained.
• An “addition” is the addition of one amino acid residue into the sequence of the first polypeptide (including addition at either terminus of the first polypeptide).
• a “substitution” is the substitution of one amino acid residue in the sequence of the first polypeptide with one different amino acid residue. Said substitution may be conservative or non conservative.
• a “deletion” is the deletion of one amino acid residue from the sequence of the first polypeptide (including deletion at either terminus of the first polypeptide).
• glycine G or Gly
• alanine A or Ala
• valine V or Val
• leucine L or Leu
• isoleucine I or lie
• proline P or Pro
• phenylalanine F or Phe
• tyrosine Y or Tyr
• tryptophan W or Trp
• lysine K or Lys
• arginine R or Arg
• histidine H or His
• aspartic acid D or Asp
• glutamic acid E orGlu
• asparagine N or Asn
• glutamine Q or Gin
• cysteine C or Cys
• methionine M or Met
• serine S or Ser
• Threonine T or Thr
• a residue may be aspartic acid or asparagine
• the symbols Asx or B may be used.
• a residue may be any amino acid the symbol Xaa orX may be used.
• a residue may be glutamic acid or glutamine, the symbols GlxorZ may be used. References to aspartic acid include aspartate, and glutamic acid include glutamate, unless the context specifies otherwise.
• polypeptide sequences and definitions of CDRs and FRs are as defined according to the EU and/or IMGT numbering system, as indicated in context.
• a “corresponding” amino acid residue between a first and second polypeptide sequence is an amino acid residue in a first sequence affinity which shares the same position according to the EU and/or IMGT numbering system, as indicated in context, with an amino acid residue in a second sequence, whilst the amino acid residue in the second sequence may differ in identity from the first.
• corresponding residues will share the same number (and letter) if the framework and CDRs are the same length according to EU or IMGT definition. Alignment can be achieved manually or by using, for example, a known computer algorithm for sequence alignment such as NCBI BLAST v2.0 (BLASTP or BLASTN) using standard settings.
• references herein to an “epitope” refer to the portion of the target which is specifically bound by the antibody or antigen-binding fragment thereof. Epitopes may also be referred to as “antigenic determinants”.
• An antibody binds “essentially the same epitope” as another antibody when they both recognize identical or sterically overlapping epitopes. Commonly used methods to determine whether two antibodies bind to identical or overlapping epitopes are competition assays, which can be configured in a number of different formats (e.g. well plates using radioactive or enzyme labels, or flow cytometry on antigen-expressing cells) using either labelled antigen or labelled antibody.
• An antibody binds “the same epitope” as another antibody when they both recognize identical epitopes (i.e. all contact points between the antigen and the antibody are the same).
• Linear epitopes are formed by a continuous sequence of amino acids in a protein antigen.
• Conformational epitopes are formed of amino acids that are discontinuous in the protein sequence, but which are brought together upon folding of the protein into its three-dimensional structure.
• vector is intended to refer to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked.
• plasmid refers to a circular double stranded DNA loop into which additional DNA segments may be ligated.
• viral vector Another type of vector is a viral vector, wherein additional DNA segments may be ligated into the viral genome.
• Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g. bacterial vectors having a bacterial origin of replication and episomal mammalian and yeast vectors). Other vectors (e.g.
• non- episomal mammalian vectors can be integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome.
• certain vectors are capable of directing the expression of genes to which they are operatively linked.
• Such vectors are referred to herein as “recombinant expression vectors” (or simply, “expression vectors”).
• expression vectors of utility in recombinant DNA techniques are often in the form of plasmids.
• plasmid and vector may be used interchangeably as the plasmid is the most commonly used form of vector.
• the invention is intended to include such other forms of expression vectors, such as viral vectors (e.g.
• recombinant host cell (or simply “host cell”), as used herein, is intended to refer to a cell into which a recombinant expression vector has been introduced. Such terms are intended to refer not only to the particular subject cell but to the progeny of such a cell, for example, when said progeny are employed to make a cell line or cell bank which is then optionally stored, provided, sold, transferred, or employed to manufacture an antibody or antigen-binding fragment thereof as described herein.
• references to “subject”, “patient” or “individual” refer to a subject, in particular a mammalian subject, to be treated.
• Mammalian subjects include humans, non-human primates, farm animals (such as cows), sports animals, or pet animals, such as dogs, cats, guinea pigs, rabbits, rats or mice.
• the subject is a human.
• the subject is a non-human mammal, such as a mouse.
• the term “sufficient amount” means an amount sufficient to produce a desired effect.
• the term “therapeutically effective amount” is an amount that is effective to ameliorate a symptom of a disease or disorder.
• a therapeutically effective amount can be a “prophylactically effective amount” as prophylaxis can be considered therapy.
• a disease or disorder is “ameliorated” if the severity of a sign or symptom of the disease or disorder, the frequency with which such a sign or symptom is experienced by a subject, or both, is reduced (compared to an earlier point in time, for example, prior to administration of any antibody).
• treating a disease or disorder means reducing the frequency and/or severity of at least one sign or symptom of the disease or disorder experienced by a subject (compared to an earlier point in time, for example, prior to administration of any antibody).
• Cancer refers to the abnormal growth or division of cells. Generally, the growth and/or life span of a cancer cell exceeds, and is not coordinated with, that of the normal cells and tissues around it. Cancers may be benign, pre-malignant or malignant.
• Cancer occurs in a variety of cells and tissues, including the oral cavity (e.g., mouth, tongue, pharynx, etc.), digestive system (e.g., esophagus, stomach, small intestine, colon, rectum, liver, bile duct, gall bladder, pancreas, etc.), respiratory system (e.g., larynx, lung, bronchus, etc.), bones, joints, skin (e.g., basal cell, squamous cell, meningioma, etc.), breast, genital system, (e.g., uterus, ovary, prostate, testis, etc.), urinary system (e.g., bladder, kidney, ureter, etc.), eye, nervous system (e.g., brain, etc.), endocrine system (e.g., thyroid, etc.), and hematopoietic system (e.g., lymphoma, myeloma, leukemia, acute lymphocytic le
• the term “about” when used herein includes up to and including 10% greater and up to and including 10% lower than the value specified, suitably up to and including 5% greater and up to and including 5% lower than the value specified, especially the value specified.
• the term “between”, includes the values of the specified boundaries.
• multispecific antibodies capable of specifically binding to the delta variable 1 chain (V61) of a gd T Cell Receptor (TCR), and also capable of specifically binding to EGFR.
• the invention relates to the use of said antibodies as medicaments for administration to a subject to be treated.
• the antibody or antigen-binding fragment thereof is an scFv, Fab, Fab’, F(ab')2, Fv, variable domain (e.g. VH or VL), diabody, minibody or monoclonal antibody.
• the antibody or antigen-binding fragment thereof is an scFv.
• Multispecific antibodies of the invention can be of any class, e.g. IgG, IgA, IgM, IgE, IgD, or isotypes thereof, and can comprise a kappa or lambda light chain.
• the antibody is an IgG antibody, for example, at least one of isotypes, lgG1 , lgG2, lgG3 or lgG4.
• the antibody may be in a format, such as an IgG format, that has been modified to confer desired properties, such as having the Fc mutated to reduce effector function, extend half-life, alter ADCC, or improve hinge stability. Such modifications are well known in the art.
• the antibody or antigen-binding fragment thereof is human.
• the antibody or antigen-binding fragment thereof may be derived from a human immunoglobulin (Ig) sequence.
• the CDR, framework and/or constant region of the antibody (or antigen-binding fragment thereof) may be derived from a human Ig sequence, in particular a human IgG sequence.
• the CDR, framework and/or constant region may be substantially identical for a human Ig sequence, in particular a human IgG sequence.
• An antibody or antigen-binding fragment thereof can also be chimeric, for example a mouse-human antibody chimera.
• the antibody or antigen-binding fragment thereof is derived from a non-human species, such as a mouse.
• a non-human species such as a mouse.
• Such non-human antibodies can be modified to increase their similarity to antibody variants produced naturally in humans, thus the antibody or antigen-binding fragment thereof can be partially or fully humanised. Therefore, in one embodiment, the antibody or antigen-binding fragment thereof is humanised.
• the present invention provides multispecific antibodies wherein the Fab regions are derived from parental antibody ADT1 -4 (having a variable heavy region sequence according to SEQ ID NO: 1 and a variable light region sequence according to SEQ ID NO: 26), and antibodies derived from parental antibody ADT1-7 (having a variable heavy region sequence according to SEQ ID NO: 106 and a variable light region sequence according to SEQ ID No: 118).
• ADT1-4 is also referred to herein as G04, and ADT1-4 and G04 are used interchangeably.
• ADT1-7 is also referred to herein as E07, and ADT1-7 and E07 are used interchangeably.
• the invention provides multispecific antibodies, the anti-TCR delta variable 1 (anti- V 1) binding Fab region comprising: a heavy chain variable region comprising or consisting of a VHCDR3 comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to a sequence selected from the group consisting of SEQ ID NOs: 55 to 78 and 133 to 143; and/or a light chain variable region comprising a VLCDR3 comprising or consisting of an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or
• the invention provides multispecific antibodies, the anti-TCR delta variable 1 (anti- V61) binding Fab region comprising: a heavy chain variable region comprising: a VHCDR1 comprising or consisting of an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to a sequence selected from the group consisting of: SEQ ID NOs: 51, 52 and 130; a VHCDR2 comprising or consisting of an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to a sequence selected from the group consisting of: SEQ ID NOs: 51
• VLCDR2 comprising or consisting of an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to a sequence selected from the group consisting of: SEQ ID NO:
• VLCDR3 comprising or consisting of an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to a sequence selected from the group consisting of: SEQ ID NOs: 82 to 105 and 147 to 157.
• Certain amino acid substitutions may be made to provide one or more variant Fab regions as described herein.
• the invention provides multispecific antibodies, the anti-TCR delta variable 1 (anti- V61) binding Fab region comprising: a heavy chain variable region comprising or consisting of a sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to a sequence selected from the group consisting of SEQ ID NOs: 2 to 25 and 107 to 117; and/or a light chain variable region comprising or consisting of a sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to a sequence selected from the group consisting of SEQ ID NOs: 27 to 50
• the present invention provides multispecific antibodies comprising Fab regions derived from parental antibody ADT1 -4 (having a variable heavy region sequence according to SEQ ID NO: 1 and a variable light region sequence according to SEQ ID NO: 26), for example as set out in the following.
• ADT1-4 is also referred to herein as G04, and ADT1-4 and G04 are used interchangeably.
• Antibodies comprising particular CDR sequences derived from ADT1-4
• the multispecific antibodies provided herein include the following Fab regions having particular sequences derived from ADT1-4.
• multispecific antibodies the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising or consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 55 to 78; and/or a light chain variable region comprising a VLCDR3 comprising or consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 82 to 105.
• Certain amino acid substitutions may be made to provide one or more variant antibodies as described herein.
• the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising or consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 55 to 77; and/or a light chain variable region comprising a VLCDR3 comprising or consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 82 to 104. Certain amino acid substitutions may be made to provide one or more variant antibodies as described herein.
• the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising or consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 58, 60, 61 , 62, 65, 66, 68, 74, 76 and 77; and/or a light chain variable region comprising a VLCDR3 comprising or consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 85, 87, 88, 89, 92, 93, 95, 101 , 103 and 104. Certain amino acid substitutions may be made to provide one or more variant antibodies as described herein.
• the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising: a VHCDR1 comprising or consisting of an amino acid sequence selected from the group consisting of: SEQ ID NOs: 51 and 52; a VHCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO:
• VHCDR3 comprising or consisting of an amino acid sequence selected from the group consisting of: SEQ ID NOs: 55 to 78; and a light chain variable region comprising: a VLCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 79; a VLCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO:
• VLCDR3 comprising or consisting of an amino acid sequence selected from the group consisting of: SEQ ID NOs: 82 to 105.
• Certain amino acid substitutions may be made to provide one or more variant antibodies as described herein.
• the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising: a VHCDR1 comprising or consisting of an amino acid sequence selected from the group consisting of: SEQ ID NOs: 51 and 52; a VHCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO:
• VHCDR3 comprising or consisting of an amino acid sequence selected from the group consisting of: SEQ ID NOs: 55 to 77; and a light chain variable region comprising: a VLCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 79; a VLCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO:
• VLCDR3 comprising or consisting of an amino acid sequence selected from the group consisting of: SEQ ID NOs: 82 to 104.
• Certain amino acid substitutions may be made to provide one or more variant antibodies as described herein.
• anti-TCR delta variable 1 (anti-V 1) binding Fab region comprising: a heavy chain variable region comprising: a VHCDR1 comprising or consisting of an amino acid sequence selected from the group consisting of: SEQ ID NOs: 51 and 52; a VHCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO:
• VHCDR3 comprising or consisting of an amino acid sequence selected from the group consisting of: SEQ ID NOs: 58, 60, 61 , 62, 65, 66, 68, 74, 76 and 77; and a light chain variable region comprising: a VLCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 79; a VLCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO:
• VLCDR3 comprising or consisting of an amino acid sequence selected from the group consisting of: SEQ ID NOs: 85, 87, 88, 89, 92, 93, 95, 101 , 103 and 104.
• Certain amino acid substitutions may be made to provide one or more variant antibodies as described herein.
• the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising a) a VHCDR1 , a VHCDR2 and a VHCDR3 comprising or consisting of the amino acid sequences of SEQ ID NO: 51 , 53 and 55, respectively, and a VLCDR1 , a VLCDR2 and a VLCDR3 comprising or consisting of the amino acid sequences of SEQ ID NOs: 79, 80 and 82, respectively; b) a VHCDR1 , a VHCDR2 and a VHCDR3 comprising or consisting of the amino acid sequences of SEQ ID NO: 51 , 53 and 56, respectively, and a VLCDR1 , a VLCDR2 and a VLCDR3 comprising or consisting of the amino acid sequences of SEQ ID NOs: 79, 80 and 83, respectively; c) a VHCDR1 , a VHCDR2 and a VHCDR3 comprising or consisting of the amino acid sequence
• VHCDR1 , a VHCDR2 and a VHCDR3 comprising or consisting of the amino acid sequences of SEQ ID NO: 52, 53 and 66, respectively, and a VLCDR1 , a VLCDR2 and a VLCDR3 comprising or consisting of the amino acid sequences of SEQ ID NOs: 79, 80 and 93, respectively;
• n) a VHCDR1 , a VHCDR2 and a VHCDR3 comprising or consisting of the amino acid sequences of SEQ ID NO: 51 , 53 and 68, respectively, and a V
• the multispecific antibodies may comprise a kappa light chain variable sequence (or comprise a variable light chain that is derived from a kappa light chain variable sequence), wherein the residue at position 74 of the kappa light chain variable sequence according to the IMGT numbering system is not serine, for example a non-human-germline residue and/or a non-polar residue at position 74, for example the residue at position 74 is a leucine residue.
• Certain embodiments relate to the antibody ADT 1 -4-105 and fragments and variants thereof.
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 55 and/or a light chain variable region comprising a VLCDR3 comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 82.
• an antibody or antigen-binding-fragment or variant thereof comprising a heavy chain variable region comprising a VHCDR3 comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 55 and/or a light chain variable region comprising a VLCDR3 comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 82.
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 55 and/or a light chain variable region comprising a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 82.
• Amino acid substitutions may be made to provide variant antibodies with Fab regions derived from ADT1- 4-105, for example multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 55, optionally comprising 1 or 2 amino acid substitutions, and/or a light chain variable region comprising a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 82, optionally comprising 1 or 2 amino acid substitutions.
• the amino acid substitutions may be conservative amino acid substitutions.
• the anti-TCR delta variable 1 (anti-V51) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 51 , a VHCDR2 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 53 and a VHCDR3 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 99% or 100% identity to the amino acid
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 51 , a VHCDR2 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 53 and a VHCDR3 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 55; and/or a light chain variable region comprising a VLCDR1 comprising the at least 90% identity to the amino acid sequence of SEQ ID NO: 79, a VLCDR2 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 80 and a VLCDR3 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 82.
• a heavy chain variable region comprising a VHCDR1 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 51
• a VHCDR2 comprising at least 90% identity to the amino acid sequence of
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V51) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence of SEQ ID NO: 51 , a VHCDR2 comprising the amino acid sequence of SEQ ID NO: 53 and a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 55; and a light chain variable region comprising a VLCDR1 comprising the amino acid sequence of SEQ ID NO: 79, a VLCDR2 comprising the amino acid sequence of SEQ ID NO: 80 and a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 82.
• Amino acid substitutions may be made to provide variant antibodies with Fab regions derived from ADT1- 4-105, for example multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence of SEQ ID NO: 51 optionally comprising 1 or 2 amino acid substitutions, a VHCDR2 comprising the amino acid sequence of SEQ ID NO: 53 optionally comprising 1 or 2 amino acid substitutions, and a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 55 optionally comprising 1 or 2 amino acid substitutions; and/or a light chain variable region comprising a VLCDR1 comprising the amino acid sequence of SEQ ID NO: 79 optionally comprising 1 or 2 amino acid substitutions, a VLCDR2 comprising the amino acid sequence of SEQ ID NO: 80 optionally comprising 1 or 2 amino acid substitutions and a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 82 optionally
• the antibodies may alternatively consist of the specified sequences (with or without amino acid substitutions).
• Certain embodiments relate to the antibody ADT 1 -4-107 and fragments and variants thereof.
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 56 and/or a light chain variable region comprising a VLCDR3 comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO:83.
• an antibody or antigen-binding-fragment or variant thereof comprising a heavy chain variable region comprising a VHCDR3 comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 56 and/or a light chain variable region comprising a VLCDR3 comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 83.
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 56 and/or a light chain variable region comprising a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 83.
• Amino acid substitutions may be made to provide variant antibodies comprising Fab regions derived from ADT1-4-107, for example multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V51) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 56, optionally comprising 1 or 2 amino acid substitutions, and/or a light chain variable region comprising a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 83, optionally comprising 1 or 2 amino acid substitutions.
• the amino acid substitutions may be conservative amino acid substitutions.
• the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 51 , a VHCDR2 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 53 and a VHCDR3 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 99% or 100% identity to the amino acid
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VFICDR1 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 51 , a VFICDR2 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 53 and a VFICDR3 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 56; and/or a light chain variable region comprising a VLCDR1 comprising the at least 90% identity to the amino acid sequence of SEQ ID NO: 79, a VLCDR2 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 80 and a VLCDR3 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 83.
• a heavy chain variable region comprising a VFICDR1 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 51
• a VFICDR2 comprising at least 90% identity to
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VFICDR1 comprising the amino acid sequence of SEQ ID NO: 51 , a VFICDR2 comprising the amino acid sequence of SEQ ID NO: 53 and a VFICDR3 comprising the amino acid sequence of SEQ ID NO: 56; and a light chain variable region comprising a VLCDR1 comprising the amino acid sequence of SEQ ID NO: 79, a VLCDR2 comprising the amino acid sequence of SEQ ID NO: 80 and a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 83.
• Amino acid substitutions may be made to provide variant antibodies comprising Fab regions derived from ADT1-4-107, for example multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence of SEQ ID NO: 51 optionally comprising 1 or 2 amino acid substitutions, a VHCDR2 comprising the amino acid sequence of SEQ ID NO: 53 optionally comprising 1 or 2 amino acid substitutions, and a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 56 optionally comprising 1 or 2 amino acid substitutions; and/or a light chain variable region comprising a VLCDR1 comprising the amino acid sequence of SEQ ID NO: 79 optionally comprising 1 or 2 amino acid substitutions, a VLCDR2 comprising the amino acid sequence of SEQ ID NO: 80 optionally comprising 1 or 2 amino acid substitutions and a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 83 optionally
• the antibodies may alternatively consist of the specified sequences (with or without amino acid substitutions).
• Certain embodiments relate to the antibody ADT 1 -4-110 and fragments and variants thereof.
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 57 and/or a light chain variable region comprising a VLCDR3 comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 84.
• an antibody or antigen-binding-fragment or variant thereof comprising a heavy chain variable region comprising a VHCDR3 comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 57 and/or a light chain variable region comprising a VLCDR3 comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 84.
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 57 and/or a light chain variable region comprising a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 84.
• Amino acid substitutions may be made to provide variant antibodies comprising Fab regions derived from ADT1-4-110, for example multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V51) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 57, optionally comprising 1 or 2 amino acid substitutions, and/or a light chain variable region comprising a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 84, optionally comprising 1 or 2 amino acid substitutions.
• the amino acid substitutions may be conservative amino acid substitutions.
• the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 51 , a VHCDR2 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 53 and a VHCDR3 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 99% or 100% identity to the amino acid
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 51 , a VHCDR2 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 53 and a VHCDR3 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 57; and/or a light chain variable region comprising a VLCDR1 comprising the at least 90% identity to the amino acid sequence of SEQ ID NO: 79, a VLCDR2 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 80 and a VLCDR3 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 84.
• a heavy chain variable region comprising a VHCDR1 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 51
• a VHCDR2 comprising at least 90% identity to the amino acid sequence
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence of SEQ ID NO: 51 , a VHCDR2 comprising the amino acid sequence of SEQ ID NO: 53 and a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 57; and a light chain variable region comprising a VLCDR1 comprising the amino acid sequence of SEQ ID NO: 79, a VLCDR2 comprising the amino acid sequence of SEQ ID NO: 80 and a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 84.
• Amino acid substitutions may be made to provide variant antibodies comprising Fab regions derived from ADT1-4-110, for example multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V51) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence of SEQ ID NO: 51 optionally comprising 1 or 2 amino acid substitutions, a VHCDR2 comprising the amino acid sequence of SEQ ID NO: 53 optionally comprising 1 or 2 amino acid substitutions, and a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 57 optionally comprising 1 or 2 amino acid substitutions; and/or a light chain variable region comprising a VLCDR1 comprising the amino acid sequence of SEQ ID NO: 79 optionally comprising 1 or 2 amino acid substitutions, a VLCDR2 comprising the amino acid sequence of SEQ ID NO: 80 optionally comprising 1 or 2 amino acid substitutions and a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 84 optional
• the antibodies may alternatively consist of the specified sequences (with or without amino acid substitutions).
• Certain embodiments relate to the antibody ADT1 -4-112 and fragments and variants thereof.
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 58 and/or a light chain variable region comprising a VLCDR3 comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 85.
• an antibody or antigen-binding-fragment or variant thereof comprising a heavy chain variable region comprising a VHCDR3 comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 58 and/or a light chain variable region comprising a VLCDR3 comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 85.
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 58 and/or a light chain variable region comprising a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 85.
• Amino acid substitutions may be made to provide variant antibodies having Fab regions derived from ADT1- 4-112, for example multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 58, optionally comprising 1 or 2 amino acid substitutions, and/or a light chain variable region comprising a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 85, optionally comprising 1 or 2 amino acid substitutions.
• the amino acid substitutions may be conservative amino acid substitutions.
• the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 51 , a VHCDR2 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 53 and a VHCDR3 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 99% or 100% identity to the amino acid
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab regioncomprising: a heavy chain variable region comprising a VHCDR1 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 51 , a VHCDR2 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 53 and a VHCDR3 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 58; and/or a light chain variable region comprising a VLCDR1 comprising the at least 90% identity to the amino acid sequence of SEQ ID NO: 79, a VLCDR2 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 80 and a VLCDR3 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 85.
• a heavy chain variable region comprising a VHCDR1 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 51
• a VHCDR2 comprising at least 90% identity to the amino acid
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence of SEQ ID NO: 51 , a VHCDR2 comprising the amino acid sequence of SEQ ID NO: 53 and a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 58; and a light chain variable region comprising a VLCDR1 comprising the amino acid sequence of SEQ ID NO: 79, a VLCDR2 comprising the amino acid sequence of SEQ ID NO: 80 and a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 85.
• Amino acid substitutions may be made to provide variant antibodies with Fab regions derived from ADT1- 4-112, for example multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence of SEQ ID NO: 51 optionally comprising 1 or 2 amino acid substitutions, a VHCDR2 comprising the amino acid sequence of SEQ ID NO: 53 optionally comprising 1 or 2 amino acid substitutions, and a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 58 optionally comprising 1 or 2 amino acid substitutions; and/or a light chain variable region comprising a VLCDR1 comprising the amino acid sequence of SEQ ID NO: 79 optionally comprising 1 or 2 amino acid substitutions, a VLCDR2 comprising the amino acid sequence of SEQ ID NO: 80 optionally comprising 1 or 2 amino acid substitutions and a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 85 optionally
• the antibodies may alternatively consist of the specified sequences (with or without amino acid substitutions).
• Certain embodiments relate to the antibody ADT 1 -4-117 and fragments and variants thereof.
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 59 and/or a light chain variable region comprising a VLCDR3 comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 86.
• an antibody or antigen-binding-fragment or variant thereof comprising a heavy chain variable region comprising a VHCDR3 comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 59 and/or a light chain variable region comprising a VLCDR3 comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 86.
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 59 and/or a light chain variable region comprising a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 86.
• Amino acid substitutions may be made to provide variant antibodies with Fab regions derived from ADT1- 4-117, for example multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 59, optionally comprising 1 or 2 amino acid substitutions, and/or a light chain variable region comprising a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 86, optionally comprising 1 or 2 amino acid substitutions.
• the amino acid substitutions may be conservative amino acid substitutions.
• the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 51 , a VHCDR2 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 53 and a VHCDR3 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 99% or 100% identity to the amino acid
• the anti-TCR delta variable 1 (anti-V 1) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 51 , a VHCDR2 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 53 and a VHCDR3 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 59; and/or a light chain variable region comprising a VLCDR1 comprising the at least 90% identity to the amino acid sequence of SEQ ID NO: 79, a VLCDR2 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 80 and a VLCDR3 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 86.
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V51) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence of SEQ ID NO: 51 , a VHCDR2 comprising the amino acid sequence of SEQ ID NO: 53 and a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 59; and a light chain variable region comprising a VLCDR1 comprising the amino acid sequence of SEQ ID NO: 79, a VLCDR2 comprising the amino acid sequence of SEQ ID NO: 80 and a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 86.
• Amino acid substitutions may be made to provide variant antibodies with Fab regions derived from ADT1- 4-117, for example multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence of SEQ ID NO: 51 optionally comprising 1 or 2 amino acid substitutions, a VHCDR2 comprising the amino acid sequence of SEQ ID NO: 53 optionally comprising 1 or 2 amino acid substitutions, and a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 59 optionally comprising 1 or 2 amino acid substitutions; and/or a light chain variable region comprising a VLCDR1 comprising the amino acid sequence of SEQ ID NO: 79 optionally comprising 1 or 2 amino acid substitutions, a VLCDR2 comprising the amino acid sequence of SEQ ID NO: 80 optionally comprising 1 or 2 amino acid substitutions and a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 86 optional
• the antibodies may alternatively consist of the specified sequences (with or without amino acid substitutions).
• Certain embodiments relate to the antibody ADT 1 -4-19 and fragments and variants thereof.
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V 1) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 60 and/or a light chain variable region comprising a VLCDR3 comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 87.
• anti-V 1 (anti-V 1) binding Fab region comprising
• an antibody or antigen-binding-fragment or variant thereof comprising a heavy chain variable region comprising a VHCDR3 comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 60 and/or a light chain variable region comprising a VLCDR3 comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 87.
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 60 and/or a light chain variable region comprising a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 87.
• Amino acid substitutions may be made to provide variant antibodies comprising Fab regions derived from ADT1-4-19, for example multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 60, optionally comprising 1 or 2 amino acid substitutions, and/or a light chain variable region comprising a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 87, optionally comprising 1 or 2 amino acid substitutions.
• the amino acid substitutions may be conservative amino acid substitutions.
• the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 51 , a VHCDR2 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 53 and a VHCDR3 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 99% or 100% identity to the amino acid
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V51) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 51 , a VHCDR2 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 53 and a VHCDR3 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 60; and/or a light chain variable region comprising a VLCDR1 comprising the at least 90% identity to the amino acid sequence of SEQ ID NO: 79, a VLCDR2 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 80 and a VLCDR3 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 87.
• a heavy chain variable region comprising a VHCDR1 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 51
• a VHCDR2 comprising at least 90% identity to the amino acid sequence of
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V51) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence of SEQ ID NO: 51 , a VHCDR2 comprising the amino acid sequence of SEQ ID NO: 53 and a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 60; and a light chain variable region comprising a VLCDR1 comprising the amino acid sequence of SEQ ID NO: 79, a VLCDR2 comprising the amino acid sequence of SEQ ID NO: 80 and a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 87.
• Amino acid substitutions may be made to provide variant antibodies with Fab regions derived from ADT1- 4-19, for example multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence of SEQ ID NO: 51 optionally comprising 1 or 2 amino acid substitutions, a VHCDR2 comprising the amino acid sequence of SEQ ID NO: 53 optionally comprising 1 or 2 amino acid substitutions, and a VFICDR3 comprising the amino acid sequence of SEQ ID NO: 60 optionally comprising 1 or 2 amino acid substitutions; and/or a light chain variable region comprising a VLCDR1 comprising the amino acid sequence of SEQ ID NO: 79 optionally comprising 1 or 2 amino acid substitutions, a VLCDR2 comprising the amino acid sequence of SEQ ID NO: 80 optionally comprising 1 or 2 amino acid substitutions and a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 87 optional
• the antibodies may alternatively consist of the specified sequences (with or without amino acid substitutions).
• Certain embodiments relate to the antibody ADT 1 -4-21 and fragments and variants thereof.
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VFICDR3 comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 61 and/or a light chain variable region comprising a VLCDR3 comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 88.
• an antibody or antigen-binding-fragment or variant thereof comprising a heavy chain variable region comprising a VHCDR3 comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 61 and/or a light chain variable region comprising a VLCDR3 comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 88.
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 61 and/or a light chain variable region comprising a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 88.
• Amino acid substitutions may be made to provide variant antibodies with Fab regions derived from ADT1- 4-21, for example multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab regioncomprising a heavy chain variable region comprising a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 61 , optionally comprising 1 or 2 amino acid substitutions, and/or a light chain variable region comprising a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 88, optionally comprising 1 or 2 amino acid substitutions.
• the amino acid substitutions may be conservative amino acid substitutions.
• the anti-TCR delta variable 1 (anti-V51) binding Fab region comprising: a heavy chain variable region comprising a VFICDR1 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 52, a VFICDR2 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 53 and a VFICDR3 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V51) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 52, a VHCDR2 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 53 and a VHCDR3 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 61 ; and/or a light chain variable region comprising a VLCDR1 comprising the at least 90% identity to the amino acid sequence of SEQ ID NO: 79, a VLCDR2 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 80 and a VLCDR3 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 88.
• a heavy chain variable region comprising a VHCDR1 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 52, a VHCDR2 comprising at least 90% identity to the amino acid sequence of
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence of SEQ ID NO: 52, a VHCDR2 comprising the amino acid sequence of SEQ ID NO: 53 and a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 61 ; and a light chain variable region comprising a VLCDR1 comprising the amino acid sequence of SEQ ID NO: 79, a VLCDR2 comprising the amino acid sequence of SEQ ID NO: 80 and a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 88.
• Amino acid substitutions may be made to provide variant antibodies comprising Fab regions derived from ADT1-4-21 , for example multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence of SEQ ID NO: 52 optionally comprising 1 or 2 amino acid substitutions, a VHCDR2 comprising the amino acid sequence of SEQ ID NO: 53 optionally comprising 1 or 2 amino acid substitutions, and a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 61 optionally comprising 1 or 2 amino acid substitutions; and/or a light chain variable region comprising a VLCDR1 comprising the amino acid sequence of SEQ ID NO: 79 optionally comprising 1 or 2 amino acid substitutions, a VLCDR2 comprising the amino acid sequence of SEQ ID NO: 80 optionally comprising 1 or 2 amino acid substitutions and a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 88 optional
• the antibodies may alternatively consist of the specified sequences (with or without amino acid substitutions).
• Certain embodiments relate to the antibody ADT 1 -4-31 and fragments and variants thereof.
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 62 and/or a light chain variable region comprising a VLCDR3 comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 89.
• an antibody or antigen-binding-fragment or variant thereof comprising a heavy chain variable region comprising a VHCDR3 comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 62 and/or a light chain variable region comprising a VLCDR3 comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 89.
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 62 and/or a light chain variable region comprising a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 89.
• Amino acid substitutions may be made to provide variant antibodies having Fab regions derived from ADT1- 4-31, for example multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab regioncomprising a heavy chain variable region comprising a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 62, optionally comprising 1 or 2 amino acid substitutions, and/or a light chain variable region comprising a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 89, optionally comprising 1 or 2 amino acid substitutions.
• the amino acid substitutions may be conservative amino acid substitutions.
• the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 51 , a VHCDR2 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 53 and a VHCDR3 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 99% or 100% identity to the amino acid
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V51) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 51 , a VHCDR2 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 53 and a VHCDR3 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 62; and/or a light chain variable region comprising a VLCDR1 comprising the at least 90% identity to the amino acid sequence of SEQ ID NO: 79, a VLCDR2 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 80 and a VLCDR3 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 89.
• a heavy chain variable region comprising a VHCDR1 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 51
• a VHCDR2 comprising at least 90% identity to the amino acid sequence
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence of SEQ ID NO: 51 , a VHCDR2 comprising the amino acid sequence of SEQ ID NO: 53 and a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 62; and a light chain variable region comprising a VLCDR1 comprising the amino acid sequence of SEQ ID NO: 79, a VLCDR2 comprising the amino acid sequence of SEQ ID NO: 80 and a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 89.
• Amino acid substitutions may be made to provide variant antibodies having Fab regions derived from ADT1- 4-31, for example multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence of SEQ ID NO: 51 optionally comprising 1 or 2 amino acid substitutions, a VHCDR2 comprising the amino acid sequence of SEQ ID NO: 53 optionally comprising 1 or 2 amino acid substitutions, and a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 62 optionally comprising 1 or 2 amino acid substitutions; and/or a light chain variable region comprising a VLCDR1 comprising the amino acid sequence of SEQ ID NO: 79 optionally comprising 1 or 2 amino acid substitutions, a VLCDR2 comprising the amino acid sequence of SEQ ID NO: 80 optionally comprising 1 or 2 amino acid substitutions and a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 89 optional
• the antibodies may alternatively consist of the specified sequences (with or without amino acid substitutions).
• the anti-TCR delta variable 1 (anti-V51) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 63 and/or a light chain variable region comprising a VLCDR3 comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to
• an antibody or antigen-binding-fragment or variant thereof comprising a heavy chain variable region comprising a VHCDR3 comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 63 and/or a light chain variable region comprising a VLCDR3 comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 90.
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 63 and/or a light chain variable region comprising a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 90.
• Amino acid substitutions may be made to provide variant antibodies having Fab regions derived from ADT1- 4-139, for example multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 63, optionally comprising 1 or 2 amino acid substitutions, and/or a light chain variable region comprising a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 90, optionally comprising 1 or 2 amino acid substitutions.
• the amino acid substitutions may be conservative amino acid substitutions.
• the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 51 , a VHCDR2 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 53 and a VHCDR3 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 99% or 100% identity to the amino acid
• the anti-TCR delta variable 1 (anti-V 1) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 51 , a VHCDR2 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 53 and a VHCDR3 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 63; and/or a light chain variable region comprising a VLCDR1 comprising the at least 90% identity to the amino acid sequence of SEQ ID NO: 79, a VLCDR2 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 80 and a VLCDR3 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 90.
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V51) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence of SEQ ID NO: 51 , a VHCDR2 comprising the amino acid sequence of SEQ ID NO: 53 and a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 63; and a light chain variable region comprising a VLCDR1 comprising the amino acid sequence of SEQ ID NO: 79, a VLCDR2 comprising the amino acid sequence of SEQ ID NO: 80 and a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 90.
• Amino acid substitutions may be made to provide variant antibodies having Fab regions derived from ADT1- 4-139, for example multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence of SEQ ID NO: 51 optionally comprising 1 or 2 amino acid substitutions, a VHCDR2 comprising the amino acid sequence of SEQ ID NO: 53 optionally comprising 1 or 2 amino acid substitutions, and a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 63 optionally comprising 1 or 2 amino acid substitutions; and/or a light chain variable region comprising a VLCDR1 comprising the amino acid sequence of SEQ ID NO: 79 optionally comprising 1 or 2 amino acid substitutions, a VLCDR2 comprising the amino acid sequence of SEQ ID NO: 80 optionally comprising 1 or 2 amino acid substitutions and a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 90 optionally
• the antibodies may alternatively consist of the specified sequences (with or without amino acid substitutions).
• Certain embodiments relate to the antibody ADT1 -4-4 and fragments and variants thereof.
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V51) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 64 and/or a light chain variable region comprising a VLCDR3 comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 91.
• an antibody or antigen-binding-fragment or variant thereof comprising a heavy chain variable region comprising a VHCDR3 comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 64 and/or a light chain variable region comprising a VLCDR3 comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 91.
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 64 and/or a light chain variable region comprising a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 91.
• Amino acid substitutions may be made to provide variant antibodies having Fab regions derived from ADT1- 4-4, for example multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V51) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 64, optionally comprising 1 or 2 amino acid substitutions, and/or a light chain variable region comprising a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 91 , optionally comprising 1 or 2 amino acid substitutions.
• the amino acid substitutions may be conservative amino acid substitutions.
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab regioncomprising: a heavy chain variable region comprising a VHCDR1 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 51 , a VHCDR2 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 53 and a VHCDR3 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 51 , a VHCDR2 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 53 and a VHCDR3 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 64; and/or a light chain variable region comprising a VLCDR1 comprising the at least 90% identity to the amino acid sequence of SEQ ID NO: 79, a VLCDR2 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 80 and a VLCDR3 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 91.
• a heavy chain variable region comprising a VHCDR1 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 51
• a VHCDR2 comprising at least 90% identity to the amino acid sequence of
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence of SEQ ID NO: 51 , a VHCDR2 comprising the amino acid sequence of SEQ ID NO: 53 and a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 64; and a light chain variable region comprising a VLCDR1 comprising the amino acid sequence of SEQ ID NO: 79, a VLCDR2 comprising the amino acid sequence of SEQ ID NO: 80 and a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 91.
• Amino acid substitutions may be made to provide variant antibodies having Fab regions derived from ADT1- 4-4, for example multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V51) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence of SEQ ID NO: 51 optionally comprising 1 or 2 amino acid substitutions, a VHCDR2 comprising the amino acid sequence of SEQ ID NO: 53 optionally comprising 1 or 2 amino acid substitutions, and a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 64 optionally comprising 1 or 2 amino acid substitutions; and/or a light chain variable region comprising a VLCDR1 comprising the amino acid sequence of SEQ ID NO: 79 optionally comprising 1 or 2 amino acid substitutions, a VLCDR2 comprising the amino acid sequence of SEQ ID NO: 80 optionally comprising 1 or 2 amino acid substitutions and a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 91 optionally
• Certain embodiments relate to the antibody ADT1 -4-143 and fragments and variants thereof.
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 65 and/or a light chain variable region comprising a VLCDR3 comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 92.
• an antibody or antigen-binding-fragment or variant thereof comprising a heavy chain variable region comprising a VHCDR3 comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 65 and/or a light chain variable region comprising a VLCDR3 comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 92.
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 65 and/or a light chain variable region comprising a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 92.
• Amino acid substitutions may be made to provide variant antibodies having Fab regions derived from ADT1- 4-143, for example multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 65, optionally comprising 1 or 2 amino acid substitutions, and/or a light chain variable region comprising a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 92, optionally comprising 1 or 2 amino acid substitutions.
• the amino acid substitutions may be conservative amino acid substitutions.
• the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 51 , a VHCDR2 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 53 and a VHCDR3 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 99% or 100% identity to the amino acid
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 51 , a VHCDR2 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 53 and a VHCDR3 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 65; and/or a light chain variable region comprising a VLCDR1 comprising the at least 90% identity to the amino acid sequence of SEQ ID NO: 79, a VLCDR2 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 80 and a VLCDR3 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 92.
• a heavy chain variable region comprising a VHCDR1 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 51
• a VHCDR2 comprising at least 90% identity to the amino acid sequence of
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V51) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence of SEQ ID NO: 51 , a VHCDR2 comprising the amino acid sequence of SEQ ID NO: 53 and a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 65; and a light chain variable region comprising a VLCDR1 comprising the amino acid sequence of SEQ ID NO: 79, a VLCDR2 comprising the amino acid sequence of SEQ ID NO: 80 and a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 92.
• Amino acid substitutions may be made to provide variant antibodies having Fab regions derived from ADT1- 4-143, for example multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence of SEQ ID NO: 51 optionally comprising 1 or 2 amino acid substitutions, a VHCDR2 comprising the amino acid sequence of SEQ ID NO: 53 optionally comprising 1 or 2 amino acid substitutions, and a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 65 optionally comprising 1 or 2 amino acid substitutions; and/or a light chain variable region comprising a VLCDR1 comprising the amino acid sequence of SEQ ID NO: 79 optionally comprising 1 or 2 amino acid substitutions, a VLCDR2 comprising the amino acid sequence of SEQ ID NO: 80 optionally comprising 1 or 2 amino acid substitutions and a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 92 optionally
• the antibodies may alternatively consist of the specified sequences (with or without amino acid substitutions).
• Certain embodiments relate to the antibody ADT1-4-53 and fragments and variants thereof.
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 66 and/or a light chain variable region comprising a VLCDR3 comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 93.
• an antibody or antigen-binding-fragment or variant thereof comprising a heavy chain variable region comprising a VHCDR3 comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 66 and/or a light chain variable region comprising a VLCDR3 comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 93.
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 66 and/or a light chain variable region comprising a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 93.
• Amino acid substitutions may be made to provide variant antibodies having Fab regions derived from ADT1- 4-53, for example multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 66, optionally comprising 1 or 2 amino acid substitutions, and/or a light chain variable region comprising a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 93, optionally comprising 1 or 2 amino acid substitutions.
• the amino acid substitutions may be conservative amino acid substitutions.
• the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 52, a VHCDR2 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 53 and a VHCDR3 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 52, a VHCDR2 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 53 and a VHCDR3 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 66; and/or a light chain variable region comprising a VLCDR1 comprising the at least 90% identity to the amino acid sequence of SEQ ID NO: 79, a VLCDR2 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 80 and a VLCDR3 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 93.
• a heavy chain variable region comprising a VHCDR1 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 52, a VHCDR2 comprising at least 90% identity to the amino acid sequence of S
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence of SEQ ID NO: 52, a VHCDR2 comprising the amino acid sequence of SEQ ID NO: 53 and a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 66; and a light chain variable region comprising a VLCDR1 comprising the amino acid sequence of SEQ ID NO: 79, a VLCDR2 comprising the amino acid sequence of SEQ ID NO: 80 and a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 93.
• Amino acid substitutions may be made to provide variant antibodies having Fab regions derived from ADT1- 4-53, for example multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence of SEQ ID NO: 52 optionally comprising 1 or 2 amino acid substitutions, a VHCDR2 comprising the amino acid sequence of SEQ ID NO: 53 optionally comprising 1 or 2 amino acid substitutions, and a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 66 optionally comprising 1 or 2 amino acid substitutions; and/or a light chain variable region comprising a VLCDR1 comprising the amino acid sequence of SEQ ID NO: 79 optionally comprising 1 or 2 amino acid substitutions, a VLCDR2 comprising the amino acid sequence of SEQ ID NO: 80 optionally comprising 1 or 2 amino acid substitutions and a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 93 optional
• the antibodies may alternatively consist of the specified sequences (with or without amino acid substitutions).
• Certain embodiments relate to the antibody ADT 1 -4-173 and fragments and variants thereof.
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 67 and/or a light chain variable region comprising a VLCDR3 comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 94.
• an antibody or antigen-binding-fragment or variant thereof comprising a heavy chain variable region comprising a VHCDR3 comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 67 and/or a light chain variable region comprising a VLCDR3 comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 94.
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 67 and/or a light chain variable region comprising a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 94.
• Amino acid substitutions may be made to provide variant antibodies having Fab regions derived from ADT1- 4-173, for example multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 67, optionally comprising 1 or 2 amino acid substitutions, and/or a light chain variable region comprising a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 94, optionally comprising 1 or 2 amino acid substitutions.
• the amino acid substitutions may be conservative amino acid substitutions.
• the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 51 , a VHCDR2 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 53 and a VHCDR3 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 99% or 100% identity to the amino acid
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 51 , a VHCDR2 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 53 and a VHCDR3 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 67; and/or a light chain variable region comprising a VLCDR1 comprising the at least 90% identity to the amino acid sequence of SEQ ID NO: 79, a VLCDR2 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 80 and a VLCDR3 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 94.
• a heavy chain variable region comprising a VHCDR1 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 51
• a VHCDR2 comprising at least 90% identity to the amino acid sequence
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence of SEQ ID NO: 51 , a VHCDR2 comprising the amino acid sequence of SEQ ID NO: 53 and a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 67; and a light chain variable region comprising a VLCDR1 comprising the amino acid sequence of SEQ ID NO: 79, a VLCDR2 comprising the amino acid sequence of SEQ ID NO: 80 and a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 94.
• Amino acid substitutions may be made to provide variant antibodies having Fab regions derived from ADT1- 4-173, for example multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V51) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence of SEQ ID NO: 51 optionally comprising 1 or 2 amino acid substitutions, a VHCDR2 comprising the amino acid sequence of SEQ ID NO: 53 optionally comprising 1 or 2 amino acid substitutions, and a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 67 optionally comprising 1 or 2 amino acid substitutions; and/or a light chain variable region comprising a VLCDR1 comprising the amino acid sequence of SEQ ID NO: 79 optionally comprising 1 or 2 amino acid substitutions, a VLCDR2 comprising the amino acid sequence of SEQ ID NO: 80 optionally comprising 1 or 2 amino acid substitutions and a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 94 optional
• the antibodies may alternatively consist of the specified sequences (with or without amino acid substitutions).
• Certain embodiments relate to the antibody ADT1 -4-2 and fragments and variants thereof.
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 68 and/or a light chain variable region comprising a VLCDR3 comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 95.
• an antibody or antigen-binding-fragment or variant thereof comprising a heavy chain variable region comprising a VHCDR3 comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 68 and/or a light chain variable region comprising a VLCDR3 comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 95.
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 68 and/or a light chain variable region comprising a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 95.
• Amino acid substitutions may be made to provide variant antibodies having Fab regions derived from ADT1- 4-2, for example multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 68, optionally comprising 1 or 2 amino acid substitutions, and/or a light chain variable region comprising a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 95, optionally comprising 1 or 2 amino acid substitutions.
• the amino acid substitutions may be conservative amino acid substitutions.
• the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 51 , a VHCDR2 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 53 and a VHCDR3 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 99% or 100% identity to the amino acid
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 51 , a VHCDR2 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 53 and a VHCDR3 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 68; and/or a light chain variable region comprising a VLCDR1 comprising the at least 90% identity to the amino acid sequence of SEQ ID NO: 79, a VLCDR2 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 80 and a VLCDR3 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 95.
• a heavy chain variable region comprising a VHCDR1 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 51
• a VHCDR2 comprising at least 90% identity to the amino acid sequence of
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V51) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence of SEQ ID NO: 51 , a VHCDR2 comprising the amino acid sequence of SEQ ID NO: 53 and a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 68; and a light chain variable region comprising a VLCDR1 comprising the amino acid sequence of SEQ ID NO: 79, a VLCDR2 comprising the amino acid sequence of SEQ ID NO: 80 and a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 95.
• Amino acid substitutions may be made to provide variant antibodies having Fab regions derived from ADT1- 4-2, for example multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence of SEQ ID NO: 51 optionally comprising 1 or 2 amino acid substitutions, a VHCDR2 comprising the amino acid sequence of SEQ ID NO: 53 optionally comprising 1 or 2 amino acid substitutions, and a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 68 optionally comprising 1 or 2 amino acid substitutions; and/or a light chain variable region comprising a VLCDR1 comprising the amino acid sequence of SEQ ID NO: 79 optionally comprising 1 or 2 amino acid substitutions, a VLCDR2 comprising the amino acid sequence of SEQ ID NO: 80 optionally comprising 1 or 2 amino acid substitutions and a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 95 optionally compris
• the antibodies may alternatively consist of the specified sequences (with or without amino acid substitutions).
• Certain embodiments relate to the antibody ADT1 -4-8 and fragments and variants thereof.
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 69 and/or a light chain variable region comprising a VLCDR3 comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 96.
• an antibody or antigen-binding-fragment or variant thereof comprising a heavy chain variable region comprising a VHCDR3 comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 69 and/or a light chain variable region comprising a VLCDR3 comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 96.
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 69 and/or a light chain variable region comprising a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 96.
• Amino acid substitutions may be made to provide variant antibodies having Fab regions derived from ADT1- 4-8, for example multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 69, optionally comprising 1 or 2 amino acid substitutions, and/or a light chain variable region comprising a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 96, optionally comprising 1 or 2 amino acid substitutions.
• the amino acid substitutions may be conservative amino acid substitutions.
• the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 51 , a VHCDR2 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 53 and a VHCDR3 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 99% or 100% identity to the amino acid
• the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 51 , a VHCDR2 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 53 and a VHCDR3 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 69; and/or a light chain variable region comprising a VLCDR1 comprising the at least 90% identity to the amino acid sequence of SEQ ID NO: 79, a VLCDR2 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 80 and a VLCDR3 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 96.
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence of SEQ ID NO: 51 , a VHCDR2 comprising the amino acid sequence of SEQ ID NO: 53 and a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 69; and a light chain variable region comprising a VLCDR1 comprising the amino acid sequence of SEQ ID NO: 79, a VLCDR2 comprising the amino acid sequence of SEQ ID NO: 80 and a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 96.
• Amino acid substitutions may be made to provide variant antibodies having Fab regions derived from ADT1- 4-8, for example multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence of SEQ ID NO: 51 optionally comprising 1 or 2 amino acid substitutions, a VHCDR2 comprising the amino acid sequence of SEQ ID NO: 53 optionally comprising 1 or 2 amino acid substitutions, and a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 69 optionally comprising 1 or 2 amino acid substitutions; and/or a light chain variable region comprising a VLCDR1 comprising the amino acid sequence of SEQ ID NO: 79 optionally comprising 1 or 2 amino acid substitutions, a VLCDR2 comprising the amino acid sequence of SEQ ID NO: 80 optionally comprising 1 or 2 amino acid substitutions and a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 96 optional
• the antibodies may alternatively consist of the specified sequences (with or without amino acid substitutions).
• Certain embodiments relate to the antibody ADT 1 -4-82 and fragments and variants thereof.
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 70 and/or a light chain variable region comprising a VLCDR3 comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 97.
• an antibody or antigen-binding-fragment or variant thereof comprising a heavy chain variable region comprising a VHCDR3 comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 70 and/or a light chain variable region comprising a VLCDR3 comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 97.
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 70 and/or a light chain variable region comprising a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 97.
• Amino acid substitutions may be made to provide variant antibodies having Fab regions derived from ADT1- 4-82, for example multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 70, optionally comprising 1 or 2 amino acid substitutions, and/or a light chain variable region comprising a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 97, optionally comprising 1 or 2 amino acid substitutions.
• the amino acid substitutions may be conservative amino acid substitutions.
• the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 51 , a VHCDR2 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 53 and a VHCDR3 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 99% or 100% identity to the amino acid
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 51 , a VHCDR2 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 53 and a VHCDR3 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 70; and/or a light chain variable region comprising a VLCDR1 comprising the at least 90% identity to the amino acid sequence of SEQ ID NO: 79, a VLCDR2 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 80 and a VLCDR3 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 97.
• a heavy chain variable region comprising a VHCDR1 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 51
• a VHCDR2 comprising at least 90% identity to the amino acid sequence of
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence of SEQ ID NO: 51 , a VHCDR2 comprising the amino acid sequence of SEQ ID NO: 53 and a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 70; and a light chain variable region comprising a VLCDR1 comprising the amino acid sequence of SEQ ID NO: 79, a VLCDR2 comprising the amino acid sequence of SEQ ID NO: 80 and a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 97.
• Amino acid substitutions may be made to provide variant antibodies having Fab regions derived from ADT1- 4-82, for example multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence of SEQ ID NO: 51 optionally comprising 1 or 2 amino acid substitutions, a VHCDR2 comprising the amino acid sequence of SEQ ID NO: 53 optionally comprising 1 or 2 amino acid substitutions, and a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 70 optionally comprising 1 or 2 amino acid substitutions; and/or a light chain variable region comprising a VLCDR1 comprising the amino acid sequence of SEQ ID NO: 79 optionally comprising 1 or 2 amino acid substitutions, a VLCDR2 comprising the amino acid sequence of SEQ ID NO: 80 optionally comprising 1 or 2 amino acid substitutions and a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 97 optionally
• the antibodies may alternatively consist of the specified sequences (with or without amino acid substitutions).
• Certain embodiments relate to the antibody ADT 1 -4-83 and fragments and variants thereof.
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 71 and/or a light chain variable region comprising a VLCDR3 comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 98.
• an antibody or antigen-binding-fragment or variant thereof comprising a heavy chain variable region comprising a VHCDR3 comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 71 and/or a light chain variable region comprising a VLCDR3 comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 98.
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 71 and/or a light chain variable region comprising a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 98.
• Amino acid substitutions may be made to provide variant antibodies having Fab regions derived from ADT1- 4-83, for example multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 71 , optionally comprising 1 or 2 amino acid substitutions, and/or a light chain variable region comprising a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 98, optionally comprising 1 or 2 amino acid substitutions.
• the amino acid substitutions may be conservative amino acid substitutions.
• the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 51 , a VHCDR2 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 53 and a VHCDR3 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 99% or 100% identity to the amino acid
• the anti-TCR delta variable 1 (anti-V 1) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 51 , a VHCDR2 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 53 and a VHCDR3 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 71 ; and/or a light chain variable region comprising a VLCDR1 comprising the at least 90% identity to the amino acid sequence of SEQ ID NO: 79, a VLCDR2 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 80 and a VLCDR3 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 98.
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V51) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence of SEQ ID NO: 51 , a VHCDR2 comprising the amino acid sequence of SEQ ID NO: 53 and a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 71 ; and a light chain variable region comprising a VLCDR1 comprising the amino acid sequence of SEQ ID NO: 79, a VLCDR2 comprising the amino acid sequence of SEQ ID NO: 80 and a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 98.
• Amino acid substitutions may be made to provide variant antibodies having Fab regions derived from ADT1- 4-83, for example multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence of SEQ ID NO: 51 optionally comprising 1 or 2 amino acid substitutions, a VHCDR2 comprising the amino acid sequence of SEQ ID NO: 53 optionally comprising 1 or 2 amino acid substitutions, and a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 71 optionally comprising 1 or 2 amino acid substitutions; and/or a light chain variable region comprising a VLCDR1 comprising the amino acid sequence of SEQ ID NO: 79 optionally comprising 1 or 2 amino acid substitutions, a VLCDR2 comprising the amino acid sequence of SEQ ID NO: 80 optionally comprising 1 or 2 amino acid substitutions and a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 98 optional
• the antibodies may alternatively consist of the specified sequences (with or without amino acid substitutions).
• Certain embodiments relate to the antibody ADT1 -4-3 and fragments and variants thereof.
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V 1) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 72 and/or a light chain variable region comprising a VLCDR3 comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 99.
• anti-V 1 (anti-V 1) binding Fab region comprising a
• an antibody or antigen-binding-fragment or variant thereof comprising a heavy chain variable region comprising a VHCDR3 comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 72 and/or a light chain variable region comprising a VLCDR3 comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 99.
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 72 and/or a light chain variable region comprising a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 99.
• Amino acid substitutions may be made to provide variant antibodies having Fab regions derived from ADT1- 4-3, for example multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V51) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 72, optionally comprising 1 or 2 amino acid substitutions, and/or a light chain variable region comprising a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 99, optionally comprising 1 or 2 amino acid substitutions.
• the amino acid substitutions may be conservative amino acid substitutions.
• the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 51 , a VHCDR2 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 53 and a VHCDR3 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 99% or 100% identity to the amino acid
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V51) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 51 , a VHCDR2 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 53 and a VHCDR3 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 72; and/or a light chain variable region comprising a VLCDR1 comprising the at least 90% identity to the amino acid sequence of SEQ ID NO: 79, a VLCDR2 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 80 and a VLCDR3 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 99.
• a heavy chain variable region comprising a VHCDR1 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 51
• a VHCDR2 comprising at least 90% identity to the amino acid sequence of S
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V51) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence of SEQ ID NO: 51 , a VHCDR2 comprising the amino acid sequence of SEQ ID NO: 53 and a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 72; and a light chain variable region comprising a VLCDR1 comprising the amino acid sequence of SEQ ID NO: 79, a VLCDR2 comprising the amino acid sequence of SEQ ID NO: 80 and a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 99.
• Amino acid substitutions may be made to provide variant antibodies having Fab regions derived from ADT1- 4-3, for example multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence of SEQ ID NO: 51 optionally comprising 1 or 2 amino acid substitutions, a VHCDR2 comprising the amino acid sequence of SEQ ID NO: 53 optionally comprising 1 or 2 amino acid substitutions, and a VFICDR3 comprising the amino acid sequence of SEQ ID NO: 72 optionally comprising 1 or 2 amino acid substitutions; and/or a light chain variable region comprising a VLCDR1 comprising the amino acid sequence of SEQ ID NO: 79 optionally comprising 1 or 2 amino acid substitutions, a VLCDR2 comprising the amino acid sequence of SEQ ID NO: 80 optionally comprising 1 or 2 amino acid substitutions and a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 99 optionally
• the antibodies may alternatively consist of the specified sequences (with or without amino acid substitutions).
• Certain embodiments relate to the antibody ADT 1 -4-84 and fragments and variants thereof.
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VFICDR3 comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 73 and/or a light chain variable region comprising a VLCDR3 comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 100.
• an antibody or antigen-binding-fragment or variant thereof comprising a heavy chain variable region comprising a VHCDR3 comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 73 and/or a light chain variable region comprising a VLCDR3 comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 100.
• multispecific antibodies are provided, the anti- TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 73 and/or a light chain variable region comprising a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 100.
• Amino acid substitutions may be made to provide variant antibodies having Fab regions derived from ADT1- 4-84, for example multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 73, optionally comprising 1 or 2 amino acid substitutions, and/or a light chain variable region comprising a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 100, optionally comprising 1 or 2 amino acid substitutions.
• the amino acid substitutions may be conservative amino acid substitutions.
• the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VFICDR1 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 51 , a VFICDR2 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 53 and a VFICDR3 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V51) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 51 , a VHCDR2 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 53 and a VHCDR3 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 73; and/or a light chain variable region comprising a VLCDR1 comprising the at least 90% identity to the amino acid sequence of SEQ ID NO: 79, a VLCDR2 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 80 and a VLCDR3 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 100.
• a heavy chain variable region comprising a VHCDR1 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 51
• a VHCDR2 comprising at least 90% identity to the amino acid sequence of
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence of SEQ ID NO: 51 , a VHCDR2 comprising the amino acid sequence of SEQ ID NO: 53 and a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 73; and a light chain variable region comprising a VLCDR1 comprising the amino acid sequence of SEQ ID NO: 79, a VLCDR2 comprising the amino acid sequence of SEQ ID NO: 80 and a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 100.
• Amino acid substitutions may be made to provide variant antibodies having Fab regions derived from ADT1- 4-84, for example multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence of SEQ ID NO: 51 optionally comprising 1 or 2 amino acid substitutions, a VHCDR2 comprising the amino acid sequence of SEQ ID NO: 53 optionally comprising 1 or 2 amino acid substitutions, and a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 73 optionally comprising 1 or 2 amino acid substitutions; and/or a light chain variable region comprising a VLCDR1 comprising the amino acid sequence of SEQ ID NO: 79 optionally comprising 1 or 2 amino acid substitutions, a VLCDR2 comprising the amino acid sequence of SEQ ID NO: 80 optionally comprising 1 or 2 amino acid substitutions and a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 100 optionally
• the antibodies may alternatively consist of the specified sequences (with or without amino acid substitutions).
• Certain embodiments relate to the antibody ADT 1 -4-86 and fragments and variants thereof.
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 74 and/or a light chain variable region comprising a VLCDR3 comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 101.
• an antibody or antigen-binding-fragment or variant thereof comprising a heavy chain variable region comprising a VHCDR3 comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 74 and/or a light chain variable region comprising a VLCDR3 comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 101.
• multispecific antibodies are provided, the anti- TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 74 and/or a light chain variable region comprising a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 101.
• Amino acid substitutions may be made to provide variant antibodies having Fab regions derived from ADT1- 4-86, for example multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 74, optionally comprising 1 or 2 amino acid substitutions, and/or a light chain variable region comprising a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 101 , optionally comprising 1 or 2 amino acid substitutions.
• the amino acid substitutions may be conservative amino acid substitutions.
• the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 52, a VHCDR2 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 53 and a VHCDR3 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V51) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 52, a VHCDR2 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 53 and a VHCDR3 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 74; and/or a light chain variable region comprising a VLCDR1 comprising the at least 90% identity to the amino acid sequence of SEQ ID NO: 79, a VLCDR2 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 80 and a VLCDR3 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 101.
• a heavy chain variable region comprising a VHCDR1 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 52, a VHCDR2 comprising at least 90% identity to the amino acid sequence of SEQ
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence of SEQ ID NO: 52, a VHCDR2 comprising the amino acid sequence of SEQ ID NO: 53 and a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 74; and a light chain variable region comprising a VLCDR1 comprising the amino acid sequence of SEQ ID NO: 79, a VLCDR2 comprising the amino acid sequence of SEQ ID NO: 80 and a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 101.
• Amino acid substitutions may be made to provide variant antibodies having Fab regions derived from ADT1- 4-86, for example multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V01) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence of SEQ ID NO: 52 optionally comprising 1 or 2 amino acid substitutions, a VHCDR2 comprising the amino acid sequence of SEQ ID NO: 53 optionally comprising 1 or 2 amino acid substitutions, and a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 74 optionally comprising 1 or 2 amino acid substitutions; and/or a light chain variable region comprising a VLCDR1 comprising the amino acid sequence of SEQ ID NO: 79 optionally comprising 1 or 2 amino acid substitutions, a VLCDR2 comprising the amino acid sequence of SEQ ID NO: 80 optionally comprising 1 or 2 amino acid substitutions and a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 101 optionally
• the antibodies may alternatively consist of the specified sequences (with or without amino acid substitutions).
• the anti-TCR delta variable 1 (anti-V51) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 75 and/or a light chain variable region comprising a VLCDR3 comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the
• an antibody or antigen-binding-fragment or variant thereof comprising a heavy chain variable region comprising a VHCDR3 comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 75 and/or a light chain variable region comprising a VLCDR3 comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 102.
• multispecific antibodies are provided, the anti- TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 75 and/or a light chain variable region comprising a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 102.
• Amino acid substitutions may be made to provide variant antibodies having Fab regions derived from ADT1- 4-95, for example multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 75, optionally comprising 1 or 2 amino acid substitutions, and/or a light chain variable region comprising a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 102, optionally comprising 1 or 2 amino acid substitutions.
• the amino acid substitutions may be conservative amino acid substitutions.
• the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 51 , a VHCDR2 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 53 and a VHCDR3 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 99% or 100% identity to the amino acid
• the anti-TCR delta variable 1 (anti-V 1) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 51 , a VHCDR2 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 53 and a VHCDR3 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 75; and/or a light chain variable region comprising a VLCDR1 comprising the at least 90% identity to the amino acid sequence of SEQ ID NO: 79, a VLCDR2 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 80 and a VLCDR3 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 102.
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V51) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence of SEQ ID NO: 51 , a VHCDR2 comprising the amino acid sequence of SEQ ID NO: 53 and a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 75; and a light chain variable region comprising a VLCDR1 comprising the amino acid sequence of SEQ ID NO: 79, a VLCDR2 comprising the amino acid sequence of SEQ ID NO: 80 and a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 102.
• Amino acid substitutions may be made to provide variant antibodies having Fab regions derived from ADT1- 4-95, for example multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence of SEQ ID NO: 51 optionally comprising 1 or 2 amino acid substitutions, a VHCDR2 comprising the amino acid sequence of SEQ ID NO: 53 optionally comprising 1 or 2 amino acid substitutions, and a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 75 optionally comprising 1 or 2 amino acid substitutions; and/or a light chain variable region comprising a VLCDR1 comprising the amino acid sequence of SEQ ID NO: 79 optionally comprising 1 or 2 amino acid substitutions, a VLCDR2 comprising the amino acid sequence of SEQ ID NO: 80 optionally comprising 1 or 2 amino acid substitutions and a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 102 optionally
• the antibodies may alternatively consist of the specified sequences (with or without amino acid substitutions).
• ADT1-4-1 and fragments and variants thereof may alternatively consist of the specified sequences (with or without amino acid substitutions).
• Certain embodiments relate to the antibody ADT1 -4-1 and fragments and variants thereof.
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V51) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 76 and/or a light chain variable region comprising a VLCDR3 comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 103.
• an antibody or antigen-binding-fragment or variant thereof comprising a heavy chain variable region comprising a VHCDR3 comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 76 and/or a light chain variable region comprising a VLCDR3 comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 103.
• multispecific antibodies are provided, the anti- TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 76 and/or a light chain variable region comprising a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 103.
• Amino acid substitutions may be made to provide variant antibodies having Fab regions derived from ADT1- 4-1 , for example multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V51) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 76, optionally comprising 1 or 2 amino acid substitutions, and/or a light chain variable region comprising a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 103, optionally comprising 1 or 2 amino acid substitutions.
• the amino acid substitutions may be conservative amino acid substitutions.
• the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 51 , a VHCDR2 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 53 and a VHCDR3 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 99% or 100% identity to the amino acid
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 51 , a VHCDR2 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 53 and a VHCDR3 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 76; and/or a light chain variable region comprising a VLCDR1 comprising the at least 90% identity to the amino acid sequence of SEQ ID NO: 79, a VLCDR2 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 80 and a VLCDR3 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 103.
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence of SEQ ID NO: 51 , a VHCDR2 comprising the amino acid sequence of SEQ ID NO: 53 and a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 76; and a light chain variable region comprising a VLCDR1 comprising the amino acid sequence of SEQ ID NO: 79, a VLCDR2 comprising the amino acid sequence of SEQ ID NO: 80 and a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 103.
• Amino acid substitutions may be made to provide variant antibodies having Fab regions derived from ADT1- 4-1 , for example multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V51) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence of SEQ ID NO: 51 optionally comprising 1 or 2 amino acid substitutions, a VHCDR2 comprising the amino acid sequence of SEQ ID NO: 53 optionally comprising 1 or 2 amino acid substitutions, and a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 76 optionally comprising 1 or 2 amino acid substitutions; and/or a light chain variable region comprising a VLCDR1 comprising the amino acid sequence of SEQ ID NO: 79 optionally comprising 1 or 2 amino acid substitutions, a VLCDR2 comprising the amino acid sequence of SEQ ID NO: 80 optionally comprising 1 or 2 amino acid substitutions and a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 103
• Certain embodiments relate to the antibody ADT1 -4-6 and fragments and variants thereof.
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 77 and/or a light chain variable region comprising a VLCDR3 comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 104.
• an antibody or antigen-binding-fragment or variant thereof comprising a heavy chain variable region comprising a VHCDR3 comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 77 and/or a light chain variable region comprising a VLCDR3 comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 104.
• multispecific antibodies are provided, the anti- TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 77 and/or a light chain variable region comprising a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 104.
• Amino acid substitutions may be made to provide variant antibodies having Fab regions derived from ADT1- 4-6, for example multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 77, optionally comprising 1 or 2 amino acid substitutions, and/or a light chain variable region comprising a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 104, optionally comprising 1 or 2 amino acid substitutions.
• the amino acid substitutions may be conservative amino acid substitutions.
• the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 51 , a VHCDR2 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 53 and a VHCDR3 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 99% or 100% identity to the amino acid
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 51 , a VHCDR2 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 53 and a VHCDR3 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 77; and/or a light chain variable region comprising a VLCDR1 comprising the at least 90% identity to the amino acid sequence of SEQ ID NO: 79, a VLCDR2 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 80 and a VLCDR3 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 104.
• a heavy chain variable region comprising a VHCDR1 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 51
• a VHCDR2 comprising at least 90% identity to the amino acid sequence
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V51) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence of SEQ ID NO: 51 , a VHCDR2 comprising the amino acid sequence of SEQ ID NO: 53 and a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 77; and a light chain variable region comprising a VLCDR1 comprising the amino acid sequence of SEQ ID NO: 79, a VLCDR2 comprising the amino acid sequence of SEQ ID NO: 80 and a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 104.
• Amino acid substitutions may be made to provide variant antibodies having Fab regions derived from ADT1- 4-6, for example multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence of SEQ ID NO: 51 optionally comprising 1 or 2 amino acid substitutions, a VHCDR2 comprising the amino acid sequence of SEQ ID NO: 53 optionally comprising 1 or 2 amino acid substitutions, and a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 77 optionally comprising 1 or 2 amino acid substitutions; and/or a light chain variable region comprising a VLCDR1 comprising the amino acid sequence of SEQ ID NO: 79 optionally comprising 1 or 2 amino acid substitutions, a VLCDR2 comprising the amino acid sequence of SEQ ID NO: 80 optionally comprising 1 or 2 amino acid substitutions and a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 104 optional
• the antibodies may alternatively consist of the specified sequences (with or without amino acid substitutions).
• Certain embodiments relate to the antibody ADT 1 -4-138 and fragments and variants thereof.
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 78 and/or a light chain variable region comprising a VLCDR3 comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 105.
• an antibody or antigen-binding-fragment or variant thereof comprising a heavy chain variable region comprising a VHCDR3 comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 78 and/or a light chain variable region comprising a VLCDR3 comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 105.
• multispecific antibodies are provided, the anti- TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 78 and/or a light chain variable region comprising a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 105.
• Amino acid substitutions may be made to provide variant antibodies having Fab regions derived from ADT1- 4-138, for example multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V51) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 78, optionally comprising 1 or 2 amino acid substitutions, and/or a light chain variable region comprising a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 105, optionally comprising 1 or 2 amino acid substitutions.
• the amino acid substitutions may be conservative amino acid substitutions.
• the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 51 , a VHCDR2 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 53 and a VHCDR3 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 99% or 100% identity to the amino acid
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 51 , a VHCDR2 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 53 and a VHCDR3 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 78; and/or a light chain variable region comprising a VLCDR1 comprising the at least 90% identity to the amino acid sequence of SEQ ID NO: 79, a VLCDR2 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 80 and a VLCDR3 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 105.
• a heavy chain variable region comprising a VHCDR1 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 51
• a VHCDR2 comprising at least 90% identity to the amino acid sequence
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence of SEQ ID NO: 51 , a VHCDR2 comprising the amino acid sequence of SEQ ID NO: 53 and a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 78; and a light chain variable region comprising a VLCDR1 comprising the amino acid sequence of SEQ ID NO: 79, a VLCDR2 comprising the amino acid sequence of SEQ ID NO: 80 and a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 105.
• Amino acid substitutions may be made to provide variant antibodies having Fab regions derived from ADT1- 4-138, for example multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence of SEQ ID NO: 51 optionally comprising 1 or 2 amino acid substitutions, a VHCDR2 comprising the amino acid sequence of SEQ ID NO: 53 optionally comprising 1 or 2 amino acid substitutions, and a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 78 optionally comprising 1 or 2 amino acid substitutions; and/or a light chain variable region comprising a VLCDR1 comprising the amino acid sequence of SEQ ID NO: 79 optionally comprising 1 or 2 amino acid substitutions, a VLCDR2 comprising the amino acid sequence of SEQ ID NO: 80 optionally comprising 1 or 2 amino acid substitutions and a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 105 optional
• the antibodies may alternatively consist of the specified sequences (with or without amino acid substitutions).
• Antibodies comprising heavy and/or light chain variable regions derived from ADT1-4
• the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising or consisting of a sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to a sequence selected from the group consisting of SEQ ID NOs: 2 to 25; and/or a light chain variable region comprising or consisting of a sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to a sequence selected from the group consisting of SEQ ID NOs: 27 to 50.
• the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising or consisting of a sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to a sequence selected from the group consisting of SEQ ID NOs: 2 to 24; and/or a light chain variable region comprising or consisting of a sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to a sequence selected from the group consisting of SEQ ID NOs: 27 to 49.
• the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising or consisting of a sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to a sequence selected from the group consisting of SEQ ID NOs: 5, 7, 8, 9, 12, 13, 15, 21 , 23 and 24; and/or a light chain variable region comprising or consisting of a sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to a sequence selected from the group consisting of SEQ ID NOs: 30, 32, 33
• the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising or consisting of a sequence having at least 90% identity to a sequence selected from the group consisting of SEQ ID NOs: 2 to 25; and/or a light chain variable region comprising or consisting of a sequence having at least 90% identity to a sequence selected from the group consisting of SEQ ID NOs: 27 to 50.
• the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising or consisting of a sequence having at least 90% identity to a sequence selected from the group consisting of SEQ ID NOs: 2 to 24; and/or a light chain variable region comprising or consisting of a sequence having at least 90% identity to a sequence selected from the group consisting of SEQ ID NOs: 27 to 49.
• the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising or consisting of a sequence having at least 90% identity to a sequence selected from the group consisting of SEQ ID NOs: 5, 7, 8, 9, 12, 13, 15, 21 , 23 and 24; and/or a light chain variable region comprising or consisting of a sequence having at least 90% identity to a sequence selected from the group consisting of SEQ ID NOs: 30, 32, 33, 34, 37, 38, 40, 46, 48 and 49.
• the antibodies above retain the corresponding CDR sequences such that any variability in the VH and VL sequences occurs in the framework regions.
• the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising or consisting of a sequence selected from the group consisting of SEQ ID NOs: 2 to 25; and/or a light chain variable region comprising or consisting of a sequence selected from the group consisting of SEQ ID NOs: 27 to 50.
• the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising or consisting of a sequence selected from the group consisting of SEQ ID NOs: 2 to 24; and/or a light chain variable region comprising or consisting of a sequence selected from the group consisting of SEQ ID NOs: 27 to 49.
• the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising or consisting of a sequence selected from the group consisting of SEQ ID NOs: 5, 7, 8, 9, 12, 13, 15, 21 , 23 and 24; and/or a light chain variable region comprising or consisting of a sequence selected from the group consisting of SEQ ID NOs: 30, 32, 33, 34, 37, 38, 40, 46, 48 and 49.
• the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a) a VH comprising or consisting of an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 2 and a VL comprising or consisting of an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 27; b) a VH comprising or consisting of an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 3 and a VL comprising or consisting of an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 28; c) a VH comprising or consisting of an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 4 and a VL comprising or consisting of an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 29; d) a VH comprising or consisting of an amino acid
• VH comprising or consisting of an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 13 and a VL comprising or consisting of an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 38
• m a VH comprising or consisting of an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 14 and a VL comprising or consisting of an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 39
• n a VH comprising or consisting of an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 15 and a VL comprising or consisting of an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 40
• o a VH comprising or consisting of an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 16 and a VL comprising or consisting of an amino acid
• the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a) a VH comprising or consisting of an amino acid sequence that is at least 96% identical to the amino acid sequence of SEQ ID NO: 2 and a VL comprising or consisting of an amino acid sequence that is at least 96% identical to the amino acid sequence of SEQ ID NO: 27; b) a VH comprising or consisting of an amino acid sequence that is at least 96% identical to the amino acid sequence of SEQ ID NO: 3 and a VL comprising or consisting of an amino acid sequence that is at least 96% identical to the amino acid sequence of SEQ ID NO: 28; c) a VH comprising or consisting of an amino acid sequence that is at least 96% identical to the amino acid sequence of SEQ ID NO: 4 and a VL comprising or consisting of an amino acid sequence that is at least 96% identical to the amino acid sequence of SEQ ID NO: 29; d) a VH comprising or
• VH comprising or consisting of an amino acid sequence that is at least 96% identical to the amino acid sequence of SEQ ID NO: 13 and a VL comprising or consisting of an amino acid sequence that is at least 96% identical to the amino acid sequence of SEQ ID NO: 38
• m a VH comprising or consisting of an amino acid sequence that is at least 96% identical to the amino acid sequence of SEQ ID NO: 14 and a VL comprising or consisting of an amino acid sequence that is at least 96% identical to the amino acid sequence of SEQ ID NO: 39
• n a VH comprising or consisting of an amino acid sequence that is at least 96% identical to the amino acid sequence of SEQ ID NO: 15 and a VL comprising or consisting of an amino acid sequence that is at least 96% identical to the amino acid sequence of SEQ ID NO: 40
• o a VH comprising or consisting of an amino acid sequence that is at least 96% identical to the amino acid sequence of SEQ ID NO: 16 and a VL comprising
• the antibodies above retain the corresponding CDR sequences such that any variability in the VH and VL sequences occurs in the framework regions.
• the antibodies above retain the corresponding CDR sequences such that any variability in the VH and VL sequences occurs in the framework regions.
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a) a VH comprising or consisting of the amino acid sequence of SEQ ID NO: 2 and a VL comprising or consisting of the amino acid sequence of SEQ ID NO: 27 optionally comprising up to 5, up to 4, up to 3, up to 2 or 1 amino acid substitutions across both variable regions; b) a VH comprising or consisting of the amino acid sequence of SEQ ID NO: 3 and a VL comprising or consisting of the amino acid sequence of SEQ ID NO: 28 optionally comprising up to 5, up to 4, up to 3, up to 2 or 1 amino acid substitutions across both variable regions; c) a VH comprising or consisting of the amino acid sequence of SEQ ID NO: 4 and a VL comprising or consisting of the amino acid sequence of SEQ ID NO:
• VH comprising or consisting of the amino acid sequence of SEQ ID NO: 13 and a VL comprising or consisting of the amino acid sequence of SEQ ID NO: 38 optionally comprising up to 5, up to 4, up to 3, up to 2 or 1 amino acid substitutions across both variable regions
• the antibody may comprise up to the specified number of substitutions in total when considering both the heavy and light chain variable regions.
• the amino acid substitutions may be conservative amino acid substitutions.
• the substitutions (if present) may occur anywhere in the variable region sequences.
• the substitutions (if present) may be limited to the framework regions. Accordingly, in some embodiments, the amino acid substitutions do not occur in a CDR sequence.
• the antibodies above retain the corresponding CDR sequences such that any variability in the VH and VL sequences occurs in the framework regions.
• the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a) a VH comprising or consisting of the amino acid sequence of SEQ ID NO: 2 and a VL comprising or consisting of the amino acid sequence of SEQ ID NO: 27; b) a VH comprising or consisting of the amino acid sequence of SEQ ID NO: 3 and a VL comprising or consisting of the amino acid sequence of SEQ ID NO: 28; c) a VH comprising or consisting of the amino acid sequence of SEQ ID NO: 4 and a VL comprising or consisting of the amino acid sequence of SEQ ID NO: 29; d) a VH comprising or consisting of the amino acid sequence of SEQ ID NO: 5 and a VL comprising or consisting of the amino acid sequence of SEQ ID NO: 30; e) a VH comprising or consisting of the amino acid sequence of SEQ ID NO: 6 and a VL comprising or consisting of the amino acid sequence of SEQ ID NO:
• VH comprising or consisting of the amino acid sequence of SEQ ID NO: 13 and a VL comprising or consisting of the amino acid sequence of SEQ ID NO: 38; m) a VH comprising or consisting of the amino acid sequence of SEQ ID NO: 14 and a VL comprising or consisting of the amino acid sequence of SEQ ID NO: 39; n) a VH comprising or consisting of the amino acid sequence of SEQ ID NO: 15 and a VL comprising or consisting of the amino acid sequence of SEQ ID NO: 40; o) a VH comprising or consisting of the amino acid sequence of SEQ ID NO: 16 and a VL comprising or consisting of the amino acid sequence of SEQ ID NO: 41 ; p) a VH comprising or consisting of the amino acid sequence of SEQ ID NO: 17 and a VL comprising or consisting of the amino acid sequence of SEQ ID NO: 42; q) a VH comprising or consisting of the amino acid sequence of SEQ
• Certain amino acid substitutions may be made to provide one or more variant antibodies as described herein.
• VH sequence is not SEQ ID NO: 1 and the VL sequence is not SEQ ID NO: 26.
• the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a) an HCDR1 sequence comprising or consisting of the sequence of GDSVSSKSXiA (SEQ ID NO:
• an HCDR2 sequence comprising or consisting of the sequence of SEQ ID NO: 53
• an HCDR3 sequence comprising or consisting of the sequence of X 2 WX3X 4 X5X6DX7 (SEQ ID NO:
• HCDR3 sequence is not SEQ ID NO: 54; d) an LCDR1 sequence comprising or consisting of the sequence of SEQ ID NO: 79; e) an LCDR2 sequence comprising or consisting of the sequence of SEQ ID NO: 80; and f) an LCDR3 sequence comprising or consisting of the sequence of QQX8YX9X 10 X 11 X 12 X 13 T (SEQ ID NO: 166), wherein the LCDR3 sequence is not SEQ ID NO: 81 ; and wherein each of Xi to X 13 is a naturally occurring amino acid.
• the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a) an HCDR1 sequence comprising or consisting of the sequence of GDSVSSKSXiA (SEQ ID NO:
• an HCDR2 sequence comprising or consisting of the sequence of SEQ ID NO: 53
• an HCDR3 sequence comprising or consisting of the sequence of X 2 WX3X 4 X5X6DX7 (SEQ ID NO:
• HCDR3 sequence is not SEQ ID NO: 54; d) an LCDR1 sequence comprising or consisting of the sequence of SEQ ID NO: 79; e) an LCDR2 sequence comprising or consisting of the sequence of SEQ ID NO: 80; and f) an LCDR3 sequence comprising or consisting of the sequence of QQX8YX9X 10 X 11 X 12 X 13 T (SEQ ID NO: 167), wherein the LCDR3 sequence is not SEQ ID NO: 81 ; and wherein: Xi is selected from the group consisting of A selected from the group consisting of S and T; X is selected from the group consisting of V, A selected from the group consisting is selected from the group consisting of Y s selected from the group consisting selected from the group consisting of V, s selected from the group consisting s selected from the group consisting of S s selected from the group consisting D; Xn is selected from the group consisting of P, is selected from the group consisting of
• the antibody may further comprise an HFR1 sequence comprising the sequence of SEQ ID NO: 170 or 171 ; an HFR2 sequence comprising the sequence of SEQ ID NO: 172; an HFR3 sequence comprising the sequence of SEQ ID NO: 173; an HFR4 sequence comprising the sequence of SEQ ID NO: 174; an LFR1 sequence comprising the sequence of SEQ ID NO: 175; an LFR2 sequence comprising the sequence of SEQ ID NO: 176; an LFR3 sequence comprising the sequence of SEQ ID NO: 177 or 178; and an LFR4 sequence comprising the sequence of SEQ ID NO: 179, 180, 181 or 182.
• the anti-TCR delta variable 1 (anti-V51) binding Fab region comprising: a) an HCDR1 sequence comprising or consisting of the sequence of GDSVSSKSX A (SEQ ID NO: 160); b) an HCDR2 sequence comprising or consisting of the sequence of SEQ ID NO: 53 c) an HCDR3 sequence comprising or consisting of the sequence of X WX X X X DX (SEQ ID NO: 164), wherein the HCDR3 sequence is not SEQ ID NO: 54; d) an LCDR1 sequence comprising or consisting of the sequence of SEQ ID NO: 79; e) an LCDR2 sequence comprising or consisting of the sequence of SEQ ID NO: 80; and f) an LCDR3 sequence comprising or consisting of the sequence of QQX8YX9X 10 X 11 X 12 X 13 T (SEQ ID NO: 168), wherein the LCDR3 sequence is not SEQ ID NO: 81
• the antibody may further comprise an HFR1 sequence comprising the sequence of SEQ ID NO: 170 or 171 , an HFR2 sequence comprising the sequence of SEQ ID NO: 172, an HFR3 sequence comprising the sequence of SEQ ID NO: 173, an HFR4 sequence comprising the sequence of SEQ ID NO: 174, an LFR1 sequence comprising the sequence of SEQ ID NO: 175, an LFR2 sequence comprising the sequence of SEQ ID NO: 176, an LFR3 sequence comprising the sequence of SEQ ID NO: 177 and an LFR4 sequence comprising the sequence of SEQ ID NO: 179, 180, 181 or 182.
• the anti-TCR delta variable 1 (anti-V51) binding Fab region comprising: a) an HCDR1 sequence comprising or consisting of the sequence of GDSVSSKSXiA (SEQ ID NO: 161); b) an HCDR2 sequence comprising or consisting of the sequence of SEQ ID NO: 53 c) an HCDR3 sequence comprising or consisting of the sequence of X WX X X X DX (SEQ ID NO: 165), wherein the HCDR3 sequence is not SEQ ID NO: 54; d) an LCDR1 sequence comprising or consisting of the sequence of SEQ ID NO: 79; e) an LCDR2 sequence comprising or consisting of the sequence of SEQ ID NO: 80; and f) an LCDR3 sequence comprising or consisting of the sequence of QQX8YX9X 10 X 11 X 12 X 13 T (SEQ ID NO: 169), wherein the LCDR3 sequence is not SEQ ID NO:
• the antibody may further comprise an HFR1 sequence comprising the sequence of SEQ ID NO: 170 or 171 ; an HFR2 sequence comprising the sequence of SEQ ID NO: 172; an HFR3 sequence comprising the sequence of SEQ ID NO: 173; an HFR4 sequence comprising the sequence of SEQ ID NO: 174; an LFR1 sequence comprising the sequence of SEQ ID NO: 175; an LFR2 sequence comprising the sequence of SEQ ID NO: 176; an LFR3 sequence comprising the sequence of SEQ ID NO: 177; and an LFR4 sequence comprising the sequence of SEQ ID NO: 179 or 181.
• the present invention provides multispecific antibodies comprising Fab regions derived from parental antibody ADT1-7 (having a variable heavy region sequence according to SEQ ID NO: 106 and a variable light region sequence according to SEQ ID No: 118), for example as set out in the following.
• ADT1-7 is also referred to herein as E07, and ADT1-7 and E07 are used interchangeably.
• Antibodies comprising particular CDR sequences derived from ADT1-7
• the multispecific antibodies provided herein include the following Fab regions having particular sequences derived from ADT1-7.
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V51) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising or consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 133 to 143; and/or a light chain variable region comprising a VLCDR3 comprising or consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 147 to 157.
• Certain amino acid substitutions may be made to provide one or more variant antibodies as described herein.
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising or consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 138, 142 and 143 and/or a light chain variable region comprising a VLCDR3 comprising or consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 152, 156 and 157, Certain amino acid substitutions may be made to provide one or more variant antibodies as described herein.
• the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising: a VHCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO:
• VHCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 131
• VHCDR3 comprising or consisting of an amino acid sequence selected from the group consisting of: SEQ ID NOs: 133 to 143
• a light chain variable region comprising: a VLCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO:
• VLCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 145
• VLCDR3 comprising or consisting of an amino acid sequence selected from the group consisting of: SEQ ID NOs: 147 to 157.
• Certain amino acid substitutions may be made to provide one or more variant antibodies as described herein.
• the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising: a VHCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO:
• VHCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 131
• VHCDR3 comprising or consisting of an amino acid sequence selected from the group consisting of: SEQ ID NOs: 138, 142 and 143
• a light chain variable region comprising: a VLCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO:
• VLCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 145
• VLCDR3 comprising or consisting of an amino acid sequence selected from the group consisting of: SEQ ID NOs: 152, 156 and 157.
• Certain amino acid substitutions may be made to provide one or more variant antibodies as described herein.
• Certain embodiments relate to the antibody ADT 1 -7-10 and fragments and variants thereof.
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 133 and/or a light chain variable region comprising a VLCDR3 comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 147.
• an antibody or antigen-binding-fragment or variant thereof comprising a heavy chain variable region comprising a VHCDR3 comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 133 and/or a light chain variable region comprising a VLCDR3 comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 147.
• multispecific antibodies are provided, the anti- TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 133 and/or a light chain variable region comprising a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 147.
• Amino acid substitutions may be made to provide variant antibodies having Fab regions derived from ADT1- 7-10, for example multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 133, optionally comprising 1 or 2 amino acid substitutions, and/or a light chain variable region comprising a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 147, optionally comprising 1 or 2 amino acid substitutions.
• the amino acid substitutions may be conservative amino acid substitutions.
• the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 130, a VHCDR2 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 131 and a VHCDR3 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 99% or 100% identity to the amino acid
• multispecific antibodies comprising: a heavy chain variable region comprising a VHCDR1 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 130, a VHCDR2 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 131 and a VHCDR3 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 133; and/or a light chain variable region comprising a VLCDR1 comprising the at least 90% identity to the amino acid sequence of SEQ ID NO: 144, a VLCDR2 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 145 and a VLCDR3 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 147.
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V51) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence of SEQ ID NO: 130, a VHCDR2 comprising the amino acid sequence of SEQ ID NO: 131 and a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 133; and a light chain variable region comprising a VLCDR1 comprising the amino acid sequence of SEQ ID NO: 144, a VLCDR2 comprising the amino acid sequence of SEQ ID NO: 145 and a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 147.
• Amino acid substitutions may be made to provide variant antibodies having Fab regions derived from ADT1- 7-10, for example multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence of SEQ ID NO: 130 optionally comprising 1 or 2 amino acid substitutions, a VHCDR2 comprising the amino acid sequence of SEQ ID NO: 131 optionally comprising 1 or 2 amino acid substitutions, and a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 133 optionally comprising 1 or 2 amino acid substitutions; and/or a light chain variable region comprising a VLCDR1 comprising the amino acid sequence of SEQ ID NO: 144 optionally comprising 1 or 2 amino acid substitutions, a VLCDR2 comprising the amino acid sequence of SEQ ID NO: 145 optionally comprising 1 or 2 amino acid substitutions and a VLCDR3 comprising the amino acid sequence of SEQ ID NO:
• the antibodies may alternatively consist of the specified sequences (with or without amino acid substitutions).
• Certain embodiments relate to the antibody ADT 1 -7-15 and fragments and variants thereof.
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 134 and/or a light chain variable region comprising a VLCDR3 comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 148.
• an antibody or antigen-binding-fragment or variant thereof comprising a heavy chain variable region comprising a VHCDR3 comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 134 and/or a light chain variable region comprising a VLCDR3 comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 148.
• multispecific antibodies are provided, the anti- TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 134 and/or a light chain variable region comprising a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 148.
• Amino acid substitutions may be made to provide variant antibodies having Fab regions derived from ADT1- 7-15, for example multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 134, optionally comprising 1 or 2 amino acid substitutions, and/or a light chain variable region comprising a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 148, optionally comprising 1 or 2 amino acid substitutions.
• the amino acid substitutions may be conservative amino acid substitutions.
• the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 130, a VHCDR2 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 131 and a VHCDR3 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 99% or 100% identity to the amino acid
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VFICDR1 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 130, a VFICDR2 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 131 and a VFICDR3 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 134; and/or a light chain variable region comprising a VLCDR1 comprising the at least 90% identity to the amino acid sequence of SEQ ID NO: 144, a VLCDR2 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 145 and a VLCDR3 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 148.
• a heavy chain variable region comprising a VFICDR1 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 130, a VFICDR2 comprising at least 90% identity
• the anti-TCR delta variable 1 (anti-V 1) binding Fab region comprising: a heavy chain variable region comprising a VFICDR1 comprising the amino acid sequence of SEQ ID NO: 130, a VFICDR2 comprising the amino acid sequence of SEQ ID NO: 131 and a VFICDR3 comprising the amino acid sequence of SEQ ID NO: 134; and a light chain variable region comprising a VLCDR1 comprising the amino acid sequence of SEQ ID NO: 144, a VLCDR2 comprising the amino acid sequence of SEQ ID NO: 145 and a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 148.
• Amino acid substitutions may be made to provide variant antibodies having Fab regions derived from ADT1- 7-15, for example multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence of SEQ ID NO: 130 optionally comprising 1 or 2 amino acid substitutions, a VHCDR2 comprising the amino acid sequence of SEQ ID NO: 131 optionally comprising 1 or 2 amino acid substitutions, and a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 134 optionally comprising 1 or 2 amino acid substitutions; and/or a light chain variable region comprising a VLCDR1 comprising the amino acid sequence of SEQ ID NO: 144 optionally comprising 1 or 2 amino acid substitutions, a VLCDR2 comprising the amino acid sequence of SEQ ID NO: 145 optionally comprising 1 or 2 amino acid substitutions and a VLCDR3 comprising the amino acid sequence of SEQ ID NO:
• the antibodies may alternatively consist of the specified sequences (with or without amino acid substitutions).
• Certain embodiments relate to the antibody ADT 1 -7-17 and fragments and variants thereof.
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 135 and/or a light chain variable region comprising a VLCDR3 comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 149.
• an antibody or antigen-binding-fragment or variant thereof comprising a heavy chain variable region comprising a VHCDR3 comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 135 and/or a light chain variable region comprising a VLCDR3 comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 149.
• multispecific antibodies are provided, the anti- TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 135 and/or a light chain variable region comprising a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 149.
• Amino acid substitutions may be made to provide variant antibodies having Fab regions derived from ADT1- 7-17, for example multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 135, optionally comprising 1 or 2 amino acid substitutions, and/or a light chain variable region comprising a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 149, optionally comprising 1 or 2 amino acid substitutions.
• the amino acid substitutions may be conservative amino acid substitutions.
• the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 130, a VHCDR2 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 131 and a VHCDR3 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 99% or 100% identity to the amino acid
• multispecific antibodies comprising: a heavy chain variable region comprising a VHCDR1 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 130, a VHCDR2 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 131 and a VHCDR3 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 135; and/or a light chain variable region comprising a VLCDR1 comprising the at least 90% identity to the amino acid sequence of SEQ ID NO: 144, a VLCDR2 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 145 and a VLCDR3 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 149.
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence of SEQ ID NO: 130, a VHCDR2 comprising the amino acid sequence of SEQ ID NO: 131 and a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 135; and a light chain variable region comprising a VLCDR1 comprising the amino acid sequence of SEQ ID NO: 144, a VLCDR2 comprising the amino acid sequence of SEQ ID NO: 145 and a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 149.
• a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence of SEQ ID NO: 130, a VHCDR2 comprising the amino acid sequence of SEQ ID NO: 131 and a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 135
• a light chain variable region comprising a VLC
• Amino acid substitutions may be made to provide variant antibodies having Fab regions derived from ADT1- 7-17, for example multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence of SEQ ID NO: 130 optionally comprising 1 or 2 amino acid substitutions, a VHCDR2 comprising the amino acid sequence of SEQ ID NO: 131 optionally comprising 1 or 2 amino acid substitutions, and a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 135 optionally comprising 1 or 2 amino acid substitutions; and/or a light chain variable region comprising a VLCDR1 comprising the amino acid sequence of SEQ ID NO: 144 optionally comprising 1 or 2 amino acid substitutions, a VLCDR2 comprising the amino acid sequence of SEQ ID NO: 145 optionally comprising 1 or 2 amino acid substitutions and a VLCDR3 comprising the amino acid sequence of SEQ ID NO:
• the antibodies may alternatively consist of the specified sequences (with or without amino acid substitutions).
• Certain embodiments relate to the antibody ADT 1 -7-18 and fragments and variants thereof.
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 136 and/or a light chain variable region comprising a VLCDR3 comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 150.
• an antibody or antigen-binding-fragment or variant thereof comprising a heavy chain variable region comprising a VHCDR3 comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 136 and/or a light chain variable region comprising a VLCDR3 comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 150.
• multispecific antibodies are provided, the anti- TCR delta variable 1 (anti-V51) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 136 and/or a light chain variable region comprising a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 150.
• Amino acid substitutions may be made to provide variant antibodies having Fab regions derived from ADT1- 7-18, for example multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 136, optionally comprising 1 or 2 amino acid substitutions, and/or a light chain variable region comprising a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 150, optionally comprising 1 or 2 amino acid substitutions.
• the amino acid substitutions may be conservative amino acid substitutions.
• the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 130, a VHCDR2 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 131 and a VHCDR3 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 99% or 100% identity to the amino acid
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 130, a VHCDR2 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 131 and a VHCDR3 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 136; and/or a light chain variable region comprising a VLCDR1 comprising the at least 90% identity to the amino acid sequence of SEQ ID NO: 144, a VLCDR2 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 145 and a VLCDR3 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 150.
• a heavy chain variable region comprising a VHCDR1 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 130, a VHCDR2 comprising at least 90% identity to the amino acid sequence of
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence of SEQ ID NO: 130, a VHCDR2 comprising the amino acid sequence of SEQ ID NO: 131 and a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 136; and a light chain variable region comprising a VLCDR1 comprising the amino acid sequence of SEQ ID NO: 144, a VLCDR2 comprising the amino acid sequence of SEQ ID NO: 145 and a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 150.
• a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence of SEQ ID NO: 130, a VHCDR2 comprising the amino acid sequence of SEQ ID NO: 131 and a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 136
• a light chain variable region comprising a VLCDR
• Amino acid substitutions may be made to provide variant antibodies having Fab regions derived from ADT1- 7-18, for example multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence of SEQ ID NO: 130 optionally comprising 1 or 2 amino acid substitutions, a VHCDR2 comprising the amino acid sequence of SEQ ID NO: 131 optionally comprising 1 or 2 amino acid substitutions, and a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 136 optionally comprising 1 or 2 amino acid substitutions; and/or a light chain variable region comprising a VLCDR1 comprising the amino acid sequence of SEQ ID NO: 144 optionally comprising 1 or 2 amino acid substitutions, a VLCDR2 comprising the amino acid sequence of SEQ ID NO: 145 optionally comprising 1 or 2 amino acid substitutions and a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 150
• the antibodies may alternatively consist of the specified sequences (with or without amino acid substitutions).
• Certain embodiments relate to the antibody ADT 1 -7-19 and fragments and variants thereof.
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 137 and/or a light chain variable region comprising a VLCDR3 comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 151.
• an antibody or antigen-binding-fragment or variant thereof comprising a heavy chain variable region comprising a VHCDR3 comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 137 and/or a light chain variable region comprising a VLCDR3 comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 151.
• multispecific antibodies are provided, the anti- TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 137 and/or a light chain variable region comprising a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 151.
• Amino acid substitutions may be made to provide variant antibodies having Fab regions derived from ADT1- 7-19, for example multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 137, optionally comprising 1 or 2 amino acid substitutions, and/or a light chain variable region comprising a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 151 , optionally comprising 1 or 2 amino acid substitutions.
• the amino acid substitutions may be conservative amino acid substitutions.
• the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 130, a VHCDR2 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 131 and a VHCDR3 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 99% or 100% identity to the amino acid
• the anti-TCR delta variable 1 (anti-V 1) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 130, a VHCDR2 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 131 and a VHCDR3 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 137; and/or a light chain variable region comprising a VLCDR1 comprising the at least 90% identity to the amino acid sequence of SEQ ID NO: 144, a VLCDR2 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 145 and a VLCDR3 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 151.
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V51) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence of SEQ ID NO: 130, a VHCDR2 comprising the amino acid sequence of SEQ ID NO: 131 and a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 137; and a light chain variable region comprising a VLCDR1 comprising the amino acid sequence of SEQ ID NO: 144, a VLCDR2 comprising the amino acid sequence of SEQ ID NO: 145 and a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 151.
• a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence of SEQ ID NO: 130, a VHCDR2 comprising the amino acid sequence of SEQ ID NO: 131 and a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 137
• a light chain variable region comprising a VLC
• Amino acid substitutions may be made to provide variant antibodies having Fab regions derived from ADT1- 7-19, for example multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence of SEQ ID NO: 130 optionally comprising 1 or 2 amino acid substitutions, a VHCDR2 comprising the amino acid sequence of SEQ ID NO: 131 optionally comprising 1 or 2 amino acid substitutions, and a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 137 optionally comprising 1 or 2 amino acid substitutions; and/or a light chain variable region comprising a VLCDR1 comprising the amino acid sequence of SEQ ID NO: 144 optionally comprising 1 or 2 amino acid substitutions, a VLCDR2 comprising the amino acid sequence of SEQ ID NO: 145 optionally comprising 1 or 2 amino acid substitutions and a VLCDR3 comprising the amino acid sequence of SEQ ID NO:
• the antibodies may alternatively consist of the specified sequences (with or without amino acid substitutions).
• Certain embodiments relate to the antibody ADT 1 -7-20 and fragments and variants thereof.
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V 1) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 138 and/or a light chain variable region comprising a VLCDR3 comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 152.
• anti-V 1 (anti-V 1) binding Fab region comprising
• an antibody or antigen-binding-fragment or variant thereof comprising a heavy chain variable region comprising a VHCDR3 comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 138 and/or a light chain variable region comprising a VLCDR3 comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 152.
• multispecific antibodies are provided, the anti- TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 138 and/or a light chain variable region comprising a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 152.
• Amino acid substitutions may be made to provide variant antibodies having Fab regions derived from ADT1- 7-20, for example multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-Vd1) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 138, optionally comprising 1 or 2 amino acid substitutions, and/or a light chain variable region comprising a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 152, optionally comprising 1 or 2 amino acid substitutions.
• the amino acid substitutions may be conservative amino acid substitutions.
• the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 130, a VHCDR2 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 131 and a VHCDR3 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 99% or 100% identity to the amino acid
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V51) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 130, a VHCDR2 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 131 and a VHCDR3 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 138; and/or a light chain variable region comprising a VLCDR1 comprising the at least 90% identity to the amino acid sequence of SEQ ID NO: 144, a VLCDR2 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 145 and a VLCDR3 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 152.
• a heavy chain variable region comprising a VHCDR1 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 130, a VHCDR2 comprising at least 90% identity to the amino acid sequence
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V51) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence of SEQ ID NO: 130, a VHCDR2 comprising the amino acid sequence of SEQ ID NO: 131 and a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 138; and a light chain variable region comprising a VLCDR1 comprising the amino acid sequence of SEQ ID NO: 144, a VLCDR2 comprising the amino acid sequence of SEQ ID NO: 145 and a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 152.
• a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence of SEQ ID NO: 130, a VHCDR2 comprising the amino acid sequence of SEQ ID NO: 131 and a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 138
• a light chain variable region comprising a VLC
• Amino acid substitutions may be made to provide variant antibodies having Fab regions derived from ADT1- 7-20, for example multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence of SEQ ID NO: 130 optionally comprising 1 or 2 amino acid substitutions, a VFICDR2 comprising the amino acid sequence of SEQ ID NO: 131 optionally comprising 1 or 2 amino acid substitutions, and a VFICDR3 comprising the amino acid sequence of SEQ ID NO: 138 optionally comprising 1 or 2 amino acid substitutions; and/or a light chain variable region comprising a VLCDR1 comprising the amino acid sequence of SEQ ID NO: 144 optionally comprising 1 or 2 amino acid substitutions, a VLCDR2 comprising the amino acid sequence of SEQ ID NO: 145 optionally comprising 1 or 2 amino acid substitutions and a VLCDR3 comprising the amino acid sequence of SEQ ID NO
• the antibodies may alternatively consist of the specified sequences (with or without amino acid substitutions).
• Certain embodiments relate to the antibody ADT 1 -7-22 and fragments and variants thereof.
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VFICDR3 comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 139 and/or a light chain variable region comprising a VLCDR3 comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 153.
• an antibody or antigen-binding-fragment or variant thereof comprising a heavy chain variable region comprising a VHCDR3 comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 139 and/or a light chain variable region comprising a VLCDR3 comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 153.
• multispecific antibodies are provided, the anti- TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 139 and/or a light chain variable region comprising a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 153.
• Amino acid substitutions may be made to provide variant antibodies having Fab regions derived from ADT1- 7-22, for example multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 139, optionally comprising 1 or 2 amino acid substitutions, and/or a light chain variable region comprising a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 153, optionally comprising 1 or 2 amino acid substitutions.
• the amino acid substitutions may be conservative amino acid substitutions.
• the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VFICDR1 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 130, a VFICDR2 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 131 and a VFICDR3 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V51) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 130, a VHCDR2 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 131 and a VHCDR3 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 139; and/or a light chain variable region comprising a VLCDR1 comprising the at least 90% identity to the amino acid sequence of SEQ ID NO: 144, a VLCDR2 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 145 and a VLCDR3 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 153.
• a heavy chain variable region comprising a VHCDR1 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 130, a VHCDR2 comprising at least 90% identity to the amino acid sequence
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence of SEQ ID NO: 130, a VHCDR2 comprising the amino acid sequence of SEQ ID NO: 131 and a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 139; and a light chain variable region comprising a VLCDR1 comprising the amino acid sequence of SEQ ID NO: 144, a VLCDR2 comprising the amino acid sequence of SEQ ID NO: 145 and a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 153.
• Amino acid substitutions may be made to provide variant antibodies having Fab regions derived from ADT1- 7-22, for example multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence of SEQ ID NO: 130 optionally comprising 1 or 2 amino acid substitutions, a VHCDR2 comprising the amino acid sequence of SEQ ID NO: 131 optionally comprising 1 or 2 amino acid substitutions, and a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 139 optionally comprising 1 or 2 amino acid substitutions; and/or a light chain variable region comprising a VLCDR1 comprising the amino acid sequence of SEQ ID NO: 144 optionally comprising 1 or 2 amino acid substitutions, a VLCDR2 comprising the amino acid sequence of SEQ ID NO: 145 optionally comprising 1 or 2 amino acid substitutions and a VLCDR3 comprising the amino acid sequence of SEQ ID NO:
• the antibodies may alternatively consist of the specified sequences (with or without amino acid substitutions).
• Certain embodiments relate to the antibody ADT 1 -7-23 and fragments and variants thereof.
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 140 and/or a light chain variable region comprising a VLCDR3 comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 154.
• an antibody or antigen-binding-fragment or variant thereof comprising a heavy chain variable region comprising a VHCDR3 comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 140 and/or a light chain variable region comprising a VLCDR3 comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 154.
• multispecific antibodies are provided, the anti- TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 140 and/or a light chain variable region comprising a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 154.
• Amino acid substitutions may be made to provide variant antibodies having Fab regions derived from ADT1- 7-23, for example multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 140, optionally comprising 1 or 2 amino acid substitutions, and/or a light chain variable region comprising a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 154, optionally comprising 1 or 2 amino acid substitutions.
• the amino acid substitutions may be conservative amino acid substitutions.
• the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 130, a VHCDR2 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 131 and a VHCDR3 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 99% or 100% identity to the amino acid
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V51) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 130, a VHCDR2 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 131 and a VHCDR3 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 140; and/or a light chain variable region comprising a VLCDR1 comprising the at least 90% identity to the amino acid sequence of SEQ ID NO: 144, a VLCDR2 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 145 and a VLCDR3 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 154.
• a heavy chain variable region comprising a VHCDR1 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 130, a VHCDR2 comprising at least 90% identity to the amino acid sequence of
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence of SEQ ID NO: 130, a VHCDR2 comprising the amino acid sequence of SEQ ID NO: 131 and a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 140; and a light chain variable region comprising a VLCDR1 comprising the amino acid sequence of SEQ ID NO: 144, a VLCDR2 comprising the amino acid sequence of SEQ ID NO: 145 and a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 154.
• a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence of SEQ ID NO: 130, a VHCDR2 comprising the amino acid sequence of SEQ ID NO: 131 and a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 140
• a light chain variable region comprising a VLCDR1
• Amino acid substitutions may be made to provide variant antibodies having Fab regions derived from ADT1- 7-23, for example multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence of SEQ ID NO: 130 optionally comprising 1 or 2 amino acid substitutions, a VHCDR2 comprising the amino acid sequence of SEQ ID NO: 131 optionally comprising 1 or 2 amino acid substitutions, and a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 140 optionally comprising 1 or 2 amino acid substitutions; and/or a light chain variable region comprising a VLCDR1 comprising the amino acid sequence of SEQ ID NO: 144 optionally comprising 1 or 2 amino acid substitutions, a VLCDR2 comprising the amino acid sequence of SEQ ID NO: 145 optionally comprising 1 or 2 amino acid substitutions and a VLCDR3 comprising the amino acid sequence of SEQ ID NO:
• the antibodies may alternatively consist of the specified sequences (with or without amino acid substitutions).
• the anti-TCR delta variable 1 (anti-V51) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 141 and/or a light chain variable region comprising a VLCDR3 comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to
• an antibody or antigen-binding-fragment or variant thereof comprising a heavy chain variable region comprising a VHCDR3 comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 141 and/or a light chain variable region comprising a VLCDR3 comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 155.
• multispecific antibodies are provided, the anti- TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 141 and/or a light chain variable region comprising a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 155.
• Amino acid substitutions may be made to provide variant antibodies having Fab regions derived from ADT1- 7-42, for example multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 141 , optionally comprising 1 or 2 amino acid substitutions, and/or a light chain variable region comprising a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 155, optionally comprising 1 or 2 amino acid substitutions.
• the amino acid substitutions may be conservative amino acid substitutions.
• the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 130, a VHCDR2 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 131 and a VHCDR3 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 99% or 100% identity to the amino acid
• the anti-TCR delta variable 1 (anti-V 1) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 130, a VHCDR2 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 131 and a VHCDR3 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 141 ; and/or a light chain variable region comprising a VLCDR1 comprising the at least 90% identity to the amino acid sequence of SEQ ID NO: 144, a VLCDR2 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 145 and a VLCDR3 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 155.
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V51) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence of SEQ ID NO: 130, a VHCDR2 comprising the amino acid sequence of SEQ ID NO: 131 and a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 141 ; and a light chain variable region comprising a VLCDR1 comprising the amino acid sequence of SEQ ID NO: 144, a VLCDR2 comprising the amino acid sequence of SEQ ID NO: 145 and a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 155.
• Amino acid substitutions may be made to provide variant antibodies having Fab regions derived from ADT1- 7-42, for example multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence of SEQ ID NO: 130 optionally comprising 1 or 2 amino acid substitutions, a VHCDR2 comprising the amino acid sequence of SEQ ID NO: 131 optionally comprising 1 or 2 amino acid substitutions, and a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 141 optionally comprising 1 or 2 amino acid substitutions; and/or a light chain variable region comprising a VLCDR1 comprising the amino acid sequence of SEQ ID NO: 144 optionally comprising 1 or 2 amino acid substitutions, a VLCDR2 comprising the amino acid sequence of SEQ ID NO: 145 optionally comprising 1 or 2 amino acid substitutions and a VLCDR3 comprising the amino acid sequence of SEQ ID NO:
• the antibodies may alternatively consist of the specified sequences (with or without amino acid substitutions).
• ADT1-7-3 and fragments and variants thereof may alternatively consist of the specified sequences (with or without amino acid substitutions).
• Certain embodiments relate to the antibody ADT1 -7-3 and fragments and variants thereof.
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V51) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 142 and/or a light chain variable region comprising a VLCDR3 comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 156.
• an antibody or antigen-binding-fragment or variant thereof comprising a heavy chain variable region comprising a VHCDR3 comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 142 and/or a light chain variable region comprising a VLCDR3 comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 156.
• multispecific antibodies are provided, the anti- TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 142 and/or a light chain variable region comprising a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 156.
• Amino acid substitutions may be made to provide variant antibodies having Fab regions derived from ADT1- 7-3, for example multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V51) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 142, optionally comprising 1 or 2 amino acid substitutions, and/or a light chain variable region comprising a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 156, optionally comprising 1 or 2 amino acid substitutions.
• the amino acid substitutions may be conservative amino acid substitutions.
• the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 130, a VHCDR2 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 131 and a VHCDR3 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 99% or 100% identity to the amino acid
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 130, a VHCDR2 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 131 and a VHCDR3 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 142; and/or a light chain variable region comprising a VLCDR1 comprising the at least 90% identity to the amino acid sequence of SEQ ID NO: 144, a VLCDR2 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 145 and a VLCDR3 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 156.
• a heavy chain variable region comprising a VHCDR1 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 130, a VHCDR2 comprising at least 90% identity to the amino acid sequence
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence of SEQ ID NO: 130, a VHCDR2 comprising the amino acid sequence of SEQ ID NO: 131 and a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 142; and a light chain variable region comprising a VLCDR1 comprising the amino acid sequence of SEQ ID NO: 144, a VLCDR2 comprising the amino acid sequence of SEQ ID NO: 145 and a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 156.
• a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence of SEQ ID NO: 130, a VHCDR2 comprising the amino acid sequence of SEQ ID NO: 131 and a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 142
• a light chain variable region comprising a VLC
• Amino acid substitutions may be made to provide variant antibodies having Fab regions derived from ADT1- 7-3, for example multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V51) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence of SEQ ID NO: 130 optionally comprising 1 or 2 amino acid substitutions, a VHCDR2 comprising the amino acid sequence of SEQ ID NO: 131 optionally comprising 1 or 2 amino acid substitutions, and a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 142 optionally comprising 1 or 2 amino acid substitutions; and/or a light chain variable region comprising a VLCDR1 comprising the amino acid sequence of SEQ ID NO: 144 optionally comprising 1 or 2 amino acid substitutions, a VLCDR2 comprising the amino acid sequence of SEQ ID NO: 145 optionally comprising 1 or 2 amino acid substitutions and a VLCDR3 comprising the amino acid sequence of SEQ ID NO:
• Certain embodiments relate to the antibody ADT 1 -7-61 and fragments and variants thereof.
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 143 and/or a light chain variable region comprising a VLCDR3 comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 157.
• an antibody or antigen-binding-fragment or variant thereof comprising a heavy chain variable region comprising a VHCDR3 comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 143 and/or a light chain variable region comprising a VLCDR3 comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 157.
• multispecific antibodies are provided, the anti- TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 143 and/or a light chain variable region comprising a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 157.
• Amino acid substitutions may be made to provide variant antibodies having Fab regions derived from ADT1- 7-61, for example multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising a heavy chain variable region comprising a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 143, optionally comprising 1 or 2 amino acid substitutions, and/or a light chain variable region comprising a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 157, optionally comprising 1 or 2 amino acid substitutions.
• the amino acid substitutions may be conservative amino acid substitutions.
• the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 130, a VHCDR2 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 131 and a VHCDR3 comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 99% or 100% identity to the amino acid
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 130, a VHCDR2 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 131 and a VHCDR3 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 143; and/or a light chain variable region comprising a VLCDR1 comprising the at least 90% identity to the amino acid sequence of SEQ ID NO: 144, a VLCDR2 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 145 and a VLCDR3 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 157.
• a heavy chain variable region comprising a VHCDR1 comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 130, a VHCDR2 comprising at least 90% identity to the amino acid sequence
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V51) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence of SEQ ID NO: 130, a VHCDR2 comprising the amino acid sequence of SEQ ID NO: 131 and a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 143; and a light chain variable region comprising a VLCDR1 comprising the amino acid sequence of SEQ ID NO: 144, a VLCDR2 comprising the amino acid sequence of SEQ ID NO: 145 and a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 157.
• Amino acid substitutions may be made to provide variant antibodies having Fab regions derived from ADT1- 7-61, for example multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence of SEQ ID NO: 130 optionally comprising 1 or 2 amino acid substitutions, a VHCDR2 comprising the amino acid sequence of SEQ ID NO: 131 optionally comprising 1 or 2 amino acid substitutions, and a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 143 optionally comprising 1 or 2 amino acid substitutions; and/or a light chain variable region comprising a VLCDR1 comprising the amino acid sequence of SEQ ID NO: 144 optionally comprising 1 or 2 amino acid substitutions, a VLCDR2 comprising the amino acid sequence of SEQ ID NO: 145 optionally comprising 1 or 2 amino acid substitutions and a VLCDR3 comprising the amino acid sequence of SEQ ID NO:
• the antibodies may alternatively consist of the specified sequences (with or without amino acid substitutions).
• Antibodies comprising heavy and/or light chain variable regions derived from ADT1-7
• the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising or consisting of a sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to a sequence selected from the group consisting of SEQ ID NOs: 107 to 117; and/or a light chain variable region comprising or consisting of a sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to a sequence selected from the group consisting of SEQ ID NOs: 119 to 129.
• the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising or consisting of a sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to a sequence selected from the group consisting of SEQ ID NOs: 112, 116 and 117; and/or a light chain variable region comprising or consisting of a sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to a sequence selected from the group consisting of SEQ ID NOs: 124, 128 and 129.
• the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising or consisting of a sequence having at least 90% identity to a sequence selected from the group consisting of SEQ ID NOs: 107 to 117; and/or a light chain variable region comprising or consisting of a sequence having at least 90% identity to a sequence selected from the group consisting of SEQ ID NOs: 119 to 129.
• the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising or consisting of a sequence having at least 90% identity to a sequence selected from the group consisting of SEQ ID NOs: 112, 116 and 117; and/or a light chain variable region comprising or consisting of a sequence having at least 90% identity to a sequence selected from the group consisting of SEQ ID NOs: 124, 128 and 129.
• the antibodies above retain the corresponding CDR sequences such that any variability in the VH and VL sequences occurs in the framework regions.
• the anti-TCR delta variable 1 (anti-V51) binding Fab region comprising: a heavy chain variable region comprising or consisting of a sequence selected from the group consisting of SEQ ID NOs: 107 to 117; and/or a light chain variable region comprising or consisting of a sequence selected from the group consisting of SEQ ID NOs: 119 to 129.
• the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a heavy chain variable region comprising or consisting of a sequence selected from the group consisting of SEQ ID NOs: 112, 116 and 117; and/or a light chain variable region comprising or consisting of a sequence selected from the group consisting of SEQ ID NOs: 124, 128 and 129.
• the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a) a VH comprising or consisting of an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 107 and a VL comprising or consisting of an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 119; b) a VH comprising or consisting of an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 108 and a VL comprising or consisting of an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 120; c) a VH comprising or consisting of an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 109 and a VL comprising or consisting of an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 121 ; d) a VH comprising or
• the antibodies above retain the corresponding CDR sequences such that any variability in the VH and VL sequences occurs in the framework regions.
• the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a) a VH comprising or consisting of the amino acid sequence of SEQ ID NO: 107 and a VL comprising or consisting of the amino acid sequence of SEQ ID NO: 119 optionally comprising up to 5, up to 4, up to 3, up to 2 or 1 amino acid substitutions across both variable regions; b) a VH comprising or consisting of the amino acid sequence of SEQ ID NO: 108 and a VL comprising or consisting of the amino acid sequence of SEQ ID NO: 120 optionally comprising up to 5, up to 4, up to 3, up to 2 or 1 amino acid substitutions across both variable regions; c) a VH comprising or consisting of the amino acid sequence of SEQ ID NO: 109 and a VL comprising or consisting of the amino acid sequence of SEQ ID NO: 121 optionally comprising up to 5, up to 4, up to 3, up to 2 or 1 amino acid substitutions across both variable regions
• the antibody may comprise up to the specified number of substitutions in total when considering both the heavy and light chain variable regions.
• the amino acid substitutions may be conservative amino acid substitutions.
• the substitutions (if present) may occur anywhere in the variable region sequences.
• the substitutions (if present) may be limited to the framework regions. Accordingly in some embodiments, the amino acid substitutions do not occur in a CDR sequence.
• the antibodies above retain the corresponding CDR sequences such that any variability in the VH and VL sequences occurs in the framework regions.
• multispecific antibodies are provided, the anti-TCR delta variable 1 (anti-V51) binding Fab region comprising: a) a VH comprising or consisting of the amino acid sequence of SEQ ID NO: 107 and a VL comprising or consisting of the amino acid sequence of SEQ ID NO: 119; b) a VH comprising or consisting of the amino acid sequence of SEQ ID NO: 108 and a VL comprising or consisting of the amino acid sequence of SEQ ID NO: 120; c) a VH comprising or consisting of the amino acid sequence of SEQ ID NO: 109 and a VL comprising or consisting of the amino acid sequence of SEQ ID NO: 121 ; d) a VH comprising or consisting of the amino acid sequence of SEQ ID NO: 110 and a VL comprising or consisting of the amino acid sequence of SEQ ID NO: 122; e) a VH comprising or consisting of the amino acid sequence of SEQ ID NO: 111 and a
• Certain amino acid substitutions may be made to provide one or more variant antibodies as described herein.
• VH sequence is not SEQ ID NO: 106 and the VL sequence is not SEQ ID NO: 118.
• the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a) an HCDR1 sequence comprising or consisting of the sequence of SEQ ID NO: 130; b) an HCDR2 sequence comprising or consisting of the sequence of SEQ ID NO: 131 ; c) an HCDR3 sequence comprising or consisting of the sequence of X 1 X 2 YX3X 4 AFDI (SEQ ID NO:
• HCDR3 sequence is not SEQ ID NO: 132; d) an LCDR1 sequence comprising or consisting of the sequence of SEQ ID NO: 144; e) an LCDR2 sequence comprising or consisting of the sequence of SEQ ID NO: 145; and f) an LCDR3 sequence comprising or consisting of the sequence of QQXsXsXyXsLXeT (SEQ ID NO:
• LCDR3 sequence is no SEQ ID NO: 146; wherein each of Xi to X is a naturally occurring amino acid.
• the anti-TCR delta variable 1 (anti-V51) binding Fab region comprising: a) an HCDR1 sequence comprising or consisting of the sequence of SEQ ID NO: 130; b) an HCDR2 sequence comprising or consisting of the sequence of SEQ ID NO: 131 ; c) an HCDR3 sequence comprising or consisting of the sequence of X 1 X 2 YX3X 4 AFDI (SEQ ID NO:
• HCDR3 sequence is not SEQ ID NO: 132; d) an LCDR1 sequence comprising or consisting of the sequence of SEQ ID NO: 144; e) an LCDR2 sequence comprising or consisting of the sequence of SEQ ID NO: 145; and f) an LCDR3 sequence comprising or consisting of the sequence of QQXsXeXyXeLXgT (SEQ ID NO:
• LCDR3 sequence is no SEQ ID NO: 146; wherein Xi is selected from the group consisting of D, I and V; X 2 is selected from the group consisting of D and S; X3 is selected from the group consisting of N, E, D, Q and A; X is selected from the group consisting of D and E; Xs is selected from the group consisting of T and S; Cb is selected from the group consisting of A, G, Y and S; X7 is selected from the group consisting of S and D; Xe is selected from the group consisting of T, E and G; and Xg is selected from the group consisting of L and D.
• the antibody may further comprise an HFR1 sequence comprising the sequence of SEQ ID NO: 189; an HFR2 sequence comprising the sequence of SEQ ID NO: 190; an HFR3 sequence comprising the sequence of SEQ ID NO: 191 ; an FIFR4 sequence comprising the sequence of SEQ ID NO: 192; an LFR1 sequence comprising the sequence of SEQ ID NO: 193 and 194; an LFR2 sequence comprising the sequence of SEQ ID NO: 195; an LFR3 sequence comprising the sequence of SEQ ID NO: 196; and an LFR4 sequence comprising the sequence of SEQ ID NO: 197.
• the anti-TCR delta variable 1 (anti-V61) binding Fab region comprising: a) an FICDR1 sequence comprising or consisting of the sequence of SEQ ID NO: 130 b) an FICDR2 sequence comprising or consisting of the sequence of SEQ ID NO: 131 c) an HCDR3 sequence comprising or consisting of the sequence of X 1 X 2 YX3X 4 AFDI (SEQ ID NO:
• the FICDR3 sequence is not SEQ ID NO: 132; d) an LCDR1 sequence comprising or consisting of the sequence of SEQ ID NO: 144; e) an LCDR2 sequence comprising or consisting of the sequence of SEQ ID NO: 145; and f) an LCDR3 sequence comprising or consisting of the sequence of QQXsXeXyXaLXgT (SEQ ID NO:
• LCDR3 sequence is no SEQ ID NO: 146; wherein Xi is selected from the group consisting of D and V; X is selected from the group consisting of D and S; X3 is selected from the group consisting of D, Q and A; X is selected from the group consisting of D and E; X5 is S; Cb is selected from the group consisting of A and Y; X7 is S; Xs is selected from the group consisting of E and G; and Xs is selected from the group consisting of L and D.
• the antibody may further comprise an HFR1 sequence comprising the sequence of SEQ ID NO: 189; an HFR2 sequence comprising the sequence of SEQ ID NO: 190; an FIFR3 sequence comprising the sequence of SEQ ID NO: 191 ; an HFR4 sequence comprising the sequence of SEQ ID NO: 192; an LFR1 sequence comprising the sequence of SEQ ID NO: 193; an LFR2 sequence comprising the sequence of SEQ ID NO: 195; an LFR3 sequence comprising the sequence of SEQ ID NO: 196; and an LFR4 sequence comprising the sequence of SEQ ID NO: 197.
• amino acids have similar properties.
• One or more such amino acids of a substance can often be substituted by one or more other such amino acids without eliminating a desired activity of that substance.
• amino acids glycine, alanine, valine, leucine and isoleucine can often be substituted for one another (amino acids having aliphatic side chains).
• amino acids having aliphatic side chains amino acids having aliphatic side chains.
• glycine and alanine are used to substitute for one another (since they have relatively short side chains) and that valine, leucine and isoleucine are used to substitute for one another (since they have larger aliphatic side chains which are hydrophobic).
• amino acids which can often be substituted for one another include: phenylalanine, tyrosine and tryptophan (amino acids having aromatic side chains); lysine, arginine and histidine (amino acids having basic side chains); aspartate and glutamate (amino acids having acidic side chains); asparagine and glutamine (amino acids having amide side chains); and cysteine and methionine (amino acids having sulphur containing side chains).
• a “conservative” amino acid substitution is an amino acid substitution in which an amino acid residue is replaced with another amino acid residue of similar chemical structure and which is expected to have little influence on the function, activity or other biological properties of the polypeptide.
• conservative substitutions suitably are substitutions in which one amino acid within the following groups is substituted by another amino acid residue from within the same group:
• a hydrophobic amino acid residue is a non-polar amino acid. More suitably, a hydrophobic amino acid residue is selected from V, I, L, M, F, WorC. In some embodiments, a hydrophobic amino acid residue is selected from glycine, alanine, valine, methionine, leucine, isoleucine, phenylalanine, tyrosine, or tryptophan.
• references to “conservative” amino acid substitutions refer to amino acid substitutions in which one or more of the amino acids in the sequence of the antibody (e.g. in the CDRs or in the VH or VL sequences) is substituted with another amino acid in the same class as indicated above.
• Conservative amino acid substitutions may be preferred in the CDR regions to minimise adverse effects on the function of the antibody.
• conservative amino acid substitutions may also occur in the framework regions. Therefore, in some embodiments, any substitutions in the CDRs may be conservative substitutions, whereas substitutions in the framework regions may by substitutions of naturally occurring amino acids with another other naturally occurring amino acids.
• Amino acid deletions or insertions can also be made relative to the amino acid sequences provided for the antibodies described herein.
• amino acids which do not have a substantial effect on the activity of the polypeptide, or at least which do not eliminate such activity can be deleted.
• deletions can be advantageous since the overall length and the molecular weight of a polypeptide can be reduced whilst still retaining activity. This can enable the amount of polypeptide required for a particular purpose to be reduced - for example, dosage levels can be reduced.
• Amino acid changes relative to the sequences provided herein can be made using any suitable technique e.g. by using site-directed mutagenesis or solid-state synthesis.
• amino acid substitutions or insertions within the scope of the present invention can be made using naturally occurring or non-naturally occurring amino acids, although naturally occurring amino acids may be preferred. Whether or not natural or synthetic amino acids are used, it may be preferred that only L- amino acids are present.
• antibodies, or antigen-binding fragment thereof, of the invention comprising up to 10, suitably up to 5, or suitably up to 2 amino acid substitutions in the antibody binding domain or antigen-binding domains.
• an V61 antibody or antigen-binding fragment thereof wherein the antibody or antigen-binding fragment thereof comprises the 6 CDR regions of an antibody selected from the group consisting of ADT1-4-105, ADT1-4-107, ADT1-4-110, ADT1-4-112, ADT1-4-117, ADT1-4-19, ADT1 -4-21 , ADT1 -4-31 , ADT1 -4-139, ADT1-4-4, ADT1-4-143, ADT1-4-53, ADT1-4-173, ADT1-4-2, ADT1- 4-8, ADT1-4-82, ADT1-4-83, ADT1-4-3, ADT1-4-84, ADT1-4-86, ADT1-4-95, ADT1-4-1 , ADT1-4-6, ADT1- 4-138, ADT1-7-10, ADT1-7-15, ADT1-7-17, ADT1-7-18, ADT1-7-19, ADT1-7-20, ADT1-7-22, ADT1-7-23, ADT1-7-42
• an anti-V61 antibody or antigen-binding fragment thereof wherein the antibody or antigen-binding fragment thereof comprises the VH and VL sequences of an antibody selected from the group consisting of ADT1-4-105, ADT1-4-107, ADT1-4-110, ADT1-4-112, ADT1-4-117, ADT1-4-19, ADT1-4-21 , ADT1-4-31 , ADT1-4-139, ADT1-4-4, ADT1-4-143, ADT1-4-53, ADT1-4-173, ADT1-4-2, ADT1-4-8, ADT1-4-82, ADT1-4-83, ADT1-4-3, ADT1-4- 84, ADT1-4-86, ADT1-4-95, ADT1-4-1 , ADT1-4-6, ADT1-4-138, ADT1-7-10, ADT1-7-15, ADT1-7-17, ADT1-7-18, ADT1-7-19, ADT1-7-20, ADT1-7-22, ADT1-7-23, ADT1-7-42, ADT1
• an anti-V61 antibody or antigen-binding fragment thereof wherein the antibody or antigen binding fragment thereof is an antibody selected from the group consisting of ADT1-4-105, ADT1-4-107, ADT1-4-110, ADT1-4-112, ADT1-4-117, ADT1-4-19, ADT1-4-21 , ADT1-4-31 , ADT1-4-139, ADT1-4-4, ADT1-4-143, ADT1-4-53, ADT1-4-173, ADT1-4-2, ADT1-4-8, ADT1-4-82, ADT1-4-83, ADT1-4-3, ADT1-4- 84, ADT1-4-86, ADT1-4-95, ADT1-4-1 , ADT1-4-6, ADT1-4-138, ADT1-7-10, ADT1-7-15, ADT1-7-17, ADT1-7-18, ADT1-7-19, ADT1-7-20, ADT1-7-22, ADT1-7-23, ADT1-7-42, ADT1-7-3 and ADT1-7-61
• the one or more amino acid substitutions are in the CDR region or regions. In other embodiments, the one or more amino acid substitutions are in the framework regions, i.e. in the variable heavy and light chains but not in the CDR region or regions. In other embodiments, the one or more amino acid substitutions may be at any position in the variable heavy and/or variable light regions. In some embodiments, the amino acid substitutions do not occur in a CDR sequence.
• the amino acid substitutions do not adversely affect the binding specificity and/or affinity of the antibody. Accordingly, the variant antibody may have the same (or substantially the same) or a superior functional profile as the antibody from which is it derived.
• amino acid substitutions may be made to increase the binding affinity of the antibody to a particular antigen.
• a substitution may be made to increase the cross reactivity of the antibody for a the cyno homolog of the human antigen against which the antibody was prepared. Unlike other substitutions described above, this substitution may preferably be nonconservative.
• the substitution may be a substitution of the serine at position 74 to a non-polar amino acid (for example to an amino acid selected from the group consisting of glycine, alanine, valine, methionine, leucine and isoleucine).
• the serine may be substituted with a non-human- germline amino acid (for example to an amino acid selected from the group consisting of arginine, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, tyrosine and valine).
• the serine may be substituted with an amino acid that is both non-human-germline and non-polar, i.e. an amino acid selected from the group consisting of glycine, valine, methionine, leucine and isoleucine.
• the serine may be substituted with a leucine.
• multispecific antibodies or antigen-binding fragments thereof which bind to an epitope of the V61 chain of a gd TCR. Such binding may optionally have an effect on gd TCR activity, such as activation.
• the multispecific antibodies of the invention are specific for the V61 chain of a gd TCR, and do not bind epitopes of other antigens, such as the V62 chain of a gd TCR or the V63 chain of a gd TCR.
• the antibodies of the present invention may be considered agonistic antibodies, at least with respect to the agonistic effect conferred upon V61 cells upon binding.
• the epitope may be an activating epitope of a gd T cell.
• An “activating” epitope can include, for example, stimulating a TCR function, such as cell degranulation, TCR downregulation, cytotoxicity, proliferation, mobilisation, increased survival or resistance to exhaustion, intracellular signalling, cytokine or growth factor secretion, phenotypic change, or a change in gene expression.
• the binding of the activating epitope may stimulate expansion ( i.e . proliferation) of the gd T cell population, preferably the V61+ T cell population. Accordingly, these antibodies can be used to modulate y5 T cell activation, and, thereby, to modulate the immune response.
• binding of the activating epitope downregulates the gd TCR.
• binding of the activating epitope activates degranulation of the gd T cell.
• binding of the activating epitope promotes gd T cell mediated killing.
• an activating epitope of TRDV1 is one that, upon being bound by an antibody, results in down-regulation of the receptor and optionally activates the V61 cell.
• the activating epitope is one that upregulates expression of activatory markers on the V61 cell, for example CD107a, CD25, CD69 and/or Ki67.
• the activating epitope is one that upregulates expression of activatory markers on the nd1 cell, for example CD107 and CD25, and optionally CD69 and/or Ki67.
• upregulation of the one or more activatory markers may be upregulation in the presence of cancer cells.
• the antibodies bind activating epitopes of TRDV1 , in particular via the TRDV1-binding domain.
• the T-cell receptors are often complexed with other proteins
• downregulation of the T-cell receptor via V61 antibody binding may cause downregulation of other proteins associated with the T-cell receptor (i.e. the binding of the V61 antibody causes down regulation of the T-cell receptor complex).
• an activating epitope of TRDV1 is one that upon binding, down-regulates the TCR/CD3 receptor complex.
• the antibodies of the invention may cause indirect downregulation of cell surface proteins that are not bound by the antibody, but are complexed to the T-cell receptor.
• the multispecific antibodies of the invention can be used to selectively (and indirectly) downregulate proteins in the TCR complex, such as CD3, by only downregulating them in V61 cells.
• a T-cell receptor complex activating epitope is one that upon activation, downregulates the T-cell receptor complex, whilst not downregulating CD3 molecules not associated with said TRDV1 TCR complex.
• the epitope is preferably comprised of or consists of at least one extracellular, soluble, hydrophilic or external portion of the V61 chain of a gd TCR.
• the epitope does not comprise or consist of an epitope found in a hypervariable region of the V61 chain of the gd TCR, in particular CDR3 of the V61 chain.
• the epitope is within the non-variable region of the V61 chain of the gd TCR. It will be appreciated that such binding allows for the unique recognition of the V61 chain without the restriction to the sequences of the TCR which are highly variable (in particular CDR3).
• Various gd TCR complexes which recognise antigen may be recognised in this way, solely by presence of the V61 chain.
• the epitope comprises or consists of one or more amino acid residues within amino acid regions 1-24 and/or 35-90 of SEQ ID NO: 272, e.g. the portions of the V51 chain which are not part of the CDR1 and/or CDR3 sequences. In one embodiment, the epitope does not comprise or consist of amino acid residues within amino acid region 91-105 (CDR3) of SEQ ID NO: 272.
• the epitope comprises or consists of amino acids in the TRDV-1 CDR2 sequence.
• gd T cells utilize a distinct set of somatically rearranged variable (V), diversity (D), joining (J), and constant (C) genes, although gd T cells contain fewer V, D, and J segments than ab T cells.
• the epitope of V61 bound by the multispecific antibodies (or antigen-binding fragments thereof) does not comprise or consist of an epitope found in the J region of the nd1 chain (e.g.
• the epitope of nd1 bound by the multispecific antibodies (or antigen-binding fragments thereof) does not comprise or consist of an epitope found in the N-terminal leader sequence of the V61 chain (e.g. SEQ ID NO: 299).
• the antibody or fragment may therefore only bind in the V region of the V61 chain (e.g. SEQ ID NO: 300).
• the epitope consists of an epitope in the V region of the gd TCR (e.g. amino acid residues 1-90 of SEQ ID NO: 272).
• SEQ ID NO: 272 represents a soluble TCR comprising or consisting of a V region (also referred to as the variable domain), a D region, a J region and a TCR constant region.
• the V region comprises or consists of amino acid residues 1-90
• the D region comprises or consists of amino acid residues 91-104
• the J region comprises or consists of amino acid residues 105-115
• the constant region (derived from T-cell receptor alpha) comprises or consists of amino acid residues 116-209.
• CDR1 is defined as amino acid residues 25-34 of SEQ ID NO: 272
• CDR2 is defined as amino acid residues 50-54 of SEQ ID NO: 272
• CDR3 is defined as amino acid residues 93-104 of SEQ ID NO: 272 (Xu et al., PNAS USA 108(6):2414-2419 (2011)).
• an isolated antibody or antigen-binding fragment thereof which binds to an epitope of a variable delta 1 (V61) chain of a gd T cell receptor (TCR) comprising or consisting of one or more amino acid residues within amino acid regions:
• the multispecific antibodies additionally recognize the polymorphic V region comprising or consisting of amino acid residues 1-90 epitope of SEQ ID NO: 306.
• amino acids 1- 90 of SEQ ID NO: 272 and the polymorphic germline variant sequence may be considered interchangeable when defining epitopes described herein. Studies presented herein have demonstrated multispecific antibodies of the invention can recognize both variants of this germline sequence.
• multispecific antibodies or antigen-binding fragments thereof as defined herein recognize epitopes comprising or consisting of one or more amino acid residues within amino acid regions 1-24 and/or 35-90 of SEQ ID NO: 272, they additionally recognise equivalent epitopes (i.e. at the same position) in SEQ ID NO: 306..
• multispecific antibodies or antigen-binding fragments thereof recognize one or more amino acid residues within amino acid regions 1-90 of SEQ ID NO: 272. More specifically, in one embodiment multispecific antibodies or antigen-binding fragments thereof as defined herein recognize a human germline epitope wherein said germline encodes either an alanine (A) or valine (V) at position 71 of SEQ ID NO: 272.
• the epitope comprises or consists of one or more, such as two, three, four, five, six, seven, eight, nine, ten or more amino acid residues within the described regions.
• the epitope comprises or consists of one or more (such as 5 or more, such as 10 or more) amino acid residues within amino acid region 3-20 of SEQ ID NO: 272.
• the epitope comprises or consists of one or more (such as 5 or more, such as 10 or more) amino acid residues within amino acid region 37-77 of SEQ ID NO: 272 (such as amino acid region 50-54).
• the epitope comprises or consists of one or more (such as 5 or more, such as 10 or more) amino acid residues within amino acid region 3-20 (such as 5-20 or 3-17) and one or more (such as 5 or more, such as 10 or more) amino acid residues within amino acid region 37-77 (such as 62- 77 or 62-69) of SEQ ID NO: 272.
• said antibody does not need to bind to all amino acids within the defined range.
• Such epitopes may be referred to as linear epitopes.
• an antibody which binds to an epitope comprising or consisting of amino acid residues within amino acid region 5-20 of SEQ ID NO: 272 may only bind with one or more of the amino acid residues in said range, e.g. the amino acid residues at each end of the range (i.e. amino acids 5 and 20), optionally including amino acids within the range (i.e. amino acids 5, 9, 16 and 20).
• the epitope comprises or consists of at least one of amino acid residues 3, 5, 9, 10, 12, 16, 17, 20, 37, 42, 50, 53, 59, 62, 64, 68, 69, 72 or 77 of SEQ ID NO: 272. In further embodiments, the epitope comprises or consists of one, two, three, four, five, six, seven, eight, nine, ten, eleven or twelve amino acids selected from amino acid residues 3, 5, 9, 10, 12, 16, 17, 20, 37, 42, 50, 53, 59, 62, 64, 68, 69, 72 or 77 of SEQ ID NO: 272. In one embodiment, the epitope comprises or consists of one or more amino acid residues within the following amino acid regions of SEQ ID NO: 272:
• the epitope comprises or consists of one or more amino acid residues within amino acid regions: 5-20 and 62-77 (for example, although not limited to, embodiments relating to antibodies derived from the parental clone E07, such as affinity matured variants thereof); 50-64 (for example, although not limited to, embodiments relating to antibodies derived from the parental clone C08, such as affinity matured variants thereof); 37-53 and 59-72 (for example, although not limited to, embodiments relating to antibodies derived from the parental clone G04, such as affinity matured variants thereof); 59-77 (for example, although not limited to, embodiments relating to antibodies derived from the parental clone C05, such as affinity matured variants thereof); or 3-17 and 62-69 (for example, although not limited to, embodiments relating to antibodies derived from the parental clone E01 , such as affinity matured variants thereof), of SEQ ID NO: 272.
• the epitope consists of one or more amino acid residues within amino acid regions: 5-20 and 62-77; 50-64; 37-53 and 59-72; 59-77; or 3-17 and 62-69, of SEQ ID NO: 272.
• the epitope comprises or consists of amino acid residues: 3, 5, 9, 10, 12, 16, 17, 62, 64, 68 and 69 of SEQ ID NO: 272, or suitably consists of amino acid residues: 3, 5, 9, 10, 12, 16, 17, 62, 64, 68 and 69 of SEQ ID NO: 272 (for example, although not limited to, embodiments relating to antibodies derived from the parental clone E01 , such as affinity matured variants thereof).
• the epitope comprises or consists of amino acid residues: 5, 9, 16, 20, 62, 64, 72 and 77 of SEQ ID NO: 272, or suitably consists of amino acid residues: 5, 9, 16, 20, 62, 64, 72 and 77 of SEQ ID NO: 272 (for example, although not limited to, embodiments relating to antibodies derived from the parental clone E07, such as affinity matured variants thereof).
• the epitope comprises or consists of the amino acid residues: 37, 42, 50, 53, 59, 64, 68, 69, 72, 73 and 77 of SEQ ID NO: 272, or suitably consists of amino acid residues: 37, 42, 50, 53, 59, 64, 68, 69, 72, 73 and 77 of SEQ ID NO: 272 (for example, although not limited to, embodiments relating to antibodies derived from the parental clone G04, such as affinity matured variants thereof).
• the epitope comprises or consists of the amino acid residues: 50, 53, 59, 62 and 64 of SEQ ID NO: 272, or suitably consists of amino acid residues: 50, 53, 59, 62 and 64 of SEQ ID NO: 272 (for example, although not limited to, embodiments relating to antibodies derived from the parental clone C08, such as affinity matured variants thereof).
• the epitope comprises or consists of amino acid residues: 59, 60, 68 and 72 of SEQ ID NO: 272, or suitably consists of amino acid residues: 59, 60, 68 and 72 of SEQ ID NO: 272 (for example, although not limited to, embodiments relating to antibodies derived from the parental clone C05, such as affinity matured variants thereof).
• the epitope comprises or consists of one or more amino acid residues within amino acid regions 37-53 and/or 59-77 of SEQ ID NO: 272. In a further embodiment, the epitope consists of one or more amino acid residues within amino acid regions 37-53 and 59-77 of SEQ ID NO: 272. In an alternative further embodiment, the epitope comprises or consists of one or more amino acid residues within amino acid regions 37-53 or 59-77 of SEQ ID NO: 272. Multispecific antibodies or antigen-binding fragments thereof having such epitopes may have some or all of the sequences of G04, or such antibodies or antigen-binding fragments thereof may be derived from G04. For example, multispecific antibodies or antigen-binding fragments thereof having one or more CDR sequences of G04 or one or both of the VH and VL sequences of G04 may bind such epitopes.
• the epitope comprises or consists of one or more amino acid residues within amino acid regions 5-20 and/or 62-77 of SEQ ID NO: 272. In a further embodiment, the epitope consists of one or more amino acid residues within amino acid regions 5-20 and 62-77 of SEQ ID NO: 272. In an alternative further embodiment, the epitope comprises or consists of one or more amino acid residues within amino acid regions 5-20 or 62-77 of SEQ ID NO: 272. Multispecific antibodies or antigen-binding fragments thereof having such epitopes may have some or all of the sequences of E07, or such antibodies or antigen-binding fragments thereof may be derived from E07. For example, multispecific antibodies or antigen-binding fragments thereof having one or more CDR sequences of E07 or one or both of the VH and VL sequences of E07 may bind such epitopes.
• the epitope comprises or consists of one or more amino acid residues within amino acid region 50-64 of SEQ ID NO: 272. In a further embodiment, the epitope consists of one or more amino acid residues within amino acid region 50-64 of SEQ ID NO: 272.
• Multispecific antibodies or antigen-binding fragments thereof having such epitopes may have some or all of the sequences of C08, or such antibodies or antigen-binding fragments thereof may be derived from C08. For example, multispecific antibodies or antigen-binding fragments thereof having one or more CDR sequences of C08 or one or both of the VH and VL sequences of C08 may bind such epitopes.
• the epitope comprises or consists of one or more amino acid residues within amino acid region 59-72 of SEQ ID NO: 272. In a further embodiment, the epitope consists of one or more amino acid residues within amino acid region 59-72 of SEQ ID NO: 272.
• Multispecific antibodies or antigen-binding fragments thereof having such epitopes may have some or all of the sequences of C05, or such antibodies or antigen-binding fragments thereof may be derived from C05. For example, multispecific antibodies or antigen-binding fragments thereof having one or more CDR sequences of C05 or one or both of the VH and VL sequences of C05 may bind such epitopes.
• the epitope does not comprise or consist of amino acid residues within amino acid region 11-21 of SEQ ID NO: 272. In one embodiment, the epitope does not comprise or consist of amino acid residues within amino acid region 21-28 of SEQ ID NO: 272. In one embodiment, the epitope does not comprise or consist of amino acid residues within amino acid region 59 and 60 of SEQ ID NO: 272. In one embodiment, the epitope does not comprise or consist of amino acid residues within amino acid region 67- 82 of SEQ ID NO: 272.
• the epitopes of affinity matured antibodies will generally be the same as the epitopes identified herein for the parental clone.
• the positions of the epitopes of the affinity matured antibodies will generally the same positions as the epitopes identified for the corresponding parental clone.
• the reference to “positions” is necessary since the skilled person would appreciate the identity of some of the amino acids in the epitopes differ from human TRDV1. Despite these variations between human and cyno TRDV1 , such antibodies are still able to specifically bind to both antigens.
• the epitope is not the same epitope bound by a commercially available anti-V61 antibody, such as TS-1 or TS8.2.
• a commercially available anti-V61 antibody such as TS-1 or TS8.2.
• binding of TS-1 and TS8.2 to soluble TCRs was detected when the d1 chain included V61 J1 and V61 J2 sequences but not to the V61 J3 chain, indicating that the binding of TS-1 and TS8.2 involved critical residues in the delta J1 and delta J2 region.
• references to “within” herein include the extremities of the define range.
• “within amino acid regions 5-20” refers to all of amino acid resides from and including residue 5 up to and including residue 20.
• exemplary techniques include, for example, routine cross-blocking assays, alanine scanning mutational analysis, peptide blot analysis, peptide cleavage analysis crystallographic studies and NMR analysis.
• methods such as epitope excision, epitope extraction and chemical modification of antigens can be employed.
• Another method that can be used to identify the amino acids within a polypeptide with which an antibody interacts is hydrogen/deuterium exchange detected by mass spectrometry (as described in Example 9).
• the hydrogen/deuterium exchange method involves deuterium-labelling the protein of interest, followed by binding the antibody to the deuterium-labelled protein.
• the protein/antibody complex is transferred to water and exchangeable protons within amino acids that are protected by the antibody complex undergo deuterium-to-hydrogen back-exchange at a slower rate than exchangeable protons within amino acids that are not part of the interface.
• amino acids that form part of the protein/antibody interface may retain deuterium and therefore exhibit relatively higher mass compared to amino acids not included in the interface.
• the target protein is subjected to protease cleavage and mass spectrometry analysis, thereby revealing the deuterium- labelled residues which correspond to the specific amino acids with which the antibody interacts.
• the multispecific antibodies and antigen-binding fragments therefor suitably specifically bind to both human TRDV1 (SEQ ID NO: 272 and the polymorphic variant of SEQ ID NO: 306) as well as an ortholog in cynomolgus monkey, cyno TRDV1 (SEQ ID NO: 308 see also UniProtKB - G7P9S6 (G7P9S6_MACFA)).
• the multispecific antibodies or antigen-binding fragments thereof are G04-derived antibodies that specifically bind to both human and cyno TRDV1 .
• the epitopes bound by the multispecific antibodies of the invention may be particularly advantageous, since it allows the provision of anti-V61 antibodies that are specific to V61 (i.e. do not bind similar antigens, such as V62 or V63) but also provide cross-reactivity to polymorphic variants of V51 (i.e.
• TRDV1 SEQ ID NO: 272 and TRDV1 SEQ ID NO: 306 despite the polymorphism at residue position 20 and this being identified as a possible contact residue or close to an identified contact residue for some antibodies) and provides cross-reactivity between human and cyno V 1 (despite all of residues 42, 50, 54, 59, 60, 68, 73, 75 and 76 occurring within the region of amino acid resides 37 to 77 of SEQ ID NOs: 272 and 308 being different between human and cyno TRDV1 sequences).
• the ADT1-4-derived antibodies bind the same or substantially the same epitope as the ADT1-4 parental antibody. Accordingly, in some embodiments, in particular those relating to antibodies derived from or related to the ADT1 -4 parental antibody, the anti-V61 antibody or antigen-binding fragment binds an epitope comprising or consisting of one or more amino acid residues within amino acid region 37 to 77, for example within amino acid regions 37-53 and/or 59-77, of SEQ ID NO: 272 (or SEQ ID NO: 306).
• the epitope comprises or consists of amino acid residues 37, 42, 50, 53, 59, 64, 68, 69, 72, 73 and 77 of SEQ ID NO: 272 (or SEQ ID NO: 306). In some embodiments, the epitope consists of amino acid residues 37, 42, 50, 53, 59, 64, 68, 69, 72, 73 and 77 of SEQ ID NO: 272 (or SEQ ID NO: 306).
• the ADT1-4-derived antibodies also bind to epitope of the cyno variable delta 1 (V61) chain of a gd T cell receptor (TCR), aka cyno TRDV1 (SEQ ID NO: 308).
• V61 cyno variable delta 1
• TCR gd T cell receptor
• SEQ ID NO: 308 cyno TRDV1
• the anti-V61 antibody or antigenbinding fragment binds an epitope comprising or consisting of one or more amino acid residues within amino acid region 37 to 77, for example within amino acid regions 37-53 and/or 59-77, of SEQ ID NO: 308.
• the epitope comprises or consists of amino acid residues 37, 42, 50, 53, 59, 64, 68, 69, 72, 73 and 77 of SEQ ID NO: 308. In some embodiments, the epitope consists of amino acid residues 37, 42, 50, 53, 59, 64, 68, 69, 72, 73 and 77 of SEQ ID NO: 308.
• the anti-V61 antibody or antigen binding fragment binds an epitope comprising or consisting of one or more amino acid residues within amino acid region 37 to 77, for example within amino acid regions 37-53 and/or 59-77, of SEQ ID NOs: 272, 306 and 308.
• the epitope comprises or consists of amino acid residues 37, 42, 50, 53, 59, 64, 68, 69, 72, 73 and 77 of SEQ ID NO: : 272, 306 and 308. In some embodiments, the epitope consists of amino acid residues 37, 42, 50, 53, 59, 64, 68, 69, 72, 73 and 77 of SEQ ID NOs : 272, 306 and 308.
• the ADT1-7-derived antibodies bind the same or substantially the same epitope as the ADT1-7 parental antibody. Accordingly, in some embodiments, in particular those relating to antibodies derived from or related to the ADT 1 -7 parental antibody, the anti-V61 antibody or antigen-binding fragment binds an epitope comprising or consisting of one or more amino acid residues within amino acid regions 5-20 and/or 62-77 of SEQ ID NO: 272 (or SEQ ID NO: 306). In some embodiment, the epitope comprises or consists of amino acid residues 5, 9, 16, 20, 62, 64, 72 and 77 of SEQ ID NO: 272 (or SEQ ID NO: 306). In some embodiments, the epitope consists of amino acid residues 5, 9, 16, 20, 62, 64, 72 and 77 of SEQ ID NO: 272 (or SEQ ID NO: 306).
• the VH and VL regions of the multispecific antibodies or antigen-binding fragments of the invention each comprise four framework regions (FR1-FR4).
• the antibody or antigen-binding fragment thereof comprises a framework region (e.g. FR1 , FR2, FR3 and/or FR4) comprising a sequence having at least 80% sequence identity with the framework region in any one of SEQ ID NOs: 2 to 25 (for example in the case of light chain variable sequences derived from G04), SEQ ID NOs: 27 to 50 (for example in the case of heavy chain variable sequences derived from G04), SEQ ID NOs: 107 to 117 (for example in the case of light chain variable sequence derived from E07) or SEQ ID NOs: 119 to 129 (for example in the case of light chain variable sequence derived from E07).
• a framework region e.g. FR1 , FR2, FR3 and/or FR4 comprising a sequence having at least 80% sequence identity with the framework region in any one of S
• the antibody or antigen-binding fragment thereof comprises a framework region ⁇ e.g. FR1 , FR2, FR3 and/or FR4) comprising a sequence having at least 90%, such as at least 95%, 97% or 99% sequence identity with the framework region in any one of SEQ ID NOs: 2 to 25 (for example in the case of light chain variable sequences derived from G04), SEQ ID NOs: 27 to 50 (for example in the case of heavy chain variable sequences derived from G04), SEQ ID NOs: 107 to 117 (for example in the case of light chain variable sequence derived from E07) or SEQ ID NOs: 119 to 129 (for example in the case of light chain variable sequence derived from E07).
• a framework region ⁇ e.g. FR1 , FR2, FR3 and/or FR4
• SEQ ID NOs: 27 to 50 for example in the case of heavy chain variable sequences derived from G04
• SEQ ID NOs: 107 to 117 for example in the
• the antibody or antigen-binding fragment thereof comprises a framework region ⁇ e.g. FR1 , FR2, FR3 and/or FR4) comprising a sequence in any one of SEQ ID NOs: 2 to 25 (for example in the case of light chain variable sequences derived from G04), SEQ ID NOs: 27 to 50 (for example in the case of heavy chain variable sequences derived from G04), SEQ ID NOs: 107 to 117 (for example in the case of light chain variable sequence derived from E07) or SEQ ID NOs: 119 to 129 (for example in the case of light chain variable sequence derived from E07).
• the antibody or antigen-binding fragment thereof comprises a framework region ⁇ e.g.
• FR1 , FR2, FR3 and/or FR4 consisting of a sequence in any one of SEQ ID NOs: 2 to 25 (for example in the case of light chain variable sequences derived from G04), SEQ ID NOs: 27 to 50 (for example in the case of heavy chain variable sequences derived from G04), SEQ ID NOs: 107 to 117 (for example in the case of light chain variable sequence derived from E07) or SEQ ID NOs: 119 to 129 (for example in the case of light chain variable sequence derived from E07).
• the anti-V61 antibody or antigen-binding fragment thereof may comprise an HFR1 (i.e.
• heavy framework 1 region sequence comprising or consisting of the sequence of SEQ ID NO: 170 or 171 ; an HFR2 sequence comprising or consisting of the sequence of SEQ ID NO: 172; an HFR3 sequence comprising or consisting of the sequence of SEQ ID NO: 173; an HFR4 sequence comprising or consisting of the sequence of SEQ ID NO: 174; an LFR1 sequence comprising or consisting of the sequence of SEQ ID NO: 175; an LFR2 sequence comprising or consisting of the sequence of SEQ ID NO: 176; an LFR3 sequence comprising or consisting of the sequence of SEQ ID NO: 177 or 178; and/or an LFR4 sequence comprising or consisting of the sequence of SEQ ID NO: 179, 180, 181 or 182.
• the anti-V61 antibody or antigen-binding fragment thereof may comprise an HFR1 (i.e. heavy framework 1 region) sequence comprising or consisting of the sequence of SEQ ID NO: 170 or 171 ; an HFR2 sequence comprising or consisting of the sequence of SEQ ID NO: 172; an HFR3 sequence comprising or consisting of the sequence of SEQ ID NO: 173; an HFR4 sequence comprising or consisting of the sequence of SEQ ID NO: 174; an LFR1 sequence comprising or consisting of the sequence of SEQ ID NO: 175; an LFR2 sequence comprising or consisting of the sequence of SEQ ID NO: 176; an LFR3 sequence comprising or consisting of the sequence of SEQ ID NO: 177; and/or an LFR4 sequence comprising or consisting of the sequence of SEQ ID NO: 179, 180, 181 or 182.
• HFR1 i.e. heavy framework 1 region
• the anti-V61 antibody or antigen-binding fragment thereof may comprise an HFR1 (i.e. heavy framework 1 region) sequence comprising or consisting of the sequence of SEQ ID NO: 170 or 171 ; an HFR2 sequence comprising or consisting of the sequence of SEQ ID NO: 172; an HFR3 sequence comprising or consisting of the sequence of SEQ ID NO: 173; an HFR4 sequence comprising or consisting of the sequence of SEQ ID NO: 174; an LFR1 sequence comprising or consisting of the sequence of SEQ ID NO: 175; an LFR2 sequence comprising or consisting of the sequence of SEQ ID NO: 176; an LFR3 sequence comprising or consisting of the sequence of SEQ ID NO: 177; and/or an LFR4 sequence comprising or consisting of the sequence of SEQ ID NO: 179 or 181.
• HFR1 i.e. heavy framework 1 region
• the anti-V61 antibody or antigen-binding fragment thereof may comprise an HFR1 sequence comprising or consisting of the sequence of SEQ ID NO: 189; an HFR2 sequence comprising or consisting of the sequence of SEQ ID NO: 190; an HFR3 sequence comprising or consisting of the sequence of SEQ ID NO: 191 ; an HFR4 sequence comprising or consisting of the sequence of SEQ ID NO: 192; an LFR1 sequence comprising or consisting of the sequence of SEQ ID NO: 193 and 194; an LFR2 sequence comprising or consisting of the sequence of SEQ ID NO: 195; an LFR3 sequence comprising or consisting of the sequence of SEQ ID NO: 196; and an LFR4 sequence comprising or consisting of the sequence of SEQ ID NO: 197.
• the anti-V61 antibody or antigen-binding fragment thereof may comprise an HFR1 sequence comprising or consisting of the sequence of SEQ ID NO: 189; an HFR2 sequence comprising or consisting of the sequence of SEQ ID NO: 190; an HFR3 sequence comprising or consisting of the sequence of SEQ ID NO: 191 ; an HFR4 sequence comprising or consisting of the sequence of SEQ ID NO: 192; an LFR1 sequence comprising or consisting of the sequence of SEQ ID NO: 193; an LFR2 sequence comprising or consisting of the sequence of SEQ ID NO: 195; an LFR3 sequence comprising or consisting of the sequence of SEQ ID NO: 196; and an LFR4 sequence comprising or consisting of the sequence of SEQ ID NO: 197.
• the antibody fragment described herein may comprise an scFv, i.e. a fragment comprising a VH region and a VL region joined by a linker.
• the VH and VL region are joined by a (e.g. synthetic) polypeptide linker.
• the linker comprises SEQ ID NO: 291 .
• the linker consists of SEQ ID NO: 291.
• scFv constructs may be designed and made inclusive of N-terminal and C-terminal modifications to aid with translation, purification and detection.
• N-terminus of an scFv sequence an additional methionine and/or alanine amino acid residue may be included ahead of the canonical VH sequences (e.g. starting QVQ or EVQ).
• C-terminus i.e.
• additional sequences may be included such as (i) a partial sequence of the constant domain and/or (ii) additional synthetic sequences inclusive of tags, such as His-tags and Flag-tags, to aid with purification and detection (for example the tags of any of SEQ ID NOs: 292 to 295).
• the antibodies may be in any format.
• the antibody is in an lgG1 (e.g. human lgG1) format (ie. the antibody is a human lgG1 antibody).
• the antibody or antigen-binding fragment thereof comprises a light chain constant region comprising the sequence of SEQ ID NO: 296 or SEQ ID NO: 307 (or a sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO: 296 or SEQ ID NO: 307) and/or a heavy chain constant region comprising the sequence of SEQ ID NO: 297 or SEQ ID NO: 298 (or a sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO: 297 or SEQ ID NO: 298)
• effector function of the heavy chain constant region may be reduced or disabled (effector function disabling mutations).
• Suitable mutations to attenuate the effector functions are known to the skilled person.
• the antibody or antigen-binding fragment thereof comprises a light chain constant region comprising the sequence of SEQ ID NO: 296 and/or a heavy chain constant region comprising the sequence of SEQ ID NO: 297 or SEQ ID NO: 298.
• the antibody binds to the same, or essentially the same, epitope as, or competes with, an antibody or antigen-binding fragment thereof as defined herein.
• test antibody If the test antibody is able to bind to V61 following saturation binding with the reference anti-V61 antibody, it can be concluded that the test antibody binds to a different epitope than the reference anti-V61 antibody. On the other hand, if the test antibody is not able to bind to the V61 chain following saturation binding with the reference anti-V61 antibody, then the test antibody may bind to the same epitope as the epitope bound by the reference anti-V61 antibody of the invention.
• the present invention also includes anti-V51 antibodies that compete for binding to V61 with an antibody or antigen-binding fragment thereof as defined herein, or an antibody having the CDR sequences of any of the exemplary antibodies described herein.
• competitive assays can be performed with the antibody of the present invention in order to determine what proteins, antibodies, and other antagonists compete for binding to the V61 chain with the antibody of the present invention and/or share the epitope.
• assays are readily known to those of skill in the art; they evaluate competition between antagonists or ligands for a limited number of binding sites on a protein, e.g. V61.
• the antibody (or antigen-binding fragment thereof) is immobilized or insolubilized before or after the competition and the sample bound to the V61 chain is separated from the unbound sample, for example, by decanting (where the antibody was pre-insolubilized) or by centrifuging (where the antibody was precipitated after the competitive reaction).
• the competitive binding may be determined by whether the function is altered by the binding or lack of binding of the antibody to the protein, e.g. whether the antibody molecule inhibits or potentiates the enzymatic activity of, for example, a label.
• ELISA and other functional assays may be used, as known in the art and described herein.
• Two antibodies bind to the same or overlapping epitope if each competitively inhibits (blocks) binding of the other to the target antigen. That is, a 1 -, 5-, 10-, 20- or 100-fold excess of one antibody inhibits binding of the other by at least 50% but preferably 75%, 90% or even 99% as measured in a competitive binding assay.
• two antibodies have the same epitope if essentially all amino acid mutations in the target antigen that reduce or eliminate binding of one antibody reduce or eliminate binding of the other.
• Additional routine experimentation e.g. peptide mutation and binding analyses
• peptide mutation and binding analyses can then be carried out to confirm whether the observed lack of binding of the test antibody is in fact due to binding to the same epitope as the reference antibody or if steric blocking (or another phenomenon) is responsible for the lack of observed binding.
• steric blocking or another phenomenon
• this sort can be performed using ELISA, RIA, surface plasmon resonance, flow cytometry or any other quantitative or qualitative antibody-binding assay available in the art.
• Antibody bindinq and pharmacoloqical properties of the antibodies may have favourable binding and/or pharmacological properties, for example as described below.
• the binding affinity of the antibody or antigen-binding fragment thereof is established by coating the antibody or antigen-binding fragment thereof directly or indirectly (e.g. by capture with an anti-human IgG Fc) onto the surface of a sensor (e.g. an amine high capacity chip or equivalent), wherein the target bound by the antibody or antigen-binding fragment thereof (i.e . the V61 chain of a gd TCR or EGFR) is flowed overthe chip to detect binding.
• a MASS-2 instrument (which may also be referred to as Sierra SPR-32) is used at 25 °C in PBS + 0.02 % Tween 20 running buffer at 30 pl/min.
• the multispecific antibody or antigen-binding fragment thereof described herein may be assessed by gd TCR engagement, e g. measuring downregulation of the gd TCR upon antibody binding.
• Surface expression of the gd TCR following application of the antibody or antigen-binding fragment thereof (optionally presented on the surface of a cell) can be measured, e.g. by flow cytometry.
• the antibody or antigen-binding fragment thereof described herein may also be assessed by measuring gd T cell degranulation.
• expression of CD107a can be measured following application of the antibody or antigen-binding fragment thereof (optionally presented on the surface of a cell) to gd T cells, e.g. by flow cytometry.
• the antibody or antigen-binding fragment thereof described herein may also be assessed by measuring gd T cell mediated killing activity (to test if the antibody has an effect on the killing activity of the gd T cell).
• target cells may be incubated with gd T cells in the presence of the antibody or antigen-binding fragment thereof (optionally presented on the surface of a cell). Following incubation, the culture may be stained with a cell viability dye to distinguish between live and dead target cells. The proportion of dead cells can then be measured, e.g. by flow cytometry.
• assays which may be used to define multispecific antibody function as assessed in assays comprising a mixture of at least two different cell types comprising seperate gd TCR+ve cells and EGFR+ve cells. These assays help to further highlight some of the surprising technical effects of the multispecific antibodies described herein, whereby further enhanced effects are observed (eg. increased TCR downregulation) when multispecific antibody function is assessed and defined in assays comprising such cell mixtures.
• the affinity matured clones (and multispecific antibodies derived or related to such clones) will have an affinity for their antigen(s) that is higher than the parental clones.
• the affinity for human TRDV1 (SEQ ID NOs 272 or 306) will be at least 20%, at least 30%, at least 40%, at least 50%, at least 100% or at least 500% greater affinity than the parental antibody.
• the multispecific antibodies or antigen-binding fragments thereof of the invention may bind to human TRDV1 (SEQ ID NOs 272 or 306) with a binding affinity (KD, for example as measured by surface plasmon resonance) of less than about 100 nM, preferably less than about 50 nM.
• the multispecific antibodies or antigen-binding fragments thereof may further be defined as binding to human TRDV1 (SEQ ID NOs 272 or 306) with a binding affinity (KD, for example as measured by surface plasmon resonance) of less than about 10 nM, preferably less than about 5 nM.
• the multispecific antibodies or antigen-binding fragments thereof relating to or derived from the ADT1-4 lineage may bind to human TRDV1 with KD of less than about 100 nM, preferably less than about 50 nM.
• the multispecific antibodies or antigen-binding fragments thereof of the invention may bind to human TRDV1 with Ko of less than about 10 nM, preferably less than about 5 nM.
• the multispecific antibodies or antigen-binding fragments thereof of the invention may bind to human TRDV1 with KD of less than about 10 nM, preferably less than about 1 nM.
• the multispecific antibodies or antigen-binding fragments thereof of the invention may bind to cyno TRDV1 (SEQ ID NO 308) with a binding affinity (KD, for example as measured by surface plasmon resonance) of less than about 100 nM, preferably less than about 50 nM.
• KD binding affinity
• the multispecific antibodies or antigen-binding fragments thereof of the invention may bind to cyno TRDV1 with Ko of less than about 100 nM, preferably less than about 50 nM.
• the multispecific antibodies or antigen-binding fragments thereof relating to or derived from the ADT1-4 lineage members ADT1-4-19, ADT1-4-21 , ADT1-4-31 , ADT1-4-53, ADT1-4- 2, ADT1-4-86, ADT1-4-112, ADT1-4-143 and/or ADT1-4-1 may bind to cyno TRDV1 with KD of less than about 50 nM.
• the multispecific antibodies or antigen-binding fragments thereof of the invention may bind to human TRDV1 with Koof less than about 100 nM, preferably less than about 50 nM and bind to cyno TRDV1 with a binding affinity (KD, for example as measured by surface plasmon resonance) of less than about 100 nM, preferably less than about 50 nM.
• KD binding affinity
• the multispecific antibodies or antigenbinding fragments thereof of the invention may bind to human TRDV1 with KD of less than about 10 nM and bind to cyno TRDV1 with a binding affinity (KD, for example as measured by surface plasmon resonance) of less than about 100 nM.
• KD binding affinity
• the multispecific antibodies or antigen-binding fragments thereof of the invention may bind to human TRDV1 with KD of less than about 5 nM and bind to cyno TRDV1 with a binding affinity (KD, for example as measured by surface plasmon resonance) of less than about 50 nM.
• KD binding affinity
• the multispecific antibodies or antigen-binding fragments thereof of the invention may bind to human TRDV1 with KD of less than about 10 nM and bind to human TRDV1 with K D Of less than 50 nM.
• the multispecific antibodies or antigen-binding fragments thereof of the invention may bind to human TRDV1 with KD of less than about 1 nM and bind to cyno TRDV1 with a binding affinity (KD, for example as measured by surface plasmon resonance) of less than about 50 nM.
• KD binding affinity
• the multispecific antibodies or antigen-binding fragments thereof relating to or derived from the ADT1-7 lineage may bind to human TRDV1 with KD of less than about 10 nM, preferably less than about 5 nM.
• Table 6 Summary of the human TRDV1 affinities of exemplar multispecific antibodies of the invention, as determined by SPR.
• Increasing the binding affinity for human TRDV1 to less than about 10nM is shown to convey advantageous technical effects, such as increased binding (MFI), improved nd1 TCR downregulation, improved CD107A upregulation, increased cytotoxicity and increased proliferation (see Figure 35L).
• the multispecific antibodies of the invention may bind to EGFR with a KD of less than about 150nM, for example ADT1-4-2xFS1-65, ADT1-4-2xFS1-67, ADT1-4-2xLEE, ADT1 -4-2x747, ADT1- 4-2xLEE3, ADT1-4-2xLEE2 and ADT1-4-2xLEE1.
• the multispecific antibodies of the invention may bind to EGFR with a KD of less than about 20nM, for example ADT1-4-2xFS1-65, ADT1-4-2xFS1-67, ADT1-4-2xLEE, ADT1-4-2x747 and ADT 1 -4-2xLEE3.
• the multispecific antibodies of the invention may bind to EGFR with a KD of less than about 10nM, for example ADT1-4-2xFS1-65, ADT1-4-2xFS1-67, ADT1-4-2xLEE and ADT1-4-2x747.
• the multispecific antibodies of the invention may bind to EGFR with a KD of less than about 5nM, for example ADT1-4-2xFS1-65, ADT1-4-2xFS1-67, ADT1-4-2xLEE and ADT1-4-2x747.
• the EGFR may be human EGFR.
• Table 7 provides a summary of the EGFR affinities of exemplar multispecific antibodies of the invention, as determined by SPR.
• the multispecific antibodies of the invention may bind to human TRDV1 with a Ko of less than about 5nM and may bind to EGFR with a Ko of less than about 150nM, for example ADT1-4- 2xFS1-65, ADT 1 -4-2xFS1 -67, ADT1-4-2xLEE, ADT1 -4-2x747, ADT1-4-2xLEE3, ADT1-4-2xLEE2 and ADT1-4-2xLEE1.
• the multispecific antibodies of the invention may bind to human TRDV1 with a K ⁇ q ⁇ less than about 5nM and may bind to EGFR with a Koof less than about 20nM, for example ADT1-4-2xFS1- 65, ADT1-4-2xFS1-67, ADT1-4-2xLEE, ADT1 -4-2x747 and ADT1-4-2xLEE3.
• the multispecific antibodies of the invention may bind to human TRDV1 with a K ⁇ q ⁇ less than about 5nM and may bind to EGFR with a KoOf less than about 10nM, for example ADT1-4-2xFS1- 65, ADT1-4-2xFS1-67, ADT1-4-2xLEE and ADT1 -4-2x747.
• the multispecific antibodies of the invention may bind to human TRDV1 with a K ⁇ q ⁇ less than about 5nM and may bind to EGFR with a K ⁇ q ⁇ less than about 5nM, for example ADT1-4-2xFS1- 65, ADT1-4-2xFS1-67, ADT1-4-2xLEE and ADT1 -4-2x747.
• Increasing the binding affinity for EGFR is shown to convey advantageous technical effects, such as increased binding (MFI), improved nd1 TCR downregulation, improved degranulation, increased cytotoxicity, increased 4-1 BB upregulation and increased proliferation (see Figure 36).
• MFI increased binding
• improved nd1 TCR downregulation improved degranulation
• increased cytotoxicity increased 4-1 BB upregulation
• increased proliferation see Figure 36.
• a clustering effect is observed wherein multispecific antibodies of this invention with mid-to-high affinities to EGFR in the range of about 1nM to about 20nM affinity (ADT1-4-2xLEE, ADT1-4-2xLEE3, ADT1-4-2LEE2) functionally cluster together whilst the lower affinity molecule with an affinity of about 142nM (ADT1-4-2xLEE1) is significantly impaired and is equivalent to the non-binding (to TCR) control in this assay.
• Multispecific antibodies as presented herein comprise at least one first binding domain which binds the TRDV1 domain of V61 TCR and at least one second binding domain which binds EGFR. Each binding domain binds to its target with a different binding affinity (Kd). These binding affinities can be altered independently of each other. Fine-tuning affinities up or down to both the first binding domain and to the second binding domain impact functionality and conferred technical effects.
• TRDV1 Increasing the concentration of multispecific antibodies with lower affinities to TRDV1 (of lowerthan about 10nM) can overcome some of the observed lower activities conferred by these molecules (e.g. proliferative effects) but interestingly, not all effects can be replicated by increased concentrations of the lower affinity variant.
• Cancer cells with a higher TAA copy number can further enhance observed effects conferred by these multispecific antibodies; particularly of the lower affinity (to TRDV1) variant.
• Some multispecific antibodies of the invention with mid-range affinity for EGFR (9nm to 20nM) performed more favorably than the highest affinity variants (less than 2nM) at saturating concentrations in some instances.
• multispecific antibodies with mid-range affinities to EGFR conferred enhanced proliferative effects and 41 BB activation status when compared to both the highest affinity variants (less than 2nM, preferably less than 1 .5nM) and lowest affinity variants (of about 142nM) in the assays described.
• Dialing up and down affinity provides a “tool-box” of multispecific antibodies, some of which are optimal for lower copy number TAA scenarios, others more optimal at nM concentration/dose ranges in certain circumstances, and some more selective only for high-copy number TAA cancers.
• TCR down regulation may be measured according to the assays described herein.
• the antibody to be tested may be incubated at different concentration with a culture of gd T cells and the downregulation measured.
• cell killing for example THP-1 cell killing, or A375 cell killing
• the gd T cells are co-cultured with a suitable cell line, for example THP-1 cells or A375 cells.
• TCR down regulation may be measured flow cytometry. Cell killing may be achieved by any suitable means, for example by flow cytometry.
• the TCR downregulation assay involved ‘loading’ the antibody onto Fc gamma receptor +ve THP-1 cells (see Example 1 , Example 6 and Table 5 of WO2021/032963).
• the antibodies in this instance are presented on a cell surface ahead of co-incubation with gd T cells.
• Such loading thereby affords maximum opportunity to exploit cross-linking effects upon TCR engagement.
• alternate similar approaches to presenting the antibody on sold-surfaces may include pre-incubating the antibody on a plate (so-called plate-bound), or the use of carrier beads to present the antibody.
• the multispecific antibodies or antigen-binding fragments thereof of the invention may have an IC50 for TCR downregulation of less than about 50nM, less than about 10nM, or less than about 1 mM. Preferably the IC50 is less than about 1nM.
• the multispecific antibodies or antigen-binding fragments thereof relating to or derived from the ADT1-4 lineage may have an IC50 for TCR downregulation of less than about 50nM, less than about 10nM, or less than about 1 mM. Preferably the IC50 is less than about 1 nM.
• the multispecific antibodies or antigenbinding fragments thereof of the invention may have an IC50 for TCR downregulation of less than about 1 nM.
• the IC50 is less than about 0.5nM.
• the antibodies or multispecific antigen-binding fragments thereof of the invention may have an IC50 for TCR downregulation of less than about 1 nM.
• the IC50 is less than about 0.5nM.
• the multispecific antibodies or antigen-binding fragments thereof relating to or derived from the ADT1-7 lineage may have an IC50 for TCR downregulation of less than about 50nM, less than about 10nM, or less than about 1 mM. Preferably the IC50 is less than about 1 nM.
• the multispecific antibodies or antigen-binding fragments thereof of the invention may have an IC50 for TCR downregulation of less than about 5nM. Preferably the IC50 is less than about 10nM.
• Cell killing may be measured according to the assays described herein.
• the antibody to be tested may be incubated at different concentration with a co-culture of gd T cells and tumour cells (for example THP-1 cells or A375 cells).
• Cell killing may be measured by any suitable means, for example by flow cytometry.
• the multispecific antibodies or antigen-binding fragments thereof of the invention may have an IC50 for A375 cell killing of less than about 10nM, less than about 5nM, less than about 1 nM, less than about 0.1 nM or less than about 0.01 nM..
• the IC50 is less than about 1 nM.
• the multispecific antibodies or antigen-binding fragments thereof relating to or derived from the ADT1-4 lineage may have an IC50 for A375 cell killing of less than about 10nM, less than about 5nM, less than about 1 nM, less than about 1 nM, less than about 0.1 nM or less than about 0.01 nM.
• the IC50 is less than about 1 nM.
• the multispecific antibodies or antigen-binding fragments thereof relating to or derived from the ADT1-7 lineage may have an IC50 for A375 cell killing of less than about 5nM, less than about 1 nM, or less than about 0.1 nM. Preferably the IC50 is less than about 1 nM.
• the multispecific antibodies or antigen-binding fragments thereof of the invention may have an IC50 for A375 cell killing of less than about 10nM, less than about 5nM, less than about 1nM or less than about 0.1nM. Preferably the IC50 is less than about 1 nM.
• the advantageous pharmacological profiles of the multispecific antibodies can be combined such that the antibodies exhibit an advantageous KD and advantageous IC50 values for the various tested properties.
• the multispecific antibodies or antigen-binding fragments thereof of the invention may:
• bind to human TRDV1 SEQ ID NOs 272 or 306 with a binding affinity (KD, for example as measured by surface plasmon resonance) of less than about 100 nM (preferably less than about 50 nM);
• cyno TRDV1 SEQ ID NO 308
• KD binding affinity
• the multispecific antibodies or antigen-binding fragments thereof may: • bind to human TRDV1 with a KD of less than about 100 nM (preferably less than about 50 nM);
• multispecific antibodies or antigen-binding fragments thereof relating to or derived from the ADT1-4 lineage may:
• the multispecific antibodies or antigen-binding fragments thereof of the invention may: bind to human TRDV1 with a KD of less than about 10 nM (preferably less than about 1 nM); bind to cyno TRDV1 with a KD of less than about 50 nM; have an IC50 for TCR downregulation of less than about 1 nM (preferably less than about 0.5nM) have an IC50 for A375 cell killing of less than about 10nM (preferably less than about 5nM).
• the multispecific antibodies or antigen-binding fragments thereof may:
• the multispecific antibodies or antigen-binding fragments thereof may:
• antibodies of or derived from ADT1-4-105 may have a KD for human TRDV1 of less than about 10 nM (preferably less than about 1 nM) and/or a KD for cyno TRDV1 of less than about 50 nM.
• Antibodies of or derived from ADT1-4-107 may have a KD for human TRDV1 of less than about 10 nM (preferably less than about 1 nM) and/or a KD for cyno TRDV1 of less than about 50 nM.
• Antibodies of or derived from ADT1-4-110 may have a KD for human TRDV1 of less than about 10 nM (preferably less than about 1 nM) and/or a KD for cyno TRDV1 of less than about 50 nM.
• Antibodies of or derived from ADT1-4-112 may have a KD for human TRDV1 of less than about 10 nM (preferably less than about 1 nM) and/or a KD for cyno TRDV1 of less than about 50 nM. Such antibodies may alternatively or additionally have an IC50 for TCR down regulation of less than about 1 nM (preferably less than about 0.5 nM).
• Antibodies of or derived from ADT1-4-117 may have a KD for human TRDV1 of less than about 10 nM (preferably less than about 1 nM) and/or a KD for cyno TRDV1 of less than about 50 nM.
• Antibodies of or derived from ADT1-4-19 may have a KD for human TRDV1 of less than about 1 nM (preferably less than about 0.5 nM) and/or a KD for cyno TRDV1 of less than about 10 nM (preferably less than about 5 nM).
• Such antibodies may alternatively or additionally have an IC50 for TCR down regulation of less than about 1 nM (preferably less than about 0.5 nM).
• Antibodies of or derived from ADT1-4-21 may have a KD for human TRDV1 of less than about 10 nM (preferably less than about 1 nM) and/or a KD for cyno TRDV1 of less than about 50 nM (preferably less than about 10 nM).
• Such antibodies may alternatively or additionally have an IC50 for TCR down regulation of less than about 1 nM (preferably less than about 0.5 nM).
• Antibodies of or derived from ADT1-4-31 may have a KD for human TRDV1 of less than about 10 nM (preferably less than about 1 nM) and/or a KD for cyno TRDV1 of less than about 50 nM (preferably less than about 10 nM).
• Such antibodies may alternatively or additionally have an IC50 for TCR down regulation of less than about 1 nM (preferably less than about 0.5 nM).
• Antibodies of or derived from ADT1-4-139 may have a KD for human TRDV1 of less than about 10 nM (preferably less than about 1 nM) and/or a KD for cyno TRDV1 of less than about 50 nM.
• Antibodies of or derived from ADT1-4-4 may have a KD for human TRDV1 of less than about 10 nM (preferably less than about 1 nM) and/or a KD for cyno TRDV1 of less than about 50 nM.
• Antibodies of or derived from ADT1-4-143 may have a KD for human TRDV1 of less than about 10 nM (preferably less than about 1 nM) and/or a KD for cyno TRDV1 of less than about 50 nM (preferably less than about 10 nM).
• Such antibodies may alternatively or additionally have an IC50 for TCR down regulation of less than about 1 nM (preferably less than about 0.5 nM).
• Antibodies of or derived from ADT1-4-53 may have a KD for human TRDV1 of less than about 10 nM (preferably less than about 1 nM) and/or a KD for cyno TRDV1 of less than about 50 nM (preferably less than about 10 nM).
• Such antibodies may alternatively or additionally have an IC50 for TCR down regulation of less than about 1 nM (preferably less than about 0.5 nM).
• Antibodies of or derived from ADT1-4-173 may have a KD for human TRDV1 of less than about 10 nM (preferably less than about 1 nM) and/or a KD for cyno TRDV1 of less than about 50 nM.
• Antibodies of or derived from ADT1-4-2 may have a KD for human TRDV1 of less than about 1 nM (preferably less than about 0.5 nM) and/or a KD for cyno TRDV1 of less than about 10 nM (preferably less than about 5 nM).
• Such antibodies may alternatively or additionally have an IC50 for TCR down regulation of less than about 1nM (preferably less than about 0.5 nM).
• Antibodies of or derived from ADT1-4-8 may have a KD for human TRDV1 of less than about 10 nM (preferably less than about 1 nM) and/or a KD for cyno TRDV1 of less than about 50 nM.
• Antibodies of or derived from ADT1-4-82 may have a KD for human TRDV1 of less than about 10 nM (preferably less than about 1 nM) and/or a KD for cyno TRDV1 of less than about 50 nM.
• Antibodies of or derived from ADT1-4-83 may have a KD for human TRDV1 of less than about 10 nM (preferably less than about 1 nM) and/or a KD for cyno TRDV1 of less than about 50 nM.
• Antibodies of or derived from ADT1-4-3 may have a KD for human TRDV1 of less than about 10 nM (preferably less than about 1 nM) and/or a KD for cyno TRDV1 of less than about 50 nM.
• Antibodies of or derived from ADT1-4-84 may have a KD for human TRDV1 of less than about 10 nM (preferably less than about 1 nM) and/or a KD for cyno TRDV1 of less than about 50 nM.
• Antibodies of or derived from ADT1-4-86 may have a KD for human TRDV1 of less than about 10 nM (preferably less than about 1 nM) and/or a KD for cyno TRDV1 of less than about 50 nM (preferably less than about 10 nM).
• Such antibodies may alternatively or additionally have an IC50 for TCR down regulation of less than about 1 nM (preferably less than about 0.5 nM).
• Antibodies of or derived from ADT1-4-95 may have a KD for human TRDV1 of less than about 10 nM (preferably less than about 1 nM) and/or a KD for cyno TRDV1 of less than about 50 nM.
• Antibodies of or derived from ADT1-4-1 may have a KD for human TRDV1 of less than about 1 nM (preferably less than about 0.5 nM) and/or a KD for cyno TRDV1 of less than about 10 nM
• Such antibodies may alternatively or additionally have an IC50 for TCR down regulation of less than about 1nM (preferably less than about 0.5 nM).
• Antibodies of or derived from ADT1-4-6 may have a KD for human TRDV1 of less than about 10 nM (preferably less than about 5 nM) and/or a KD for cyno TRDV1 of less than about 10 nM (preferably less than about 1 nM).
• Such antibodies may alternatively or additionally have an IC50 for TCR down regulation of less than about 1 nM (preferably less than about 0.5 nM).
• Antibodies of or derived from ADT1-4-138 may have a KD for human TRDV1 of less than about 100 nM (preferably less than about 50 nM) and/or a KD for cyno TRDV1 of less than about 100 nM (preferably less than about 50 nM).
• Such antibodies may alternatively or additionally have an IC50 for TCR down regulation of less than about 50 nM (preferably less than about 10 nM).
• antibodies of or derived from ADT1-7-10 may have a KD for human TRDV1 of less than about 10 nM (preferably less than about 5 nM).
• Antibodies of or derived from ADT1-7-15 may have a KD for human TRDV1 of less than about 10 nM (preferably less than about 5 nM).
• Antibodies of or derived from ADT1-7-17 may have a KD for human TRDV1 of less than about 10 nM (preferably less than about 5 nM).
• Antibodies of or derived from ADT1-7-18 may have a KD for human TRDV1 of less than about 10 nM (preferably less than about 5 nM).
• Antibodies of or derived from ADT1-7-19 may have a KD for human TRDV1 of less than about 10 nM (preferably less than about 5 nM).
• Antibodies of or derived from ADT1-7-20 may have a KD for human TRDV1 of less than about 10 nM (preferably less than about 5 nM). Such antibodies may alternatively or additionally have an IC50 for TCR down regulation of less than about 5 nM (preferably less than about 1 nM).
• Antibodies of or derived from ADT1-7-22 may have a KD for human TRDV1 of less than about 10 nM (preferably less than about 5 nM).
• Antibodies of or derived from ADT1-7-23 may have a KD for human TRDV1 of less than about 10 nM (preferably less than about 5 nM).
• Antibodies of or derived from ADT1-7-42 may have a KD for human TRDV1 of less than about 10 nM (preferably less than about 5 nM).
• Antibodies of or derived from ADT1-7-3 may have a KD for human TRDV1 of less than about 10 nM (preferably less than about 1 nM).
• Such antibodies may alternatively or additionally have an IC50 for TCR down regulation of less than about 5 nM (preferably less than about 1 nM).
• Antibodies of or derived from ADT1-7-61 may have a KD for human TRDV1 of less than about 10 nM (preferably less than about 1 nM). Such antibodies may alternatively or additionally have an IC50 for TCR down regulation of less than about 50 nM (preferably less than about 10 nM).
• the antibodies of the present invention have an advantageous functional profile.
• the antibodies of the present invention are useful for the activation of V61 T-cells. Although they may cause downregulation of the TCRs on T-cells to which they bind, they do not cause V61 T-cell depletion, but rather they stimulate the T-cells and hence may be useful in therapeutic settings that would benefit from the activation of this compartment of T-cells. Activation of V61 T-cells is evident through TCR downregulation, changes in activation markers such as CD25 and Ki67 and degranulation marker CD107a.
• V 1 T-cell Activation of V 1 T-cell in turn triggers release of inflammatory cytokines such as INFy and TNFa to promote immune licencing.
• cytokines such as INFy and TNFa
• antibodies having suitably high affinity for TRDV1 elicit increased V61 T-cell killing and, unlike (for example) antibodies that target CD3, the provision of high affinity antibodies is possible without adverse effects associated with large-scale activation via CD3.
• the high affinity antibodies are able to induce strong immunostimulatory effects via tumour-infiltrating lymphocytes (TILs). This can be achieved with minimal exhaustion or killing of the V61 cells. Therefore, the antibodies of the present invention may be considered agonistic antibodies.
• an anti-V61 antibody or antigen-binding fragment thereof characterised in that it: a) causes downregulation of TCRs on V61 T-cells; b) does not exhibit CDC or ADCC; and c) does not deplete V61 T-cells.
• the multispecific anti-V61 antibody or antigen-binding fragments also stimulate V61 T-cell proliferation.
• multispecific antibodies of this invention confer one or more of
• the multispecific antibodies or antigen-binding fragments thereof may further be defined as binding to human TRDV1 (SEQ ID NOs 272 or 306) with a binding affinity (KD, for example as measured by surface plasmon resonance) of less than about 10 nM, preferably less than about 5 nM.
• KD binding affinity
• the multispecific antibodies or antigen-binding fragments thereof may further be defined as having the advantageous KD and/or IC50 values as discussed above.
• T-cell depletion is the process of T cell death removal or reduction.
• References to the antibodies or antigen binding fragments not depleting the V61 T cells refers to a depletion of less than about 30% or less than about 20% (preferably less than about 10%) of the viable V51 T+ cell population when incubated by one or more of the multispecific antibodies of the invention as described herein (for example when the antibodies is provided as an lgG1 antibody), and as measured by any via suitable means in a controlled study (for example via controlled flow cytometry methodology or via other established controlled assays such as described in Figure 18 and Figure 29).
• ADCC and CDC are mechanisms by which T-cell depletion may occur.
• Reference to the antibodies or antigen binding fragments herein not causing ADCC or CDC refers to a depletion of less than about 30% or less than about 20% (preferably less than about 10%) of the viable V61 T+ cell population via ADCC and/or CDC when incubated by one or more of the multispecific antibodies of the invention as described herein (for example when the antibodies is provided as an IgG 1 antibody), as measured by any via suitable means (for example via controlled flow cytometry methodology or via other established controlled assays such as described in Figure 18).
• an anti-Vb1 antibody or antigen-binding fragment thereof characterised in that it does not induce secretion of IL-17A.
• IL-17A (lnterleukin-17A) is a pro-tumorigenic cytokine which is produced by activated T-cells. IL-17A can enhance tumour growth and dampen the anticancer immune response.
• anti-nd ⁇ antibodies do not induce secretion of IL-17A when added to a population of cells comprising human lymphocytes that include V61+ve cells, whereas comparator anti-CD3 antibodies (such as OKT 3) do induce IL17A in such circumstances.
• reference to the antibodies or antigen binding fragments herein not inducing secretion of IL-17A refers to inducing less than about 30%, or less than about 20%, or less than about 10% of the IL-17A secretion induced by comparator anti-CD3 antibodies in such circumstances (as typified by OKT 3; the anti-CD3 comparator employed in Figure 63 G to I).
• variable domains may be re-formatted into full length IgG by sub-cloning. To accelerate the process, variable domains are often transferred using restriction enzymes. These unique restriction sites may introduce additional/alternate amino acids and away from the canonical sequence (such canonical sequences may be found, for example, in the international ImMunoGeneTics [IMGT] information system, see http://www.imgt.org). These may be introduced as kappa or lambda light chain sequence modifications.
• IMGT international ImMunoGeneTics
• variable light chain variable sequences may be cloned using restriction sites (e.g. Nhe1-Not1) during re-formatting into full length IgG. More specifically, at the light chain N-terminus, an additional Ala-Ser sequence was introduced in the parental (non-affinity matured) antibodies to support cloning. Preferably, this additional AS sequence is then removed during further development such to generate the canonical N- terminal sequence.
• light chain containing antibodies described herein do not contain an AS sequence at their N-termini, i.e. SEQ ID NOs: 26, 118, 282 to 290 or 313 do not comprise the initial AS sequence.
• the N-termini of the light chain sequences of the affinity-matured antibodies already do not comprise this AS motif.
• kappa light chain containing antibodies described herein contain a constant domain starting with the sequence RTV (for example as in SEQ ID NO: 296).
• lambda light chain variable-domain/constant domain border a lysine-to-alanine sequence change was introduced to support cloning.
• this sequence can be modified during further development such to generate the canonical lambda light constant region which starts GQPKAAPS.
• lambda light chain containing antibodies described herein contain a constant domain starting with the sequence GQPK.
• variable heavy chain sequences start with either the basic glutamine (Q) or acidic glutamate (E). However, both such sequences are then known to convert to the acidic amino acid residue, pyro-glutamate (pE).
• Q basic glutamine
• E acidic glutamate
• pE pyro-glutamate
• the Q to pE conversion results in a charge change to the antibody, whilst an E to pE conversion does not change the charge of the antibody.
• one option is to modify a starting heavy chain sequence from Q to E in the first instance.
• the heavy chain of antibody described herein having a Q residue at the N-terminus of the heavy chain may contain a Q to E modification at the N-terminus.
• the initial residue of any of SEQ ID NOs: 1 , 106, 276 to 279 or 312 may be modified from Q to E. It will be understood that this embodiment also applies to any embodiment incorporating these sequences, for example into full-length multispecific antibodies or antigen-binding fragments thereof.
• the C-terminus of the lgG1 constant domain ends with PGK.
• the terminal basic lysine K, EU position 4457
• K EU position 4457
• An alternative option is to also remove the terminal G (EU position 446).
• the heavy chain of an antibody described herein has the terminal K, or the terminal GK, removed from its C-terminus.
• the antibody or antigen-binding fragment thereof contains a modified effector function through alteration to the sugars linked to Asn 297 (EU numbering scheme).
• Asn 297 is not fucosylated or exhibits reduced fucosylation (i.e., a defucosylated antibody or a non-fucosylated antibody).
• Fucosylation includes the addition of the sugar fucose to a molecule, for example, the attachment of fucose to N-glycans, O-glycans and glycolipids. Accordingly, in a defucosylated antibody, fucose is not attached to the carbohydrate chains of the constant region.
• the antibody may be modified to prevent or inhibit fucosylation of the antibody.
• glycosylation modifications involve expressing said antibody or antigen-binding fragment thereof in a host cell containing alternate glycosylation processing capabilities either through targeted engineering or through targeted or serendipitous host or clone selection (e.g. see Example 13).
• alternate glycosylation processing capabilities either through targeted engineering or through targeted or serendipitous host or clone selection (e.g. see Example 13).
• Km1 , Km1 ,2 and Km3 which define three Km alleles (using allotype numbering): Km1 correlates with valine 153 (IMGT V45.1) and leucine 191 (IMGT L101); Km1 ,2 correlates with alanine 153 (IMGT A45.1) and leucine 191 (IMGT L101); and Km3 correlates with alanine 153 (IMGT A45.1) and valine 191 (IMGT V101).
• a L191 V (IMGT L101V) change will convert a Km1 ,2 allotype to a Km3 allotype.
• an antibody described herein contains amino acid substitutions derived from another human allotype of the same gene.
• the antibody contains a L191 V (IMGT L101V) substitution to the kappa chain to convert the c-domain from a km1 ,2 to a km3 allotype.
• the antibodies of the present invention are multispecific. They may be bispecificmultispecific. Multispecific antibodies may be specific for different epitopes of one target polypeptide or may be specific for more than one target polypeptide. Therefore, in one embodiment, the antibody or antigen-binding fragment thereof comprises a first binding specificity for V61 and a second binding specificity for EGFR.
• the present invention provides a new class of high-affinity antibodies that comprise multiple antigen-binding sites (“multispecific antibodies”), including an antigen-binding site for TCR delta variable 1 (V51) and an antigen-binding site for EGFR.
• multispecific antibodies including an antigen-binding site for TCR delta variable 1 (V51) and an antigen-binding site for EGFR.
• the multispecific antibodies of the present invention are in the format known as "mAb 2 antibodies”or “mAb squared antibodies", which are antibodies comprising an Fc region that has been engineered to contain antigen-binding loops in its CH3 domain - this modified Fc region is termed an "Fcab”.
• the mAb 2 antibody further comprises a Fab region, comprising a VH-VL domain pair providing an antigen-binding site.
• mAb 2 molecules of the present invention comprise a EGFR binding Fcab and an nd1- binding Fab.
• the TCEs of the present invention provide several advantages over the TCEs of the prior art.
• the TCEs may overcome many of the challenges associated with TCEs of the prior art by targeting the T- cell receptor complex via an entirely novel and discrete mechanism.
• the T-cell receptor complex by specifically targeting (and activating) the T-cell receptor complex solely via binding to an epitope on the TRDV1 domain, a number of advantages are realized including:
• T-cells Engaging only a sub-set of T-cells (TRDV1+ T-cells) that are predominantly ‘tissue-resident’ and whose presence often positively correlates with good prognosis in a cancer/tumour setting;
• T-cell receptor complex via TRDV1 engagement thereby affording more optionality (e.g. increasing affinity of this binding domain, as in the antibodies of the present invention).
• increased affinity may drive more favourable functionality.
• high-affinity TRDV1-binding TCEs may activate but not exhaust T-cells; and/or
• Engaging the TCE complex via said novel means and via recombinant TRDV1 binding domains may result in less deleterious effects and so reduce the need to attenuate Fc functionality in said TCE moieties. It would generally be expected that a TCE with unattenuated Fc function would induce an antibody-dependent cell-mediated cytotoxicity (ADCC) effect and thereby deplete the population of gd T-cells recognized by the antibody. However, and again, by attenuating such functionality to avoid toxicity/safety complexities, one may also attenuate a potentially important efficacy angles too e.g. by engaging CD16+ or CD32+ or CD64+ immune cells, or by reducing half- life of the bispecific (e.g.
• Methods of reducing the interaction of the FCYR and the TCE would be expected to reduce Fc-mediated immobilization of the TCE and reduce TCR clustering by cross-linking with the immobilized TCE. Reducing the need to attenuate Fc functionality in said TCE moieties then may afford additional optionality, for example by allowing TRDV1 TCEs to engage TRDV1 + cells via one binding domain, engaging a second cell type (such as a cancerous cell) by a second binding arm, and engaging other effector cells such as CD16+ or CD32+ or CD64+ immune cells via a functioning Fc domain.
• the multispecific antibodies described herein can therefore engage and activate the CD3/yb TCR complex and confer its downregulation and loss of surface expression, without unwanted depletion of nd1 T cells (see Figure 29). This enables the multispecific antibodies described herein to be employed as medicaments to treat a disease or disorder such to ameliorate at least one sign or symptom of a disease or disorder through a mechanism involving the activation of blood, tissue and tumour resident V61+ T cells.
• the present inventors have generated a novel class of recombinant TCEs. Specifically, the present inventors have discovered a new class of TCEs which engage the T-cell receptor via a TRDV1 domain rather than other domains in said T-cell receptor signalling complexes. More specifically the present inventors have discovered a new class of TCEs which engage this complex via an activating epitope on TRDV1 and which may be bound at higher affinities without potentially conferring some of the previously reported deleterious effects high-affinity T-cell receptor complex engagement. Further this new class of TCEs may engage in such a way which may allow for wild- type Fc functionality too, thereby affording additional efficacy potential too.
• the multispecific antibodies of the invention may also display improved properties compared to equivalent monospecific antibodies.
• the multispecific antibodies of the invention may also display improved properties compared to monospecific antibodies having the same antigen binding domains as the component parts of the multispecific antibodies.
• the recombinant multispecific antibody confers increased gamma delta T-cell mediated cytotoxicity towards a diseased cell expressing the second epitope compared to the cytotoxicity conferred by an equivalent amount of said first monospecific antibody.
• the multispecific antibodies of the invention may also display improved cytotoxicity towards diseased cells whilst still sparing healthy cells.
• the multispecific antibody is a human recombinant antibody encoded by a recombinant nucleic acid open reading frame or frames expressed from a recombinant host cell. In some embodiments the multispecific antibody is not a rodent or other non-human antibody derived from B-cell fusion hybridoma technologies. In some embodiments the multispecific antibody does not comprise nonhuman IgG constant domain sequence found only in non-human animal species, such as sequence found in rodent-derived hybridomas.
• the multispecific antibodies (suitably bispecific antibodies) of the invention do not specifically bind (or directly interact with) CD3.
• References herein to an antigen being “on” a cell refer to antigens that are expressed on the cell surface membrane or are associated with the (extracellular side of) the cell surface membrane of such cells.
• the second target epitope is EGFR.
• EGFR epimal growth factor receptor
• EGFR epithelial growth factor receptor
• ErbB subfamily a receptor tyrosine kinase
• EGFR is expressed in multiple organs and plays an important role in initiating signaling that directs the behaviour of epithelial cells and tumours of epithelial origin.
• EGFR-mediated signaling is also involved in controlling cell proliferation, migration, survival, and metastasis by regulating diverse cellular pathways.
• mutations affecting EGFR activity or leading to EGFR upregulation are associated with many cancers.
• EGFR inhibitors can therefore be anti-cancer agents. Indeed, certain tumour cells are dependent on EGFR signaling and thus possess an “Oncogene addiction”, which makes this receptor an attractive target for therapy.
• Monoclonal antibodies that specifically bind to epitopes of EGFR are well known in the art. For example, cetuximab is a monoclonal antibody which binds specifically to an epitope of EGFR.
• gd T-cells While the mechanisms by which gd T-cells recognize antigens and distinguish between healthy and diseased cells are not fully understood (Ming Heng and Madalene Heng, Antigen Recognition by gd T- Cells. Madame Curie Bioscience Database [Internet], Austin (TX): Austin (TX): Austin (TX): Austin (TX): Austin (TX): Austin (TX): Austin (TX): Austin (TX): Austin (TX): Austin (TX): Austin (TX): Austin (TX): Austin (TX): Austin (TX): Austin (TX): Austin (TX): Austin (TX): Austin (TX): Austin (TX): Austin (TX): Austin (TX): Austin (TX): Austin (TX): Austin (TX): Austin (TX): Austin (TX): Austin (TX): Austin (TX): Austin (TX): Austin (TX): Austin (TX):
• gd T-cell capabilities by leveraging such gd T-cell capabilities, there is provided an opportunity to treat disease while sparing healthy cells, by colocalizing gd T-cells with diseased cells even when a particular cancer antigen, inflammatory antigen, or pathogen antigen is either not known, or is also present on healthy cells, in a particular patient.
• multispecificmultispecific instead of employing such conventional approaches, provided herein are multispecific antibodies wherein at least one first binding domain is able to specifically bind V61+ cells and at least one second binding domain is able to specifically bind to EGFR, a target present on diseased tissues and cells.
• the use of such multispecific antibodies in this way may thereby result in the colocalization of V61+ cells to diseased cells expressing the second target.
• V61 + effector cells may be more preferred over conventional approaches. This is because V61 + effector cells may be capable of recognizing stress patterns in diseased or infected cells and so able to selectively kill diseased cells whilst sparing healthy cells also expressing the same target.
• the multispecific antibodies presented herein are therefore able to engage on the TCR of nd1 cells but full activation does not occur unless tumour cells are also present.
• Full engagement of the presently presented antibodies on the TCR leads to partial downregulation and it is believed the nd1 cells bound by the presently presented antibodies only become fully activated and become cytotoxic when in the presence of stressed cells such as tumour cells. This is shown, for example, in Example 18 and Figure 40 Figure).
• gd T cells One mechanism behind gd T cells being able to detect stress signals on tumour cells is believed to be due to the NCRs (natural cytotoxicity receptors) they express.
• the NCRs are able to engage NCR ligands on tumour cells.
• a dual mechanism of activation may therefore be employed, wherein the gd T cells are activated via TCR stimulation, including via NCRs, which can sense the tumour cells to enable full activation and cytotoxicity.
• multispecificmultispecificmultispecificmultispecific stimulation of gd T cells with the presently presented multispecific antibodies do not lead to such concerns because gd T cells) are able to distinguish between healthy cells and tumour cells, including via their NCR sensing mechanism and therefore selectively kill stressed cells such as cancer cells orvirally infected cells due to this diseased cell specificity multispecificmultispecificmultispecificmultispecificThe second target epitope may be on a different cell including a different T-cell, a B-cell, a tumour cell, an autoimmune tissue cell or a virally infected cell.
• multispecificmultispecificmultispecific various antibody-derived multispecific formats have been described previously and are typically built empirically from the component binding parts.
• the performance of such multispecific or multi-target binding formats as described herein may be measured in one or more of the aforementioned model systems (cell killing, cell proliferation, healthy cell sparing/diseased cell specific models etc). Optionally they are also compared to said component parts and other comparator molecules.
• the binding domain modules to each target are built from Fab and Fcab binding modules which are combined into full length antibodies. Modification and generation of multispecific antibodies and desired Fab and Fcab binding domains can be undertaken by routine molecular biology methodology well known in the art.
• oligonucleotide-based approaches with or without aid of PCR amplification can be employed to build synthetic DNA sequences encoding a desired CH3 domain and/or other elements of the desired bispecific antibody.
• these can then be correctly cloned into an open reading frame (ORF) encoding the starting antibody heavy chain (such as one described herein) via restriction enzyme based sub-cloning methodologies such to replace the starting CH3 sequence with the desired modified CH3 sequence.
• ORF open reading frame
• larger elements or indeed the entire antibody heavy chain encoding ORF can be built de-novo from a starting in-silico sequence with oligonucleotide and/or PCR methodologies to generate the entire final ORF encoding a preferred full-length heavy chain comprising a VH binding arm and modified CH3 domain of the multispecific antibody such as described herein.
• This can then be expressed, recovered and purified in combination with a preferred cognate kappa light chain such as that described herein in order to generate a final purified, multispecific antibody which binds the TRDV1 domain of human V61 TCR and is operatively linked to a modified CH3 binding domains which bind human EGFR.
• multispecific antibodies comprising at least one (first) binding domain targeting the V61 chain of a gd TCR as described herein are further enhanced when said first binding domain is formatted with a multispecific antibody format comprising at least one second binding domain against EGFR.
• Multispecific antibodies - non-limiting examples:
• multispecific antibodies comprised at least one (first) binding domain targeting the V51 chain of a gd TCR and at least one (second) binding domain targeting EGFR: V51-EGFR multisoecific antibody (LEE)
• a multispecific antibody comprising a Fab region and an Fc region, wherein the Fab region comprises a binding site specific for an epitope of the variable delta 1 (V61) chain of a gd T cell receptor (TCR); and the Fc region comprises an EGFR binding site.
• the Fab region specifically comprises a VH and cognate VL domain.
• the Fc region comprises a binding domain within a heavy chain constant domain (CH1-CH2-CH3), specifically a CH3 domain.
• the EGFR binding site may be provided by an lgG1 CH3 domain in which residues 359 to 362 (EU numbering) comprise EEGP (SEQ ID NO: 523), residues 384 to 386 (EU numbering) comprise TYG (SEQ ID NO:511), and residues 413 to 419 (EU numbering) comprise SYWRWYK (SEQ ID NO: 512).
• residues 355 to 362 form an AB loop comprising RDELEEGP (SEQ ID NO: 524)
• residues 383 to 391 form an CD loop comprising STYGPENNYKT (SEQ ID NO: 514)
• residues 413 to 422 form an EF loop comprising SYWRWYKGNV (SEQ ID NO: 515).
• the lgG1 CH3 domain may comprise the following mutations (EU numbering).
• the following mutations may be present: T359E.K360E.N361G.Q362P.
• the following mutations may be present: N384T.G385Y.Q386G.
• the EF loop the following mutations may be present: D413S.K414Y.S415W.Q418Y.Q419K.
• the amino acid sequence of the CH3 domain may be at least 90% identical to, or at least 95% identical to, or 100% identical to SEQ ID NO: 562.
• the heavy chain constant domain may comprise SEQ ID NO: 391 or SEQ ID NO: 392.
• the multispecific antibody may comprise SEQ ID NO: 389; or SEQ ID NO: 414 and SEQ ID NO: 432. In this aspect, the multispecific antibody may comprise SEQ ID NO: 400; or SEQ ID NO: 414 and SEQ ID NO: 436.
• the Fab region may be any of the Fab regions described herein (see Table 9, for example).
• the Fab region of this aspect may comprise a VHCDR1 , a VHCDR2 and a VHCDR3 comprising the amino acid sequences of SEQ ID NO: 51 , 53 and 68, respectively, and a VLCDR1 , a VLCDR2 and a VLCDR3 comprising the amino acid sequences of SEQ ID NOs: 79, 80 and 95, respectively.
• the Fab region of this aspect may comprise a VH comprising SEQ ID NO: 15 and a VL comprising SEQ ID NO: 40.
• the multispecific antibody comprises a Fab region comprising a VH comprising the amino acid sequence of SEQ ID NO: 15 and a VL sequence comprising the amino acid sequence of SEQ ID NO: 40; and an Fc region comprising a CH3 domain comprising the amino acid sequence of SEQ ID NO: 562.
• the multispecific antibodies of the invention may comprise an additional lysine (K) resisdue at the immediate C-terminus of the CH3 domain sequence (K447, EU numbering).
• the multispecific antibodies of the invention may have the terminal glycine (G) residue at the immediate C-terminus of the CH3 domain sequence removed (G446, EU numbering).
• the present disclosure includes a multispecific antibody comprising a Fab region and an Fc region wherein the Fab region comprises a binding site specific for an epitope of the variable delta 1 (V61) chain of a gd T cell receptor (TCR), wherein the Fab region comprises a VHCDR1 comprising the sequence of SEQ ID NO: 51 , a VHCDR2 comprising the sequence of SEQ ID NO: 53, a VHCDR3 comprising the sequence of SEQ ID NO: 68, a VLCDR1 comprising the sequence of SEQ ID NO: 79, a VLCDR2 comprising the sequence of SEQ ID NO: 80 and a VLCDR3 comprising the sequence of SEQ ID NO: 95; and the Fc region comprises an EGFR binding site, wherein the EGFR binding site is provided by a CH3 domain in which residues 359 to 362 (EU numbering) comprise SEQ ID NO: 523, residues 384 to 386 (EU numbering) comprise SEQ ID NO:511 and
• the human lgG1 antibodies may comprise a CFI3 domain comprising the sequence of SEQ ID NO: 562.
• Table 10 LEE - Example multispecific ndI-EGFR human lgG1 antibodies having the variable regions of antibodies derived from ADT1-4 and ADT1-7 and the related SEQ ID NOs
• the present disclosure explicitly includes an antibody having the sequences of each row of the above table.
• the present disclosure includes a multispecific antibody comprising a Fab region and an Fc region wherein the Fab region comprises a binding site specific for an epitope of the variable delta 1 (V61) chain of a gd T cell receptor (TCR), wherein the Fab region comprises a VH region comprising the sequence of SEQ ID NO: 15 and a VL region comprising the SEQUENCE of SEQ ID NO: 40; and the Fc region comprises an EGFR binding site, wherein the EGFR binding site is provided by a CH3 domain in which residues 359 to 362 (EU numbering) comprise SEQ ID NO: 523, residues 384 to 386 (EU numbering) comprise SEQ ID NO:511 and residues 413 to 419 (EU numbering) comprise SEQ ID NO: 512.
• EU numbering residues 359 to 362
• residues 384 to 386 EU numbering
• EU numbering comprise SEQ ID NO:
• the human lgG1 antibodies may comprise a CH3 domain comprising the sequence of SEQ ID NO: 562.
• V51-EGFR multisoecific antibody ( LEE1 ) V51-EGFR multisoecific antibody
• a multispecific antibody comprising a Fab region and an Fc region, wherein the Fab region comprises a binding site specific for an epitope of the variable delta 1 (V61) chain of a gd T cell receptor (TCR); and the Fc region comprises an EGFR binding site.
• the Fab region specifically comprises a VH and cognate VL domain.
• the Fc region comprises a binding domain within a heavy chain constant domain (CH1-CH2-CH3), specifically a CH3 domain.
• the EGFR binding site may be provided by an lgG1 CH3 domain in which residues 384 to 386 (EU numbering) comprise TYG (SEQ ID NO: 511 , and residues 413 to 419 (EU numbering) comprise SYWRWYK (SEQ ID NO: 512).
• residues 355 to 362 form an AB loop comprising RDELTKNQ (SEQ ID NO: 513
• residues 383 to 391 form an CD loop comprising STYGPENNYKT (SEQ ID NO: 514)
• residues 413 to 422 form an EF loop comprising SYWRWYKGNV (SEQ ID NO: 515).
• the lgG1 CH3 domain may comprise the following mutations (EU numbering).
• the AB loop may be wildtype (no mutations present).
• the following mutations may be present: N384T.G385Y.Q386G.
• the following mutations may be present:
• amino acid sequence of the CH3 domain may be at least 90% identical to, or at least 95% identical to, or 100% identical to SEQ ID NO: 510.
• the heavy chain constant domain may comprise SEQ ID NO: 508 or SEQ ID NO: 509.
• the multispecific antibody may comprise SEQ ID NO: 504; or SEQ ID NO: 414 and SEQ ID NO: 506. In this aspect, the multispecific antibody may comprise SEQ ID NO: 505; or SEQ ID NO: 414 and
• the Fab region may be any of the Fab regions described herein (see Table 11 , for example).
• the Fab region of this aspect may comprise a VHCDR1 , a VHCDR2 and a VHCDR3 comprising the amino acid sequences of SEQ ID NO: 51 , 53 and 68, respectively, and a VLCDR1 , a VLCDR2 and a VLCDR3 comprising the amino acid sequences of SEQ ID NOs: 79, 80 and 95, respectively.
• the Fab region of this aspect may comprise a VH comprising SEQ ID NO: 15 and a VL comprising SEQ ID NO: 40.
• the multispecific antibody comprises a Fab region comprising a VH comprising the amino acid sequence of SEQ ID NO: 15 and a VL sequence comprising the amino acid sequence of SEQ ID NO: 40; and an Fc region comprising a CH3 domain comprising the amino acid sequence of SEQ ID NO: 510.
• the multispecific antibodies of the invention may comprise an additional lysine (K) residue at the immediate C-terminus of the CH3 domain sequence (K447, EU numbering).
• the multispecific antibodies of the invention may have the terminal glycine (G) residue at the immediate C-terminus of the CH3 domain sequence removed (G446, EU numbering).
• V51-EGFR multisoecific antibody LEE2
• a multispecific antibody comprising a Fab region and an Fc region, wherein the Fab region comprises a binding site specific for an epitope of the variable delta 1 (V61) chain of a gd T cell receptor (TCR); and the Fc region comprises an EGFR binding site.
• the Fab region specifically comprises a VFI and cognate VL domain.
• the Fc region comprises a binding domain within a heavy chain constant domain (CFI1-CFI2-CFI3), specifically a CH3 domain.
• the EGFR binding site may be provided by an lgG1 CH3 domain in which residues 359 to 362 (EU numbering) comprise EEGP (SEQ ID NO: 523), and residues 413 to 419 (EU numbering) comprise
• residues 355 to 362 form an AB loop comprising RDELEEGP (SEQ ID NO: 524)
• residues 383 to 391 form an CD loop comprising SNGQPENNYKT (SEQ ID NO: 525)
• residues 413 to 422 form an EF loop comprising SYWRWYKGNV (SEQ ID NO:
• the lgG1 CH3 domain may comprise the following mutations (EU numbering).
• the following mutations may be present: T359E.K360E.N361G.Q362P.
• the CD loop may be wildtype (no mutations present).
• the following mutations may be present: D413S.K414Y.S415W.Q418Y.Q419K.
• the amino acid sequence of the CH3 domain may be at least 90% identical to, or at least 95% identical to, or 100% identical to SEQ ID NO: 522.
• the heavy chain constant domain may comprise SEQ ID NO: 520 or SEQ ID NO: 521 .
• the multispecific antibody may comprise SEQ ID NO: 516; or SEQ ID NO: 414 and SEQ ID NO: 518.
• the multispecific antibody may comprise SEQ ID NO: 517; or SEQ ID NO: 414 and SEQ ID NO: 519.
• the Fab region may be any of the Fab regions described herein (see Table 13, for example).
• the Fab region of this aspect may comprise a VHCDR1 , a VHCDR2 and a VHCDR3 comprising the amino acid sequences of SEQ ID NO: 51 , 53 and 68, respectively, and a VLCDR1 , a VLCDR2 and a VLCDR3 comprising the amino acid sequences of SEQ ID NOs: 79, 80 and 95, respectively.
• the Fab region of this aspect may comprise a VFI comprising SEQ ID NO: 15 and a VL comprising SEQ ID NO: 40.
• the multispecific antibody comprises a Fab region comprising a VH comprising the amino acid sequence of SEQ ID NO: 15 and a VL sequence comprising the amino acid sequence of SEQ ID NO: 40; and an Fc region comprising a CFI3 domain comprising the amino acid sequence of SEQ ID NO: 522.
• the multispecific antibodies of the invention may comprise an additional lysine (K) residue at the immediate C-terminus of the CFI3 domain sequence (K447, EU numbering) .
• the multispecific antibodies of the invention may have the terminal glycine (G) residue at the immediate C-terminus of the CFI3 domain sequence removed (G446, EU numbering).
• a multispecific antibody comprising a Fab region and an Fc region, wherein the Fab region comprises a binding site specific for an epitope of the variable delta 1 (V61) chain of a gd T cell receptor (TCR); and the Fc region comprises an EGFR binding site.
• the Fab region specifically comprises a VH and cognate VL domain.
• the Fc region comprises a binding domain within a heavy chain constant domain (CH1-CH2-CH3), specifically a CH3 domain.
• the EGFR binding site may be provided by an lgG1 CH3 domain in which residues 359 to 362 (EU numbering) comprise EEGP (SEQ ID NO: 523), residues 384 to 386 (EU numbering) comprise TYG (SEQ ID NO: 511), and residues 413 to 415 (EU numbering) comprise SYW (SEQ ID NO: 533).
• residues 355 to 362 form an AB loop comprising RDELEEGP (SEQ ID NO: 524)
• residues 383 to 391 form an CD loop comprising STYGPENNYKT (SEQ ID NO: 524)
• the lgG1 CH3 domain may comprise the following mutations (EU numbering).
• the following mutations may be present: T359E.K360E.N361G.Q362P.
• the following mutations may be present: N384T.G385Y.Q386G.
• the EF loop the following mutations may be present D413S.K414Y.S415W.
• the amino acid sequence of the CH3 domain may be at least 90% identical to, or at least 95% identical to, or 100% identical to SEQ ID NO: 532.
• the heavy chain constant domain may comprise SEQ ID NO: 530 or SEQ ID NO: 531 .
• the multispecific antibody may comprise SEQ ID NO: 526; or SEQ ID NO: 414 and SEQ ID NO: 528;. In this aspect, the multispecific antibody may comprise SEQ ID NO: 527; or SEQ ID NO: 414 and SEQ ID NO: 529.
• the Fab region may be any of the Fab regions described herein (see Table 15, for example).
• the Fab region of this aspect may comprise a VHCDR1 , a VHCDR2 and a VHCDR3 comprising the amino acid sequences of SEQ ID NO: 51 , 53 and 68, respectively, and a VLCDR1 , a VLCDR2 and a VLCDR3 comprising the amino acid sequences of SEQ ID NOs: 79, 80 and 95, respectively.
• the Fab region of this aspect may comprise a VH comprising SEQ ID NO: 15 and a VL comprising SEQ ID NO: 40.
• the multispecific antibody comprises a Fab region comprising a VH comprising the amino acid sequence of SEQ ID NO: 15 and a VL sequence comprising the amino acid sequence of SEQ ID NO: 40; and an Fc region comprising a CH3 domain comprising the amino acid sequence of SEQ ID NO: 532.
• the multispecific antibodies of the invention may comprise an additional lysine (K) residue at the immediate C-terminus of the CH3 domain sequence (K447, EU numbering).
• the multispecific antibodies of the invention may have the terminal glycine (G) resiside at the immediate C-terminus of the CH3 domain sequence removed (G446, EU numbering).
• V51-EGFR multispecific antibody ( FS1-67 )
• a multispecific antibody comprising a Fab region and an Fc region, wherein the Fab region comprises a binding site specific for an epitope of the variable delta 1 (V61) chain of a gd T cell receptor (TCR); and the Fc region comprises an EGFR binding site.
• the Fab region specifically comprises a VH and cognate VL domain.
• the Fc region comprises a binding domain within a heavy chain constant domain (CH1-CH2-CH3), specifically a CH3 domain.
• the EGFR binding site may be provided by an lgG1 CH3 domain in which residues 358 to 362 (EU numbering) comprise TDDGP (SEQ ID NO: 560), residues 384 to 386 (EU numbering) comprise TYG (SEQ ID NO: 511), and residues 413 to 419 (EU numbering) comprise SYWRWYK (SEQ ID NO: 512).
• residues 355 to 362 form an AB loop comprising RDETDDGP (SEQ ID NO: 561)
• residues 383 to 391 form an CD loop comprising STYGPENNYKT (SEQ ID NO: 511
• the lgG1 CH3 domain may comprise the following mutations (EU numbering).
• the following mutations may be present: L358T.T359D.K360D.N361G.Q362P.
• the following mutations may be present: N384T.G385Y.Q386G.
• the following mutations may be present: D413S.K414Y.S415W.Q418Y.Q419K.
• amino acid sequence of the CH3 domain may be at least 90% identical to, or at least 95% identical to, or 100% identical to SEQ ID NO: 559.
• the heavy chain constant domain may comprise SEQ ID NO: 385 or SEQ ID NO: 386.
• the multispecific antibody may comprise SEQ ID NO: 388; or SEQ ID NO: 414 and SEQ ID NO: 431 . In this aspect, the multispecific antibody may comprise SEQ ID NO: 399; or SEQ ID NO: 414 and SEQ ID NO: 435.
• the Fab region may be any of the Fab regions described herein (see Table 17, for example).
• the Fab region of this aspect may comprise a VHCDR1 , a VHCDR2 and a VHCDR3 comprising the amino acid sequences of SEQ ID NO: 51 , 53 and 68, respectively, and a VLCDR1 , a VLCDR2 and a VLCDR3 comprising the amino acid sequences of SEQ ID NOs: 79, 80 and 95, respectively.
• the Fab region of this aspect may comprise a VH comprising SEQ ID NO: 15 and a VL comprising SEQ ID NO: 40.
• the multispecific antibody comprises a Fab region comprising a VH comprising the amino acid sequence of SEQ ID NO: 15 and a VL sequence comprising the amino acid sequence of SEQ ID NO: 40; and an Fc region comprising a CH3 domain comprising the amino acid sequence of SEQ ID NO: 559.
• the multispecific antibodies of the invention may comprise an additional lysine (K) residue at the immediate C-terminus of the CH3 domain sequence (K447, EU numbering).
• the multispecific antibodies of the invention may have the terminal glycine (G) residue at the immediate C-terminus of the CH3 domain sequence removed (G446, EU numbering).
• the multispecific antibody of the invention is not ADT1-4xFS1-67.
• Table 17 FS1-67 - Example multispecific v51-EGFR human lgG1 antibodies having the CDRs of antibodies derived from ADT1-4 and ADT1-7 and the related SEQ ID NOs Table 18.
• V51-EGFR multisoecific antibody (FS1-65)
• a multispecific antibody comprising a Fab region and an Fc region, wherein the Fab region comprises a binding site specific for an epitope of the variable delta 1 (V61) chain of a gd T cell receptor (TCR); and the Fc region comprises an EGFR binding site.
• the Fab region specifically comprises a VH and cognate VL domain.
• the Fc region comprises a binding domain within a heavy chain constant domain (CH1-CH2-CH3), specifically a CH3 domain.
• the EGFR binding site may be provided by an lgG1 CH3 domain in which residues 358 to 361 , 361.1 and 362 (EU numbering) comprise LDEEGP (SEQ ID NO: 542), residues 384 to 386 (EU numbering) comprise TYG (SEQ ID NO: 511), and residues 413 to 419 (EU numbering) comprise SYWRWVK (SEQ ID NO: 543).
• residue 361.1 denotes an additional residue between residue 361 and 362 (EU numbering).
• residues 355 to 362, inclusive of residue 361.1 (EU numbering) form an AB loop comprising RDELDEGGP (SEQ ID NO: 544)
• residues 383 to 391 (EU numbering) form an CD loop comprising STYGPENNYKT (SEQ ID NO: 514)
• residues 413 to 422 (EU numbering) form an EF loop comprising SYWRWVKGNV (SEQ ID NO: 545).
• residue 361.1 denotes an additional residue between residue 361 and 362 (EU numbering).
• the lgG1 CH3 domain may comprise the following mutations (EU numbering).
• residue 361-1 denotes an additional residue between residue 361 and 362 (EU numbering).
• amino acid sequence of the CH3 domain may be at least 90% identical to, or at least 95% identical to, or 100% identical to SEQ ID NO: 541.
• the heavy chain constant domain may comprise SEQ ID NO: 539 or SEQ ID NO: 540.
• the multispecific antibody may comprise SEQ ID NO: 535; or SEQ ID NO: 414 and SEQ ID NO: 537. In this aspect, the multispecific antibody may comprise SEQ ID NO: 536; or SEQ ID NO: 414 and SEQ ID NO: 538.
• the Fab region may be any of the Fab regions described herein (see Table 19, for example).
• the Fab region of this aspect may comprise a VHCDR1 , a VHCDR2 and a VHCDR3 comprising the amino acid sequences of SEQ ID NO: 51 , 53 and 68, respectively, and a VLCDR1 , a VLCDR2 and a VLCDR3 comprising the amino acid sequences of SEQ ID NOs: 79, 80 and 95, respectively.
• the Fab region of this aspect may comprise a VH comprising SEQ ID NO: 15 and a VL comprising SEQ ID NO: 40.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Immunology (AREA)
• Organic Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Genetics & Genomics (AREA)
• Molecular Biology (AREA)
• Biophysics (AREA)
• Biochemistry (AREA)
• Oncology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Cell Biology (AREA)
• Peptides Or Proteins (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Priority Applications (18)

Applications Claiming Priority (4)

Related Child Applications (1)

Publications (3)

Family

ID=80595338

Family Applications (2)

Family Applications After (1)

Country Status (14)

Cited By (2)

Families Citing this family (7)

Citations (8)

Family Cites Families (7)

• 2022
  • 2022-02-17 AU AU2022224391A patent/AU2022224391A1/en active Pending
  • 2022-02-17 BR BR112023016580A patent/BR112023016580A2/pt unknown
  • 2022-02-17 WO PCT/EP2022/054011 patent/WO2022175414A1/en not_active Ceased
  • 2022-02-17 CA CA3207265A patent/CA3207265A1/en active Pending
  • 2022-02-17 KR KR1020237031271A patent/KR20230160253A/ko active Pending
  • 2022-02-17 IL IL305024A patent/IL305024A/en unknown
  • 2022-02-17 EP EP22705063.0A patent/EP4294527A1/en active Pending
  • 2022-02-17 TW TW111105807A patent/TW202246338A/zh unknown
  • 2022-02-17 JP JP2023548885A patent/JP2024506682A/ja active Pending
  • 2022-02-17 MX MX2023009360A patent/MX2023009360A/es unknown
  • 2022-02-17 TW TW111105808A patent/TW202302639A/zh unknown
  • 2022-02-17 WO PCT/EP2022/054004 patent/WO2022175413A1/en not_active Ceased
  • 2022-02-17 US US17/674,129 patent/US20230028110A1/en active Pending
• 2023
  • 2023-08-17 CL CL2023002435A patent/CL2023002435A1/es unknown
  • 2023-09-07 CO CONC2023/0011853A patent/CO2023011853A2/es unknown
  • 2023-09-15 EC ECSENADI202370428A patent/ECSP23070428A/es unknown

Patent Citations (8)